Transcription	B-protein
factor	I-protein
binding	O
sites	O
downstream	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
are	O
important	O
for	O
virus	O
infectivity	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	B-DNA
contains	O
a	O
nucleosome-free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	B-DNA
region	I-DNA
and	O
a	O
large	O
region	O
(	O
255	B-DNA
nucleotides	I-DNA
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

We	O
have	O
previously	O
identified	O
new	O
binding	O
sites	O
for	O
transcription	B-protein
factors	I-protein
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
nt	B-DNA
465	I-DNA
to	I-DNA
720	I-DNA
)	O
:	O
three	O
AP-1	B-DNA
sites	I-DNA
(	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
,	O
an	O
AP3-like	B-DNA
motif	I-DNA
(	O
AP3-L	B-DNA
)	O
,	O
a	O
downstream	B-DNA
binding	I-DNA
factor	I-DNA
(	I-DNA
DBF	I-DNA
)	I-DNA
site	I-DNA
,	O
and	O
juxtaposed	B-DNA
Sp1	I-DNA
sites	I-DNA
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
DBF	B-DNA
site	I-DNA
is	O
an	O
interferon-responsive	B-DNA
factor	I-DNA
(	I-DNA
IRF	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
and	O
that	O
the	O
AP3-L	B-DNA
motif	I-DNA
binds	O
the	O
T-cell-specific	B-protein
factor	I-protein
NF-AT	B-protein
.	O

Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3-L	B-DNA
site	O
as	O
well	O
as	O
the	O
double	O
mutation	B-DNA
AP-1	I-DNA
(	I-DNA
III	I-DNA
)	I-DNA
/AP3-L	I-DNA
did	O
not	O
affect	O
HIV-1	O
replication	O
compared	O
to	O
that	O
of	O
the	O
wild-type	O
virus	O
.	O

In	O
contrast	O
,	O
proviruses	O
carrying	O
mutations	O
in	O
the	O
Sp1	B-DNA
sites	I-DNA
were	O
totally	O
defective	O
in	O
terms	O
of	O
replication	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
III	I-DNA
)	I-DNA
,	O
AP3-L	B-DNA
,	O
and	O
DBF	B-DNA
sites	I-DNA
and	O
in	O
the	O
AP3-L	B-DNA
and	O
DBF-sites	B-DNA
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
I	I-DNA
,	I-DNA
II	I-DNA
,	I-DNA
III	I-DNA
)	I-DNA
and	O
AP3-L	B-DNA
sites	I-DNA
and	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3-L	B-DNA
,	O
and	O
DBF	B-DNA
sites	I-DNA
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

No	O
RNA-packaging	O
defect	O
could	O
be	O
measured	O
for	O
any	O
of	O
the	O
mutant	O
viruses	O
as	O
determined	O
by	O
quantification	O
of	O
their	O
HIV	B-RNA
genomic	I-RNA
RNA	I-RNA
.	O

Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	B-DNA
promoter	I-DNA
after	O
transient	O
transfection	O
of	O
the	O
HIV-1	B-DNA
provirus	I-DNA
DNA	I-DNA
or	O
of	O
long	B-DNA
terminal	I-DNA
repeat-luciferase	I-DNA
constructs	I-DNA
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O

JOURNAL	NULL
OF	NULL
ViRoLOGY	NULL
,	NULL
Aug.	NULL
1997	NULL
,	NULL
p.	NULL
6113-6127	NULL
0022-538X	NULL
,	NULL
/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

71	NULL
,	NULL
No	NULL
.	NULL

8	NULL
Transcription	NULL
Factor	NULL
Binding	NULL
Sites	NULL
Downstream	NULL
of	NULL
the	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Transcription	NULL
Start	NULL
Site	NULL
Are	NULL
Important	NULL
for	NULL
Virus	NULL
Infectivity	NULL
CARINE	NULL
VAN	NULL
LINT	NULL
,	NULL
CAROL	NULL
ANN	NULL
AMELLA	NULL
,	NULL
STEPHANE	NULL
MALCOLM	NULL
JOHN	NULL
,	NULL
TUN	NULL
JIE	NULL
,	NULL
anp	NULL
ERIC	NULL
VERDIN®*	NULL
The	NULL
Picower	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
,	NULL
Manhasset	NULL
,	NULL
New	NULL
York	NULL
11030	NULL
Received	NULL
8	NULL
January	NULL
1997/Accepted	NULL
1	NULL
May	NULL
1997	NULL
When	NULL
transcriptionally	NULL
active	NULL
,	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
promoter	NULL
contains	NULL
a	NULL
nucleosome-free	NULL
region	NULL
encompassing	NULL
both	NULL
the	NULL
promoter/enhancer	NULL
region	NULL
and	NULL
a	NULL
large	NULL
region	NULL
(	NULL
255	NULL
nucleotides	NULL
[	NULL
nt	NULL
]	NULL
)	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
identified	NULL
new	NULL
binding	NULL
sites	NULL
for	NULL
transcription	NULL
factors	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
nt	NULL
465	NULL
to	NULL
720	NULL
)	NULL
:	NULL
three	NULL
AP-1	NULL
sites	NULL
(	NULL
I	NULL
,	NULL
II	NULL
,	NULL
and	NULL
III	NULL
)	NULL
,	NULL
an	NULL
AP3-like	NULL
motif	NULL
(	NULL
AP3-L	NULL
)	NULL
,	NULL
a	NULL
downstream	NULL
binding	NULL
factor	NULL
(	NULL
DBF	NULL
)	NULL
site	NULL
,	NULL
and	NULL
juxtaposed	NULL
Spl	NULL
sites	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
DBF	NULL
site	NULL
is	NULL
an	NULL
interferon-responsive	NULL
factor	NULL
(	NULL
IRF	NULL
)	NULL
binding	NULL
site	NULL
and	NULL
that	NULL
the	NULL
AP3-L	NULL
motif	NULL
binds	NULL
the	NULL
T-cell-specific	NULL
factor	NULL
NF-AT	NULL
.	NULL

Mutations	NULL
that	NULL
abolish	NULL
the	NULL
binding	NULL
of	NULL
each	NULL
factor	NULL
to	NULL
its	NULL
cognate	NULL
site	NULL
are	NULL
introduced	NULL
in	NULL
an	NULL
infectious	NULL
HIV-1	NULL
molecular	NULL
clone	NULL
to	NULL
study	NULL
their	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
and	NULL
replication	NULL
.	NULL

Individual	NULL
mutation	NULL
of	NULL
the	NULL
DBF	NULL
or	NULL
AP3-L	NULL
site	NULL
as	NULL
well	NULL
as	NULL
the	NULL
double	NULL
mutation	NULL
AP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L	NULL
did	NULL
not	NULL
affect	NULL
HIV-1	NULL
replication	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
virus	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
proviruses	NULL
carrying	NULL
mutations	NULL
in	NULL
the	NULL
Spl	NULL
sites	NULL
were	NULL
totally	NULL
defective	NULL
in	NULL
terms	NULL
of	NULL
replication	NULL
.	NULL

Virus	NULL
production	NULL
occurred	NULL
with	NULL
slightly	NULL
delayed	NULL
kinetics	NULL
for	NULL
viruses	NULL
containing	NULL
combined	NULL
mutations	NULL
in	NULL
the	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
,	NULL
AP3-L	NULL
,	NULL
and	NULL
DBF	NULL
sites	NULL
and	NULL
in	NULL
the	NULL
AP3-L	NULL
and	NULL
DBF-sites	NULL
,	NULL
whereas	NULL
viruses	NULL
mutated	NULL
in	NULL
the	NULL
AP-1	NULL
(	NULL
LILIII	NULL
)	NULL
and	NULL
AP3-L	NULL
sites	NULL
and	NULL
in	NULL
the	NULL
AP-1	NULL
(	NULL
LIL	NULL
,	NULL
III	NULL
)	NULL
,	NULL
AP3-L	NULL
,	NULL
and	NULL
DBF	NULL
sites	NULL
exhibited	NULL
a	NULL
severely	NULL
defective	NULL
replicative	NULL
phenotype	NULL
.	NULL

No	NULL
RNA-packaging	NULL
defect	NULL
could	NULL
be	NULL
measured	NULL
for	NULL
any	NULL
of	NULL
the	NULL
mutant	NULL
viruses	NULL
as	NULL
determined	NULL
by	NULL
quantification	NULL
of	NULL
their	NULL
HIV	NULL
genomic	NULL
RNA	NULL
.	NULL

Measurement	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
after	NULL
transient	NULL
transfection	NULL
of	NULL
the	NULL
HIV-1	NULL
provirus	NULL
DNA	NULL
or	NULL
of	NULL
long	NULL
terminal	NULL
repeat-luciferase	NULL
constructs	NULL
showed	NULL
a	NULL
positive	NULL
correlation	NULL
between	NULL
the	NULL
transcriptional	NULL
and	NULL
the	NULL
replication	NULL
defects	NULL
for	NULL
most	NULL
mutants	NULL
.	NULL

The	NULL
replication	NULL
rate	NULL
of	NULL
integrated	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
is	NULL
controlled	NULL
primarily	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
.	NULL

This	NULL
process	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
interplay	NULL
between	NULL
cis-acting	NULL
DNA	NULL
elements	NULL
located	NULL
in	NULL
the	NULL
viral	NULL
long	NULL
terminal	NULL
repeats	NULL
(	NULL
LTRs	NULL
)	NULL
and	NULL
in	NULL
the	NULL
po	NULL
?	NULL

gene	NULL
intragenic	NULL
enhancer	NULL
(	NULL
79	NULL
)	NULL
,	NULL
by	NULL
cellular	NULL
transcription	NULL
factors	NULL
bound	NULL
at	NULL
these	NULL
sites	NULL
,	NULL
and	NULL
by	NULL
the	NULL
viral	NULL
frans-regulatory	NULL
protein	NULL
Tat	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
11	NULL
,	NULL
20	NULL
,	NULL
21	NULL
,	NULL
38	NULL
,	NULL
and	NULL
39	NULL
)	NULL
.	NULL

After	NULL
integration	NULL
into	NULL
cellular	NULL
genomic	NULL
DNA	NULL
,	NULL
the	NULL
HIV-1	NULL
provirus	NULL
is	NULL
packaged	NULL
into	NULL
chromatin	NULL
and	NULL
nucleosomes	NULL
are	NULL
deposited	NULL
within	NULL
the	NULL
promoter	NULL
region	NULL
(	NULL
80	NULL
,	NULL
81	NULL
)	NULL
.	NULL

Independently	NULL
of	NULL
the	NULL
site	NULL
of	NULL
integration	NULL
,	NULL
nucleosomes	NULL
in	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
are	NULL
precisely	NULL
positioned	NULL
with	NULL
respect	NULL
to	NULL
cis-regulatory	NULL
elements	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
the	NULL
transcriptionally	NULL
silent	NULL
provirus	NULL
,	NULL
these	NULL
nucleosomes	NULL
define	NULL
two	NULL
large	NULL
nucleosome-free	NULL
regions	NULL
encompassing	NULL
nucleotides	NULL
(	NULL
nt	NULL
)	NULL
200	NULL
to	NULL
465	NULL
and	NULL
610	NULL
to	NULL
720	NULL
.	NULL

The	NULL
first	NULL
open	NULL
chromatin	NULL
region	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
promoter/enhancer	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
and	NULL
spans	NULL
two	NULL
distinct	NULL
DNase	NULL
I-hypersensitive	NULL
sites	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
HS2	NULL
and	NULL
HS3	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
second	NULL
open	NULL
region	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
region	NULL
overlapping	NULL
the	NULL
primer	NULL
binding	NULL
site	NULL
immediately	NULL
downstream	NULL
of	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
and	NULL
spans	NULL
a	NULL
DNase	NULL
I-hypersensitive	NULL
site	NULL
called	NULL
HS4	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

These	NULL
two	NULL
open	NULL
regions	NULL
are	NULL
separated	NULL
by	NULL
a	NULL
single	NULL
nucleosome	NULL
,	NULL
called	NULL
nuc-1	NULL
,	NULL
encompassing	NULL
nt	NULL
465	NULL
to	NULL
610	NULL
(	NULL
80	NULL
,	NULL
81	NULL
)	NULL
.	NULL

nuc-1	NULL
is	NULL
specifically	NULL
and	NULL
rapidly	NULL
disrupted	NULL
during	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
so	NULL
that	NULL
the	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Virology	NULL
,	NULL
The	NULL
Picower	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
,	NULL
350	NULL
Community	NULL
Dr.	NULL
,	NULL
Manhasset	NULL
,	NULL
NY	NULL
11030	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
516	NULL
)	NULL
562-9495	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
516	NULL
)	NULL
365-5090	NULL
.	NULL

E-mail	NULL
:	NULL
verdin	NULL
@	NULL
picower.edu	NULL
.	NULL

6113	NULL
transcriptionally	NULL
active	NULL
HIV	NULL
promoter	NULL
is	NULL
characterized	NULL
by	NULL
a	NULL
large	NULL
open	NULL
chromatin	NULL
region	NULL
encompassing	NULL
nt	NULL
200	NULL
to	NULL
720	NULL
(	NULL
13	NULL
,	NULL
80	NULL
,	NULL
81	NULL
)	NULL
.	NULL

The	NULL
position	NULL
of	NULL
nuc-1	NULL
at	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
and	NULL
its	NULL
disruption	NULL
during	NULL
transcriptional	NULL
activation	NULL
suggest	NULL
that	NULL
chromatin	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
suppression	NULL
of	NULL
HIV-1	NULL
transcription	NULL
during	NULL
latency	NULL
and	NULL
that	NULL
nuc-1	NULL
disruption	NULL
is	NULL
necessary	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

These	NULL
predictions	NULL
are	NULL
supported	NULL
by	NULL
recent	NULL
experiments	NULL
examining	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
reconstituted	NULL
into	NULL
chromatin	NULL
in	NULL
vitro	NULL
(	NULL
60	NULL
,	NULL
70	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
footprinting	NULL
analysis	NULL
of	NULL
the	NULL
region	NULL
corresponding	NULL
to	NULL
nt	NULL
465	NULL
to	NULL
720	NULL
,	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
,	NULL
has	NULL
identified	NULL
recognition	NULL
sites	NULL
for	NULL
several	NULL
constitu-tive	NULL
and	NULL
inducible	NULL
transcription	NULL
factors	NULL
(	NULL
13	NULL
,	NULL
63	NULL
)	NULL
:	NULL
three	NULL
AP-1	NULL
binding	NULL
sites	NULL
(	NULL
site	NULL
I	NULL
[	NULL
nt	NULL
541	NULL
to	NULL
547	NULL
]	NULL
,	NULL
site	NULL
II	NULL
[	NULL
nt	NULL
572	NULL
to	NULL
578	NULL
]	NULL
,	NULL
and	NULL
site	NULL
III	NULL
[	NULL
nt	NULL
609	NULL
to	NULL
615	NULL
]	NULL
)	NULL
which	NULL
lie	NULL
within	NULL
the	NULL
region	NULL
protected	NULL
by	NULL
nuc-1	NULL
,	NULL
an	NULL
AP3-like	NULL
(	NULL
AP3-L	NULL
)	NULL
motif	NULL
(	NULL
nt	NULL
617	NULL
to	NULL
626	NULL
)	NULL
,	NULL
a	NULL
motif	NULL
interacting	NULL
with	NULL
a	NULL
nuclear	NULL
factor	NULL
called	NULL
downstream	NULL
binding	NULL
factor	NULL
(	NULL
DBF	NULL
)	NULL
(	NULL
nt	NULL
653	NULL
to	NULL
677	NULL
)	NULL
,	NULL
and	NULL
two	NULL
juxtaposed	NULL
Sp1	NULL
binding	NULL
sites	NULL
(	NULL
nt	NULL
724	NULL
to	NULL
743	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
further	NULL
characterized	NULL
each	NULL
of	NULL
these	NULL
binding	NULL
sites	NULL
and	NULL
their	NULL
role	NULL
in	NULL
the	NULL
HIV	NULL
replication	NULL
cycle	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
AP3-L	NULL
site	NULL
corresponds	NULL
to	NULL
an	NULL
NF-AT	NULL
site	NULL
and	NULL
that	NULL
the	NULL
DBF	NULL
site	NULL
corresponds	NULL
to	NULL
an	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
-responsive	NULL
factor	NULL
(	NULL
IRF	NULL
)	NULL
binding	NULL
site	NULL
.	NULL

Point	NULL
mutations	NULL
have	NULL
been	NULL
introduced	NULL
in	NULL
each	NULL
of	NULL
these	NULL
binding	NULL
sites	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
,	NULL
in	NULL
the	NULL
context	NULL
of	NULL
an	NULL
intact	NULL
HIV-1	NULL
provirus	NULL
.	NULL

Study	NULL
of	NULL
the	NULL
replication	NULL
of	NULL
these	NULL
mutant	NULL
viruses	NULL
shows	NULL
that	NULL
these	NULL
sites	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
HIV-1	NULL
transcription	NULL
and	NULL
replication	NULL
and	NULL
therefore	NULL
define	NULL
a	NULL
new	NULL
positive	NULL
transcriptional	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
HIV-1	NULL
provirus	NULL
.	NULL

6114	NULL
VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
HS2	NULL
_	NULL
HS3	NULL
m	NULL
NF-kB	NULL
SP1	NULL
-	NULL
TBP	NULL
J.	NULL
ViRoL	NULL
.	NULL

HS4	NULL
o	NULL
SP1	NULL
G1	NULL
DBF/IRF	NULL
$	NULL
U3	NULL
|	NULL
R	NULL
350	NULL
450	NULL
550	NULL
B	NULL
+300	NULL
TCF-lo	NULL
AGCTGCATCCGCAGTACTACAAAGACTGCTGACATCCAGCTTTCTACAA	NULL
B59	NULL
Npop	NULL
.	NULL

NFKB-I	NULL
SpI-II	NULL
®	NULL
spi	NULL
GecaCTececacccecTCcacATECTACATATAAGCACGCTCGCTTTTTECCTG	NULL
+450	NULL
U3	NULL
<	NULL
4rt	NULL
>	NULL
R	NULL
TAR	NULL
TACTGpBGTeTeTcrGoTrTacaAccAGATCTCAGCCTGocAGcTcrcrecer	NULL
+500	NULL
HD	NULL
___	NULL
AP1-L	NULL
AACTAGCCAACCCACTECTTAAGCCTCAATAAAGCTTGCCTTGAGTECTC	NULL
+550	NULL
APLII	NULL
G	NULL
6	NULL
R	NULL
US	NULL
A	NULL
$	NULL
AGTGTGTGCCCGTC	NULL
TGTgGTGgGAC	NULL
ECTGGTAACTAGAGATCCCT	NULL
+600	NULL
APL-III	NULL
NFAT/AP3	NULL
US	NULL
PBS	NULL
CACACCCTTTTACTCAGTETECAAAATCTCTACCAGTGGCGCCCGAACAG	NULL
a	NULL
C	NULL
GTTT	NULL
+650	NULL
IRFE/DBF	NULL
CCACTTCAAAGCCAAACTAAAGCCAGAGCACATCTCTCGACGCAGCACTC	NULL
eee	NULL
-	NULL
cec	NULL
sD	NULL
+700	NULL
Spl	NULL
Sp1	NULL
COCTTecrcaaGcocecAcGecAaacaGeccacecccecccactdercact	NULL
TT	NULL
TT	NULL
TT	NULL
+750	NULL
TT	NULL
T	NULL
T	NULL
GAG	NULL
ACCCCAAAAATTTTCACTAGCGCAGGCTACGAACGCGACACACATGGCTGCCA	NULL
+800	NULL
GAGCGTCGCTATTAAGCGGGGCACAATTAGATAAATCGGAAAAAATTCGG	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

Cell	NULL
lines	NULL
(	NULL
obtained	NULL
from	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Be-thesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

were	NULL
grown	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
95	NULL
%	NULL
air-5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
HyClone	NULL
)	NULL
,	NULL
50	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
mg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
glutamine	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
buffy	NULL
coats	NULL
(	NULL
New	NULL
York	NULL
Blood	NULL
Center	NULL
,	NULL
Melville	NULL
,	NULL
N.Y.	NULL
)	NULL
by	NULL
density	NULL
centrifugation	NULL
on	NULL
a	NULL
Ficoll-Hypaque	NULL
gradient	NULL
(	NULL
Pharmacia	NULL
,	NULL
Upp-sala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

Virus	NULL
production	NULL
assay	NULL
.	NULL

HIV-1	NULL
production	NULL
was	NULL
measured	NULL
by	NULL
determining	NULL
p24	NULL
antigen	NULL
secretion	NULL
in	NULL
culture	NULL
supernatants	NULL
by	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
NEN	NULL
,	NULL
Dupont	NULL
)	NULL
.	NULL

Reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
microassay	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
HS4	NULL
binding	NULL
sites	NULL
.	NULL

A	NULL
NerI-SpAI	NULL
fragment	NULL
containing	NULL
nt	NULL
1	NULL
to	NULL
1447	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
was	NULL
obtained	NULL
after	NULL
partial	NULL
digestion	NULL
with	NULL
NarT	NULL
and	NULL
complete	NULL
digestion	NULL
with	NULL
SphI	NULL
of	NULL
pNLA-3	NULL
(	NULL
2	NULL
)	NULL
(	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
)	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
subcloned	NULL
into	NULL
pUC19	NULL
digested	NULL
with	NULL
Nel	NULL
and	NULL
SphI	NULL
to	NULL
generate	NULL
pEV47	NULL
.	NULL

This	NULL
plasmid	NULL
was	NULL
used	NULL
as	NULL
a	NULL
substrate	NULL
for	NULL
the	NULL
mutagenesis	NULL
of	NULL
the	NULL
HS4	NULL
binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Mutagenesis	NULL
was	NULL
performed	NULL
on	NULL
double-stranded	NULL
plasmids	NULL
by	NULL
the	NULL
Transformer	NULL
site-directed	NULL
mu	NULL
US	NULL
650	NULL
750	NULL
nt	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Chromatin	NULL
organization	NULL
of	NULL
the	NULL
5	NULL
'	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
.	NULL

(	NULL
A	NULL
)	NULL
DNase	NULL
I-hypersensitive	NULL
sites	NULL
HS2	NULL
,	NULL
HS3	NULL
,	NULL
and	NULL
HS4	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
are	NULL
aligned	NULL
with	NULL
cis-acting	NULL
elements	NULL
and	NULL
nucleosome	NULL
positioning	NULL
in	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
.	NULL

The	NULL
location	NULL
of	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
at	NULL
the	NULL
U3-R	NULL
junction	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transcription	NULL
factor	NULL
binding	NULL
sites	NULL
and	NULL
the	NULL
mutations	NULL
introduced	NULL
are	NULL
shown	NULL
in	NULL
reference	NULL
to	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
.	NULL

Several	NULL
landmarks	NULL
(	NULL
TAR	NULL
,	NULL
PBS	NULL
[	NULL
primer	NULL
binding	NULL
site	NULL
]	NULL
,	NULL
SD	NULL
[	NULL
splice	NULL
donor	NULL
]	NULL
,	NULL
and	NULL
GAG	NULL
[	NULL
beginning	NULL
of	NULL
the	NULL
GAG	NULL
open	NULL
reading	NULL
frame	NULL
]	NULL
)	NULL
are	NULL
shown	NULL
for	NULL
reference	NULL
.	NULL

tagenesis	NULL
method	NULL
(	NULL
CLONTECH	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Six	NULL
different	NULL
mutations	NULL
were	NULL
generated	NULL
with	NULL
each	NULL
of	NULL
the	NULL
following	NULL
mutagenic	NULL
oligonucleotides	NULL
(	NULL
mutations	NULL
are	NULL
highlighted	NULL
in	NULL
bold	NULL
)	NULL
:	NULL
EV244	NULL
(	NULL
ADBF	NULL
)	NULL
,	NULL
5'-CGCCCGAACAGGGACITTGCCCG	NULL
CGCCCGTAAAGCCAGAGGAGATC-3	NULL
'	NULL
;	NULL
EV271	NULL
(	NULL
AAP3-L	NULL
)	NULL
,	NULL
5CAGACCCIT	NULL
TTAGTCAGTGGTTTAAATCTCTAGCAGTGGCG-3	NULL
'	NULL
;	NULL
EV270	NULL
[	NULL
AAP-1	NULL
(	NULL
IMY	NULL
AP3-L	NULL
]	NULL
,	NULL
5-CCTCAGACCCTITTGTAGGCAGTGGTTTIAAATCTCTAGCAGT	NULL
G-3	NULL
'	NULL
;	NULL
EV269	NULL
[	NULL
AAP-1	NULL
(	NULL
LILIMMN	NULL
)	NULL
/AP3-LJ	NULL
]	NULL
,	NULL
5°CAATAAAGCTTGCCTGGAGGGCT	NULL
CAAAGTAGTGTGTGCCCGTCTGTGGTGGGACGCTGGTAACTAGAGA	NULL
TCCCTCAGACCCTTGTAGGCAGTGGTTITAAATCTCTAGCAGTG-3	NULL
'	NULL
;	NULL
EV337	NULL
(	NULL
APS/SP1	NULL
)	NULL
,	NULL
55GAGGAGATCTCTCGAAGAAGGACTCGGCTTGCTG	NULL
AAGCGCGCACGGCAAGATTCGAGGTICTICGACTGGTGAGTACGCC	NULL
AAAA-3	NULL
'	NULL
;	NULL
and	NULL
EV336	NULL
(	NULL
ASP1	NULL
)	NULL
,	NULL
SAAGCGCGCACGGCAAGATTCGAGGTG	NULL
CGTCGACTGGTGAGTACGCCAAAA-3	NULL
'	NULL
.	NULL

The	NULL
oligonucleotide	NULL
5'-CTGAGA	NULL
GTGCACCATGGGCGGTGTGAAATACCG-3	NULL
'	NULL
,	NULL
changing	NULL
a	NULL
unique	NULL
Ndel	NULL
restriction	NULL
site	NULL
in	NULL
pEV47	NULL
into	NULL
a	NULL
Ncol	NULL
site	NULL
(	NULL
highlighted	NULL
in	NULL
bold	NULL
)	NULL
,	NULL
was	NULL
used	NULL
for	NULL
selection	NULL
during	NULL
mutagenesis	NULL
.	NULL

Mutated	NULL
clones	NULL
were	NULL
identified	NULL
by	NULL
cycle	NULL
sequencing	NULL
(	NULL
Applied	NULL
Biosystems	NULL
)	NULL
and	NULL
were	NULL
fully	NULL
resequenced	NULL
between	NULL
Mrol	NULL
and	NULL
BssHII	NULL
or	NULL
between	NULL
Mrol	NULL
and	NULL
SphI	NULL
(	NULL
see	NULL
below	NULL
)	NULL
after	NULL
identification	NULL
.	NULL

The	NULL
six	NULL
mutated	NULL
plasmids	NULL
were	NULL
designated	NULL
pADBF	NULL
,	NULL
pAAP3-L	NULL
,	NULL
pAAP-1	NULL
(	NULL
LIL	NULL
,	NULL
IT	NULL
)	NULL
AP3-L	NULL
,	NULL
pAPS/SP1	NULL
,	NULL
and	NULL
pASP1	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
three	NULL
constructs	NULL
containing	NULL
combinations	NULL
of	NULL
the	NULL
mutations	NULL
described	NULL
above	NULL
were	NULL
generated	NULL
by	NULL
sub-cloning	NULL
a	NULL
NarI-NarT	NULL
fragment	NULL
from	NULL
pAAP3-L	NULL
,	NULL
pAAP-1	NULL
(	NULL
IIN	NULL
)	NULL
/AP3-L	NULL
,	NULL
and	NULL
pAAP-1	NULL
(	NULL
LILID	NULL
)	NULL
/AP3-L	NULL
into	NULL
pADBF	NULL
digested	NULL
with	NULL
NarL	NULL
.	NULL

The	NULL
resulting	NULL
plasmids	NULL
were	NULL
designated	NULL
pAAP3-L/DBF	NULL
,	NULL
pAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L/DBF	NULL
,	NULL
and	NULL
pAAP-1	NULL
(	NULL
LIL	NULL
L/DBF	NULL
,	NULL
respectively	NULL
.	NULL

Construction	NULL
of	NULL
infectious	NULL
proviruses	NULL
containing	NULL
the	NULL
HS4	NULL
mutations	NULL
.	NULL

The	NULL
mutagenized	NULL
fragments	NULL
from	NULL
the	NULL
pEV47	NULL
recombinants	NULL
were	NULL
reintroduced	NULL
into	NULL
a	NULL
circularly	NULL
permuted	NULL
infectious	NULL
molecular	NULL
clone	NULL
of	NULL
HIV-1	NULL
,	NULL
pILIC	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
A.	NULL
Rabson	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
an	NULL
unmutated	NULL
Mrol-SpHI	NULL
(	NULL
nt	NULL
308	NULL
to	NULL
1447	NULL
)	NULL
fragment	NULL
was	NULL
purified	NULL
from	NULL
pEV47	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
unique	NULL
Mrol-SpAI	NULL
sites	NULL
of	NULL
pILIC8	NULL
.	NULL

We	NULL
refer	NULL
to	NULL
this	NULL
construct	NULL
(	NULL
a	NULL
derivative	NULL
of	NULL
pILIC	NULL
)	NULL
as	NULL
pHIV	NULL
.	NULL

A	NULL
Mrol-BssHII	NULL
fragment	NULL
(	NULL
nt	NULL
308	NULL
to	NULL
711	NULL
)	NULL
from	NULL
pADBF	NULL
,	NULL
pAAP3-L	NULL
,	NULL
pAAP-1	NULL
(	NULL
IIND	NULL
)	NULL
/AP3-L	NULL
,	NULL
and	NULL
pAAP-1	NULL
(	NULL
L	NULL
,	NULL
II	NULL
,	NULL
IID	NULL
)	NULL
/AP3-L	NULL
was	NULL
introduced	NULL
into	NULL
the	NULL
unique	NULL
Mrol-BssHII	NULL
sites	NULL
of	NULL
pILIC19	NULL
to	NULL
generate	NULL
pHIVADBF	NULL
,	NULL
pHIVAAP3-L	NULL
,	NULL
pHIVAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L	NULL
,	NULL
and	NULL
pHIVAAP-1	NULL
(	NULL
LILIIN	NULL
)	NULL
/AP3-L	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
Mrol-SpHI	NULL
fragment	NULL
(	NULL
nt	NULL
308	NULL
to	NULL
1447	NULL
)	NULL
from	NULL
pAPS/	NULL
SP1	NULL
and	NULL
pASP1	NULL
was	NULL
introduced	NULL
into	NULL
the	NULL
unique	NULL
Mrol-SpAI	NULL
sites	NULL
of	NULL
pHIV	NULL
to	NULL
generate	NULL
pHIVAPS/SP1	NULL
and	NULL
pHIVASP1	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
Mrol-BssHII	NULL
fragment	NULL
(	NULL
nt	NULL
308	NULL
to	NULL
711	NULL
)	NULL
from	NULL
pAAP3-L/DBF	NULL
,	NULL
pAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L/DBF	NULL
,	NULL
and	NULL
pAAP-1	NULL
(	NULL
LII	NULL
,	NULL
IID	NULL
)	NULL
/AP3-L/DBF	NULL
was	NULL
introduced	NULL
into	NULL
the	NULL
unique	NULL
Mrol-BssHII	NULL
sites	NULL
of	NULL
pHIV	NULL
to	NULL
generate	NULL
pHIVAAP3-L/DBF	NULL
,	NULL
pHIVAAP-1	NULL
(	NULL
IIT	NULL
)	NULL
/AP3-L/DBF	NULL
,	NULL
and	NULL
pHIVAAP-1	NULL
(	NULL
I	NULL
,	NULL
IL	NULL
ID	NULL
)	NULL
/AP3-L/DBF	NULL
,	NULL
respectively	NULL
.	NULL

Generation	NULL
of	NULL
viral	NULL
stocks	NULL
.	NULL

Wild-type	NULL
and	NULL
mutant	NULL
HIV-1	NULL
infectious	NULL
DNAs	NULL
were	NULL
generated	NULL
from	NULL
the	NULL
single-LTR-containing	NULL
proviral	NULL
constructs	NULL
described	NULL
above	NULL
by	NULL
BamHI	NULL
digestion	NULL
and	NULL
self-ligation	NULL
.	NULL

These	NULL
concatemerized	NULL
proviral	NULL
DNAs	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
10	NULL
``	NULL
JE6.1	NULL
cells	NULL
(	NULL
a	NULL
clonal	NULL
line	NULL
of	NULL
Jurkat	NULL
cells	NULL
)	NULL
by	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
(	NULL
44	NULL
,	NULL
64	NULL
)	NULL
.	NULL

At	NULL
24	NULL
h	NULL
posttransfection	NULL
,	NULL
the	NULL
cultures	NULL
were	NULL
cocultivated	NULL
with	NULL
10	NULL
``	NULL
SupT1	NULL
cells	NULL
to	NULL
allow	NULL
rapid	NULL
and	NULL
efficient	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
-	NULL
6115	NULL
TABLE	NULL
1	NULL
.	NULL

Oligonucleotides	NULL
used	NULL
in	NULL
EMSA	NULL
experiments	NULL
Name	NULL
Oligonucleotide	NULL
sequence	NULL
Source	NULL
and	NULL
genomic	NULL
position	NULL
Reference	NULL
AP-1	NULL
(	NULL
Dwt	NULL
5-TGCCITGAGTGCTCAAA-3	NULL
'	NULL
HIV-1n	NULL
,	NULL
,	NULL
;	NULL
ut	NULL
536-552	NULL
This	NULL
study	NULL
AP-1	NULL
(	NULL
Dmut	NULL
5-TGCCTGGAGGGCTCAAA-3	NULL
``	NULL
ut	NULL
536-552	NULL
This	NULL
study	NULL
AP-1	NULL
(	NULL
WMwt	NULL
5-TCTGITGTGTGACTCTG-3	NULL
'	NULL
;	NULL
ut	NULL
567-583	NULL
This	NULL
study	NULL
5-TCTGTGGTGGGACGCTG-3	NULL
'	NULL
HIV-1n	NULL
;	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
567-583	NULL
This	NULL
study	NULL
AP-1	NULL
(	NULL
ID	NULL
)	NULL
wt	NULL
5-CCCTTTTAGTCAGTGTG-3	NULL
'	NULL
HIV-1~	NULL
,	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
604-620	NULL
This	NULL
study	NULL
5-CCCTTGTAGGCAGTGTG-3	NULL
'	NULL
HIV-1n	NULL
;	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
604-620	NULL
This	NULL
study	NULL
AP3-L	NULL
wt	NULL
5-TCAGTGTGGAAAATCTCTAGCA-3	NULL
'	NULL
;	NULL
ut	NULL
613-634	NULL
This	NULL
study	NULL
AP3-L	NULL
mut	NULL
5-TCAGTGGTTTAAATCTCTAGCA-3	NULL
'	NULL
HIV-1n	NULL
;	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
613-634	NULL
This	NULL
study	NULL
AP	NULL
-3avan	NULL
5-CTACTGGGACTTITTCCACACATC-3	NULL
'	NULL
SV40	NULL
enhancer	NULL
56	NULL
NF-AT	NULL
;	NULL
5-AGAAAGGAGGAAAAACTGTITCATACAGAAGGCGT-3	NULL
'	NULL
IL-2	NULL
promoter	NULL
8	NULL
NF-AT	NULL
,	NULL
,	NULL
,	NULL
mut	NULL
5-AGAAAGGACCITTAAACTGTTTCATACAGAAGGCGT-3	NULL
'	NULL
IL-2	NULL
promoter	NULL
8	NULL
DBF	NULL
wt	NULL
5'-AGGGACTTGAAAGCGAAAGTAAAGCCAGAG-3	NULL
'	NULL
HIV-1n	NULL
;	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
648-678	NULL
This	NULL
study	NULL
DBF	NULL
mut	NULL
5'-AGGGACITTGCCCGCGCCCGTAAAGCCAGAG-3	NULL
'	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
648-678	NULL
This	NULL
study	NULL
ISREpgq1sWt	NULL
5-GATCCTCGGGAAAGGGAAACCGAAACTGAAGCC-3	NULL
'	NULL
ISG15	NULL
gene	NULL
9	NULL
RE	NULL
,	NULL
,	NULL
s	NULL
Mut	NULL
5-GATCCTCGGGAAAGGGAGGCCGAGGCTGAAGCC-3	NULL
'	NULL
ISG15	NULL
gene	NULL
9	NULL
Splwt	NULL
5-CGGCAAGAGGCGAGGGGCGGCGACTGGTGAG-3	NULL
'	NULL
HIV-1n	NULL
;	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
718-748	NULL
This	NULL
study	NULL
Splmut1	NULL
5-CGGCAAGATTCGAGGTTCITCGACTGGTGAG-3	NULL
'	NULL
HIV-1y	NULL
,	NULL
,	NULL
;	NULL
at	NULL
718-718	NULL
This	NULL
study	NULL
Splmut2	NULL
5-CGGCAAGATTCGAGGTGCGTCGACTGGTGAG-3	NULL
HIV-1n	NULL
;	NULL
,	NULL
.	NULL

;	NULL
ut	NULL
718-748	NULL
This	NULL
study	NULL
recovery	NULL
of	NULL
progeny	NULL
virus	NULL
.	NULL

Virus	NULL
stocks	NULL
were	NULL
prepared	NULL
from	NULL
supernatants	NULL
after	NULL
filtration	NULL
through	NULL
a	NULL
0.45-wm-pore-size	NULL
membrane	NULL
when	NULL
[	NULL
°HJRT	NULL
levels	NULL
exceeded	NULL
3,500	NULL
epm/pl	NULL
.	NULL

Stocks	NULL
were	NULL
quantified	NULL
by	NULL
determining	NULL
both	NULL
RT	NULL
activity	NULL
and	NULL
p24	NULL
concentration	NULL
.	NULL

Viral	NULL
infections	NULL
.	NULL

Infections	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
0.5	NULL
X	NULL
10°	NULL
cells	NULL
with	NULL
500,000	NULL
cpm	NULL
of	NULL
RT	NULL
activity	NULL
of	NULL
wild-type	NULL
or	NULL
mutant	NULL
viruses	NULL
(	NULL
at	NULL
37°C	NULL
for	NULL
2	NULL
h	NULL
in	NULL
500	NULL
pl	NULL
of	NULL
culture	NULL
medium	NULL
)	NULL
.	NULL

After	NULL
infection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
pelleted	NULL
at	NULL
300	NULL
x	NULL
g	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
1	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
,	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
standard	NULL
medium	NULL
,	NULL
and	NULL
grown	NULL
under	NULL
standard	NULL
conditions	NULL
.	NULL

Every	NULL
2	NULL
or	NULL
3	NULL
days	NULL
,	NULL
aliquots	NULL
of	NULL
200	NULL
ul	NULL
were	NULL
removed	NULL
from	NULL
the	NULL
infected	NULL
cultures	NULL
and	NULL
replaced	NULL
by	NULL
normal	NULL
medium	NULL
.	NULL

The	NULL
aliquots	NULL
were	NULL
assayed	NULL
for	NULL
RT	NULL
activity	NULL
following	NULL
centrifugation	NULL
(	NULL
800	NULL
x	NULL
g	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
viral	NULL
replication	NULL
were	NULL
monitored	NULL
by	NULL
a	NULL
[	NULL
°HJRT	NULL
assay	NULL
(	NULL
3	NULL
)	NULL
.	NULL

For	NULL
PBMC	NULL
infections	NULL
,	NULL
PBMCs	NULL
were	NULL
isolated	NULL
from	NULL
normal	NULL
donors	NULL
,	NULL
activated	NULL
with	NULL
phytohe-magglutinin	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

(	NULL
5	NULL
pg/ml	NULL
)	NULL
for	NULL
2	NULL
days	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
RPMI	NULL
,	NULL
infected	NULL
as	NULL
described	NULL
above	NULL
,	NULL
and	NULL
maintained	NULL
in	NULL
complete	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
20	NULL
U	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Sequence	NULL
analysis	NULL
of	NULL
HIV-1	NULL
genomic	NULL
RNA	NULL
.	NULL

Viral	NULL
particles	NULL
from	NULL
each	NULL
stock	NULL
were	NULL
pelleted	NULL
by	NULL
ultracentrifugation	NULL
(	NULL
1,500,000	NULL
cpm	NULL
of	NULL
RT	NULL
at	NULL
20,000	NULL
x	NULL
g	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
)	NULL
and	NULL
digested	NULL
with	NULL
RNase-free	NULL
DNase	NULL
I	NULL
(	NULL
60	NULL
U/ml	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
[	NULL
Boehringer	NULL
Mannheim	NULL
]	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RNasin	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
to	NULL
remove	NULL
contaminating	NULL
DNA	NULL
.	NULL

HIV-1	NULL
genomic	NULL
RNA	NULL
was	NULL
purified	NULL
with	NULL
Trizol	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
.	NULL

Oligo	NULL
(	NULL
dT	NULL
)	NULL
-primed	NULL
cDNA	NULL
synthesis	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
Gene	NULL
Amp	NULL
RNA	NULL
PCR	NULL
kit	NULL
method	NULL
(	NULL
Perkin-Elmer	NULL
)	NULL
.	NULL

cDNAs	NULL
were	NULL
amplified	NULL
by	NULL
PCR	NULL
with	NULL
a	NULL
5	NULL
'	NULL
oligonucleotide	NULL
primer	NULL
corresponding	NULL
to	NULL
nt	NULL
489	NULL
to	NULL
510	NULL
(	NULL
5'-AGCTCTCTG	NULL
GCTAACTAGGGAAC-3	NULL
'	NULL
)	NULL
and	NULL
a	NULL
3	NULL
'	NULL
primer	NULL
corresponding	NULL
to	NULL
nt	NULL
793	NULL
to	NULL
814	NULL
(	NULL
5'-TTAATACCGACGCTCTCGCACC-3	NULL
'	NULL
)	NULL
.	NULL

PCR	NULL
fragments	NULL
were	NULL
subcloned	NULL
into	NULL
the	NULL
vector	NULL
pCR2.1	NULL
(	NULL
TA	NULL
cloning	NULL
kit	NULL
;	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

After	NULL
identification	NULL
of	NULL
recombinant	NULL
clones	NULL
,	NULL
five	NULL
inserts	NULL
from	NULL
each	NULL
construct	NULL
were	NULL
sequenced	NULL
with	NULL
the	NULL
PRISM	NULL
dye	NULL
terminator	NULL
cycle-sequencing	NULL
kit	NULL
(	NULL
Applied	NULL
Biosys-tems	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
Calif	NULL
)	NULL
.	NULL

The	NULL
nucleotide	NULL
sequences	NULL
of	NULL
all	NULL
five	NULL
clones	NULL
were	NULL
identical	NULL
and	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
original	NULL
mutations	NULL
.	NULL

Western	NULL
immunoblot	NULL
analysis	NULL
.	NULL

HIV-1	NULL
lysates	NULL
were	NULL
prepared	NULL
by	NULL
ultracentrifugation	NULL
of	NULL
each	NULL
virus	NULL
stock	NULL
and	NULL
resuspension	NULL
of	NULL
pellets	NULL
in	NULL
Laemmli	NULL
buffer	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
30,000	NULL
cpm	NULL
of	NULL
RT/pl	NULL
.	NULL

Lysates	NULL
were	NULL
heated	NULL
at	NULL
95°C	NULL
for	NULL
5	NULL
min	NULL
,	NULL
separated	NULL
by	NULL
electrophoresis	NULL
on	NULL
an	NULL
8	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
nitro-cellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
a	NULL
1:2,000	NULL
dilution	NULL
of	NULL
purified	NULL
human	NULL
anti-HIV-1	NULL
immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
(	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
AIDS	NULL
Research	NULL
and	NULL
Reagent	NULL
Program	NULL
no	NULL
.	NULL

192	NULL
)	NULL
.	NULL

A	NULL
second	NULL
antibody	NULL
,	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-human	NULL
IgG	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
III	NULL
.	NULL
)	NULL

(	NULL
diluted	NULL
1:10,000	NULL
)	NULL
was	NULL
used	NULL
for	NULL
enhanced	NULL
chemiluminescence	NULL
detection	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

RNase	NULL
protection	NULL
analysis	NULL
.	NULL

HIV-1-specific	NULL
transcripts	NULL
were	NULL
detected	NULL
by	NULL
RNase	NULL
protection	NULL
analysis	NULL
after	NULL
lysis	NULL
of	NULL
cells	NULL
in	NULL
guanidine	NULL
thiocyanate	NULL
(	NULL
23	NULL
)	NULL
(	NULL
lysate	NULL
ribonuclease	NULL
protection	NULL
kit	NULL
;	NULL
U.S.	NULL
Biochemical	NULL
Corp.	NULL
)	NULL
.	NULL

An	NULL
HIV-1-specific	NULL
*°P-labeled	NULL
antisense	NULL
riboprobe	NULL
was	NULL
synthesized	NULL
in	NULL
vitro	NULL
by	NULL
transcription	NULL
of	NULL
pGEM23	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
M.	NULL
Laspia	NULL
)	NULL
(	NULL
43	NULL
)	NULL
with	NULL
SP6	NULL
polymerase	NULL
by	NULL
standard	NULL
methods	NULL
(	NULL
5	NULL
)	NULL
.	NULL

A	NULL
glycer-aldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
-specific	NULL
antisense	NULL
probe	NULL
(	NULL
pro-vided	NULL
with	NULL
the	NULL
lysate	NULL
ribonuclease	NULL
protection	NULL
kit	NULL
)	NULL
was	NULL
synthesized	NULL
by	NULL
the	NULL
same	NULL
method	NULL
and	NULL
used	NULL
on	NULL
the	NULL
same	NULL
cell	NULL
lysates	NULL
.	NULL

For	NULL
HIV-1	NULL
genomic	NULL
RNA	NULL
analysis	NULL
,	NULL
viral	NULL
particles	NULL
from	NULL
each	NULL
stock	NULL
were	NULL
pelleted	NULL
by	NULL
ultracentrifugation	NULL
(	NULL
1,500,000	NULL
cpm	NULL
of	NULL
RT	NULL
at	NULL
20,000	NULL
x	NULL
g	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
)	NULL
and	NULL
lysed	NULL
in	NULL
guanidine	NULL
thiocyanate	NULL
.	NULL

Viral	NULL
RNA	NULL
was	NULL
then	NULL
detected	NULL
with	NULL
the	NULL
HIV-1	NULL
riboprobe	NULL
described	NULL
above	NULL
.	NULL

EMSAs	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
nuclei	NULL
by	NULL
a	NULL
rapid	NULL
method	NULL
described	NULL
by	NULL
Osborn	NULL
(	NULL
58	NULL
)	NULL
.	NULL

All	NULL
buffers	NULL
contained	NULL
the	NULL
protease	NULL
inhibitors	NULL
antipain	NULL
(	NULL
10	NULL
ug/l	NULL
)	NULL
,	NULL
aprotinin	NULL
(	NULL
2	NULL
pg/ml	NULL
)	NULL
,	NULL
chymostatin	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
leupeptin	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
,	NULL
and	NULL
pepstatin	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Bradford	NULL
(	NULL
10	NULL
)	NULL
with	NULL
bovine	NULL
plasma	NULL
gamma	NULL
globulin	NULL
as	NULL
a	NULL
standard	NULL
.	NULL

The	NULL
DNA	NULL
sequences	NULL
of	NULL
the	NULL
coding	NULL
strands	NULL
of	NULL
oligonucleotides	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
listed	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
79	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
with	NULL
purified	NULL
Sp1	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nonspecific	NULL
competitor	NULL
DNA	NULL
as	NULL
specified	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
polyclonal	NULL
antibodies	NULL
against	NULL
Stat1	NULL
and	NULL
Stat2	NULL
(	NULL
gifts	NULL
from	NULL
Chris	NULL
Schindler	NULL
)	NULL
or	NULL
rabbit	NULL
preimmune	NULL
serum	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding-reaction	NULL
mixture	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
centrifuged	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
run	NULL
on	NULL
an	NULL
acrylamide	NULL
gel	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

Monoclonal	NULL
anti-IRF-1	NULL
and	NULL
anti-IRF-2	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
Bio-chemicals	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
were	NULL
used	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
with	NULL
a	NULL
purified	NULL
rabbit	NULL
IgG	NULL
as	NULL
the	NULL
control	NULL
(	NULL
gift	NULL
from	NULL
Christine	NULL
Metz	NULL
)	NULL
.	NULL

Transient-transfection	NULL
and	NULL
luciferase	NULL
assays	NULL
.	NULL

To	NULL
reintroduce	NULL
the	NULL
HS4	NULL
mutations	NULL
in	NULL
a	NULL
luciferase	NULL
reporter	NULL
system	NULL
,	NULL
PCR	NULL
was	NULL
used	NULL
to	NULL
amplify	NULL
the	NULL
promoter	NULL
region	NULL
(	NULL
nt	NULL
1	NULL
to	NULL
792	NULL
)	NULL
from	NULL
the	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
and	NULL
HS4	NULL
mutant	NULL
proviral	NULL
DNAs	NULL
described	NULL
above	NULL
.	NULL

KpnI	NULL
and	NULL
Xbal	NULL
sites	NULL
were	NULL
introduced	NULL
into	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
PCR	NULL
primers	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
the	NULL
KprI-Xbal-restricted	NULL
PCR	NULL
fragments	NULL
were	NULL
cloned	NULL
in	NULL
pGL2-BASIC	NULL
(	NULL
Promega	NULL
)	NULL
digested	NULL
with	NULL
KpnI	NULL
and	NULL
NheI	NULL
.	NULL

The	NULL
5	NULL
primer	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
nt	NULL
1	NULL
to	NULL
25	NULL
(	NULL
coordinates	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
BRU	NULL
provirus	NULL
)	NULL
contained	NULL
an	NULL
added	NULL
KprI	NULL
site	NULL
(	NULL
in	NULL
bold	NULL
)	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
(	NULL
5'-CGGGGTA	NULL
CCT	NULL
``	NULL
``	NULL
GGAAGGGCTAATTCACTCCCAACG-3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
3	NULL
'	NULL
primer	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
nt	NULL
769	NULL
to	NULL
788	NULL
contained	NULL
an	NULL
added	NULL
Xbel	NULL
site	NULL
(	NULL
in	NULL
bold	NULL
)	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
(	NULL
5'-GCTCTAGAC*°TCTCTCCTTCTAGCCTCCGC-3	NULL
'	NULL
)	NULL
.	NULL

Amplification	NULL
reactions	NULL
were	NULL
conducted	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
plasmid	NULL
DNA	NULL
as	NULL
specified	NULL
in	NULL
the	NULL
protocol	NULL
provided	NULL
with	NULL
the	NULL
high-fidelity	NULL
Pfu	NULL
DNA	NULL
polymerase	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
with	NULL
a	NULL
DNA	NULL
thermal	NULL
cycler	NULL
480	NULL
(	NULL
Perkin-Elmer	NULL
Cetus	NULL
)	NULL
.	NULL

Recombinant	NULL
plasmids	NULL
containing	NULL
the	NULL
wild-type	NULL
or	NULL
mutated	NULL
HS4	NULL
binding	NULL
sites	NULL
were	NULL
designated	NULL
pLTRluc	NULL
,	NULL
pLTRADBF	NULL
,	NULL
pLTRAAP3-L	NULL
,	NULL
pLTRAAP1	NULL
(	NULL
IIN	NULL
)	NULL
/AP3-L	NULL
,	NULL
pLTRAAP1	NULL
(	NULL
I	NULL
ILIIIY/AP3-L	NULL
,	NULL
pLTRAAP3-L/DBF	NULL
,	NULL
pLTRAAP1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L/DBF	NULL
,	NULL
pLTRAAP1	NULL
(	NULL
LIL	NULL
IM	NULL
)	NULL
/AP3-L/DBF	NULL
,	NULL
pLTRAPS/SP1	NULL
,	NULL
and	NULL
pLTRASP1	NULL
.	NULL

For	NULL
transfection	NULL
experiments	NULL
,	NULL
3	NULL
X	NULL
10°	NULL
exponentially	NULL
growing	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
150	NULL
ng	NULL
of	NULL
the	NULL
LTR-luciferase	NULL
construct	NULL
DNA	NULL
mixed	NULL
with	NULL
80	NULL
ng	NULL
of	NULL
pTatZex	NULL
DNA	NULL
,	NULL
a	NULL
Tat-expressing	NULL
vector	NULL
(	NULL
59	NULL
)	NULL
,	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
79	NULL
)	NULL
.	NULL

All	NULL
transfection	NULL
mixtures	NULL
also	NULL
contained	NULL
4	NULL
ng	NULL
of	NULL
pRL-TK	NULL
in	NULL
which	NULL
a	NULL
cDNA	NULL
encoding	NULL
Renilla	NULL
luciferase	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
region	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

At	NULL
24	NULL
h	NULL
posttransfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buiffered	NULL
saline	NULL
,	NULL
and	NULL
luciferase	NULL
enzyme	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
the	NULL
dual-luciferase	NULL
assay	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
with	NULL
a	NULL
luminometer	NULL
(	NULL
Turner	NULL
Designs	NULL
luminometer	NULL
[	NULL
Promega	NULL
]	NULL
)	NULL
.	NULL

Luciferase	NULL
activities	NULL
derived	NULL
from	NULL
the	NULL
HIV	NULL
promoter	NULL
are	NULL
normalized	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
Renilla	NULL
luciferase	NULL
activity	NULL
by	NULL
using	NULL
the	NULL
dual-luciferase	NULL
reporter	NULL
assay	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Eight	NULL
independent	NULL
transfections	NULL
were	NULL
performed	NULL
with	NULL
two	NULL
independent	NULL
plasmid	NULL
DNA	NULL
preparations	NULL
.	NULL

RESULTS	NULL
Mutagenesis	NULL
of	NULL
DNA	NULL
binding	NULL
sites	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
.	NULL

Mutations	NULL
were	NULL
designed	NULL
to	NULL
abolish	NULL
binding	NULL
of	NULL
factors	NULL
to	NULL
their	NULL
respective	NULL
sites	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
selected	NULL
6116	NULL
VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
AP-1	NULL
(	NULL
1	NULL
)	NULL
(	NULL
nt	NULL
541-547	NULL
)	NULL
TGCCTTGAGTGCTCAAA	NULL
t	NULL
1	NULL
c-	NULL
c	NULL
AP-1	NULL
(	NULL
11	NULL
)	NULL
(	NULL
nt	NULL
572-578	NULL
)	NULL
TCreTrerercacrere	NULL
``	NULL
ro-	NULL
T	NULL
-ma	NULL
1	NULL
U	NULL
U	NULL
c	NULL
e	NULL
-	NULL
c	NULL
AP-1	NULL
(	NULL
IIl	NULL
)	NULL
(	NULL
nt	NULL
609-615	NULL
)	NULL
cecmPrracrcacrere	NULL
-r	NULL
--	NULL
1	NULL
U	NULL
c-	NULL
c	NULL
c	NULL
TRE	NULL
ATGAGTCAC	NULL
T	NULL
PCC	NULL
aA	NULL
AP-1	NULL
(	NULL
Dwt	NULL
AP-1	NULL
(	NULL
)	NULL
mut	NULL
competitor	NULL
_	NULL
_	NULL
-_	NULL
TPA	NULL
_	NULL
-	NULL
+	NULL
+	NULL
4+	NULL
4+	NULL
4+	NULL
4+	NULL
4	NULL
4+	NULL
4	NULL
4	NULL
4	NULL
+	NULL
-+	NULL
|	NULL
<	NULL
>	NULL
dalla	NULL
tug	NULL
tue	NULL
ae	NULL
>	NULL
but	NULL
tub	NULL
tub	NULL
tut	NULL
tut	NULL
tat	NULL
tt	NULL
tt	NULL
by	NULL
ba	NULL
bo	NULL
»	NULL
»	NULL
-	NULL
tub	NULL
tt	NULL
tab	NULL
tab	NULL
tt	NULL
tt	NULL
AP-1	NULL
(	NULL
IDwt	NULL
AP-1	NULL
(	NULL
Imut	NULL
competitor	NULL
TPA	NULL
-	NULL
ot	NULL
t	NULL
t	NULL
t	NULL
4	NULL
to	NULL
to	NULL
t	NULL
4+	NULL
4+	NULL
4+	NULL
+	NULL
#	NULL
--	NULL
»	NULL
.	NULL

i	NULL
>	NULL
d	NULL
dg	NULL
ty	NULL
hat	NULL
i	NULL
tarp	NULL
tuh	NULL
tu	NULL
tuh	NULL
tah	NULL
tat	NULL
(	NULL
huh	NULL
hak	NULL
lark	NULL
tth	NULL
hat	NULL
is	NULL
:	NULL
-	NULL
>	NULL
th	NULL
tanh	NULL
tu	NULL
task	NULL
tut	NULL
to	NULL
AP-1	NULL
(	NULL
IIMD	NULL
)	NULL
wt	NULL
AP-1	NULL
(	NULL
Il	NULL
)	NULL
mut	NULL
competitor	NULL
_	NULL
_	NULL
_-TPA	NULL
-	NULL
ot	NULL
t	NULL
t+	NULL
t	NULL
4	NULL
t	NULL
to	NULL
t	NULL
4+	NULL
t	NULL
+o	NULL
+	NULL
-	NULL
_-	NULL
by	NULL
be	NULL
be	NULL
bg	NULL
bt	NULL
is	NULL
oue	NULL
C	NULL
ta	NULL
tuk	NULL
n	NULL
<	NULL
+	NULL
tuk	NULL
tat	NULL
Tuk	NULL
tah	NULL
but	NULL
=~	NULL
mutations	NULL
on	NULL
binding	NULL
affinity	NULL
was	NULL
analyzed	NULL
by	NULL
competition	NULL
EMSAs	NULL
.	NULL

(	NULL
i	NULL
)	NULL
AP-1	NULL
sites	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
binding	NULL
of	NULL
the	NULL
AP-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
has	NULL
been	NULL
extensively	NULL
characterized	NULL
,	NULL
and	NULL
mutations	NULL
abolishing	NULL
the	NULL
binding	NULL
of	NULL
AP-1	NULL
to	NULL
DNA	NULL
have	NULL
been	NULL
described	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Conserved	NULL
thymidine	NULL
residues	NULL
at	NULL
positions	NULL
2	NULL
and	NULL
6	NULL
were	NULL
substituted	NULL
with	NULL
guanine	NULL
residues	NULL
in	NULL
the	NULL
three	NULL
HS4	NULL
AP-1	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
these	NULL
2-bp	NULL
point	NULL
mutations	NULL
were	NULL
analyzed	NULL
by	NULL
competition	NULL
EMSAs	NULL
with	NULL
the	NULL
AP-1	NULL
(	NULL
II	NULL
)	NULL
wt	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
and	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
(	NULL
TPA	NULL
)	NULL
-induced	NULL
Jurkat	NULL
cells	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
appearance	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
was	NULL
observed	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

This	NULL
retarded	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
the	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
wt	NULL
,	NULL
AP-1	NULL
(	NULL
M	NULL
)	NULL
wt	NULL
,	NULL
or	NULL
AP-1	NULL
(	NULL
IM	NULL
)	NULL
wt	NULL
oligonu-	NULL
J.	NULL
ViRoL	NULL
.	NULL

ma	NULL
-	NULL
&	NULL
-	NULL
AP-1	NULL
(	NULL
I	NULL
>	NULL
120	NULL
(	NULL
Owt	NULL
E	NULL
-A-	NULL
AP-1	NULL
(	NULL
Dmut	NULL
g	NULL
3	NULL
60	NULL
O	NULL
Z	NULL
G	NULL
-	NULL
0	NULL
3	NULL
a	NULL
10	NULL
100	NULL
1000	NULL
Competitor	NULL
(	NULL
fold	NULL
molar	NULL
excess	NULL
)	NULL
120	NULL
-=-	NULL
AP-1	NULL
(	NULL
IMDwt	NULL
-O-	NULL
AP-1	NULL
(	NULL
IDmut	NULL
Relative	NULL
binding	NULL
(	NULL
%	NULL
)	NULL
O	NULL
©	NULL
wa	NULL
10	NULL
100	NULL
1000	NULL
Competitor	NULL
(	NULL
fold	NULL
molar	NULL
excess	NULL
)	NULL
&	NULL
100	NULL
-e-	NULL
AP-1	NULL
(	NULL
IIMDwt	NULL
a	NULL
-o-	NULL
AP-1	NULL
(	NULL
IIDmut	NULL
a	NULL
:	NULL
Be	NULL
©	NULL
Z	NULL
3	NULL
3	NULL
-	NULL
0	NULL
n	NULL
10	NULL
100	NULL
1000	NULL
Competitor	NULL
(	NULL
fold	NULL
molar	NULL
excess	NULL
)	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
HS4	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nucleotide	NULL
sequences	NULL
of	NULL
the	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
,	NULL
AP-1	NULL
(	NULL
I1	NULL
)	NULL
,	NULL
and	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
oligonucleotides	NULL
are	NULL
shown	NULL
with	NULL
underlined	NULL
bases	NULL
indicating	NULL
the	NULL
TPA-responsive	NULL
element	NULL
(	NULL
TRE	NULL
)	NULL
and	NULL
are	NULL
aligned	NULL
with	NULL
a	NULL
TRE	NULL
consensus	NULL
sequence	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
conserved	NULL
T	NULL
residues	NULL
which	NULL
were	NULL
mutagenized	NULL
into	NULL
G	NULL
residues	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
AP-1	NULL
wt	NULL
and	NULL
mutated	NULL
oligonucleotides	NULL
were	NULL
tested	NULL
in	NULL
competition	NULL
EMSAs	NULL
.	NULL

The	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
wt	NULL
oligonucleotide	NULL
was	NULL
5'-end	NULL
labeled	NULL
and	NULL
incubated	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
(	NULL
-	NULL
)	NULL
or	NULL
TPA-induced	NULL
(	NULL
+	NULL
)	NULL
(	NULL
10	NULL
ng/ml	NULL
for	NULL
2	NULL
h	NULL
)	NULL
Jurkat	NULL
cells	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
(	NULL
3-	NULL
,	NULL
9-	NULL
,	NULL
27-	NULL
,	NULL
81-	NULL
,	NULL
and	NULL
243-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
(	NULL
as	NULL
indicated	NULL
at	NULL
the	NULL
top	NULL
of	NULL
each	NULL
lane	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
appearance	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
induction	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Quantification	NULL
of	NULL
EMSAs	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
InstantImager	NULL
(	NULL
Packard	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
binding	NULL
in	NULL
comparison	NULL
to	NULL
binding	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

cleotide	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
indicating	NULL
binding	NULL
of	NULL
AP-1	NULL
to	NULL
these	NULL
sites	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
13	NULL
,	NULL
63	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
AP-1	NULL
(	NULL
ID	NULL
)	NULL
wt	NULL
,	NULL
AP-1	NULL
(	NULL
IM	NULL
)	NULL
wt	NULL
,	NULL
and	NULL
oligonucleotide	NULL
competitor	NULL
required	NULL
to	NULL
achieve	NULL
50	NULL
%	NULL
competition	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
half-maximal	NULL
binding	NULL
)	NULL
allowed	NULL
the	NULL
ranking	NULL
of	NULL
the	NULL
three	NULL
sites	NULL
with	NULL
respect	NULL
to	NULL
their	NULL
affinity	NULL
for	NULL
AP-1	NULL
:	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
>	NULL
AP-1	NULL
(	NULL
II	NULL
)	NULL
>	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
AP-1-specific	NULL
retarded	NULL
band	NULL
was	NULL
not	NULL
competed	NULL
by	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
base	NULL
substitutions	NULL
described	NULL
above	NULL
[	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
mut	NULL
,	NULL
AP-1	NULL
(	NULL
II	NULL
)	NULL
mut	NULL
,	NULL
and	NULL
AP-1	NULL
(	NULL
IID	NULL
)	NULL
mut	NULL
]	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
and	NULL
C	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
the	NULL
selected	NULL
mutations	NULL
abolished	NULL
binding	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
the	NULL
three	NULL
AP-1	NULL
sites	NULL
of	NULL
the	NULL
HS4	NULL
region	NULL
have	NULL
different	NULL
binding	NULL
affinities	NULL
,	NULL
each	NULL
of	NULL
the	NULL
mutations	NULL
abrogated	NULL
binding	NULL
of	NULL
AP-1	NULL
to	NULL
its	NULL
respective	NULL
site	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
AP3-like	NULL
site	NULL
.	NULL

Competition	NULL
experiments	NULL
with	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
consensus	NULL
AP-3	NULL
site	NULL
from	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
enhancer	NULL
(	NULL
54	NULL
,	NULL
55	NULL
,	NULL
68	NULL
)	NULL
showed	NULL
competition	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
HIV	NULL
AP3-L	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
AP-3	NULL
site	NULL
did	NULL
not	NULL
compete	NULL
as	NULL
efficiently	NULL
as	NULL
the	NULL
homologous	NULL
AP3-L	NULL
oligonucleotide	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
low-affinity	NULL
AP-3	NULL
binding	NULL
site	NULL
.	NULL

This	NULL
observation	NULL
suggested	NULL
that	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
present	NULL
in	NULL
this	NULL
complex	NULL
might	NULL
be	NULL
distinct	NULL
from	NULL
AP-3	NULL
.	NULL

To	NULL
address	NULL
this	NULL
possibility	NULL
,	NULL
EMSAs	NULL
were	NULL
performed	NULL
with	NULL
both	NULL
the	NULL
HIV-1	NULL
AP3-L	NULL
and	NULL
the	NULL
SV40	NULL
AP-3	NULL
sites	NULL
as	NULL
probes	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
or	NULL
stimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
the	NULL
AP3-L	NULL
,	NULL
,	NULL
,	NULL
y	NULL
,	NULL
probe	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
showed	NULL
that	NULL
complexes	NULL
bound	NULL
to	NULL
this	NULL
probe	NULL
increased	NULL
markedly	NULL
in	NULL
intensity	NULL
in	NULL
response	NULL
to	NULL
costimu-lation	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
compare	NULL
lane	NULL
1	NULL
with	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
or	NULL
in	NULL
response	NULL
to	NULL
anti-CD3	NULL
stimulation	NULL
alone	NULL
(	NULL
compare	NULL
lane	NULL
1	NULL
with	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
but	NULL
not	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
complex	NULL
observed	NULL
with	NULL
the	NULL
AP-35y	NULL
,	NULL
,	NULL
probe	NULL
was	NULL
induced	NULL
by	NULL
TPA	NULL
and	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
degree	NULL
by	NULL
CD3	NULL
or	NULL
CD3-plus-CD28	NULL
stimulation	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
6	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
binding	NULL
specificities	NULL
with	NULL
the	NULL
same	NULL
two	NULL
probes	NULL
(	NULL
AP3-Lyy	NULL
and	NULL
AP-33y	NULL
,	NULL
,	NULL
)	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
cell	NULL
lines	NULL
of	NULL
different	NULL
origins	NULL
(	NULL
SupT1	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
A3.01	NULL
[	NULL
CD4*	NULL
T-lymphocytic	NULL
cell	NULL
lines	NULL
]	NULL
,	NULL
HeLa	NULL
[	NULL
epithelial	NULL
cell	NULL
line	NULL
]	NULL
,	NULL
U937	NULL
and	NULL
KG-1	NULL
[	NULL
promonocytic/macrophage	NULL
cell	NULL
lines	NULL
]	NULL
,	NULL
and	NULL
Raji	NULL
and	NULL
Namalwa	NULL
[	NULL
B-lymphocytic	NULL
cell	NULL
lines	NULL
]	NULL
)	NULL
showed	NULL
distinct	NULL
patterns	NULL
of	NULL
factors	NULL
binding	NULL
the	NULL
two	NULL
different	NULL
probes	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
15	NULL
)	NULL
.	NULL

Factors	NULL
binding	NULL
to	NULL
the	NULL
AP3-L	NULL
motif	NULL
are	NULL
preferentially	NULL
expressed	NULL
in	NULL
lymphocytes	NULL
(	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
SV40	NULL
AP-3	NULL
probe	NULL
did	NULL
not	NULL
recognize	NULL
any	NULL
factors	NULL
in	NULL
uninduced	NULL
extracts	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
KG-1	NULL
and	NULL
RAJI	NULL
nuclear	NULL
extracts	NULL
.	NULL

We	NULL
conclude	NULL
from	NULL
these	NULL
experiments	NULL
that	NULL
distinct	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
HIV-1	NULL
AP3-L	NULL
and	NULL
the	NULL
SV40	NULL
AP	NULL
-3	NULL
sites	NULL
.	NULL

(	NULL
ili	NULL
)	NULL
The	NULL
AP3-L	NULL
site	NULL
binds	NULL
an	NULL
ijonomycin-inducible	NULL
factor	NULL
corresponding	NULL
to	NULL
NF-AT	NULL
.	NULL

Computer	NULL
analysis	NULL
of	NULL
the	NULL
DNA	NULL
sequence	NULL
of	NULL
the	NULL
AP3-L	NULL
motif	NULL
revealed	NULL
regions	NULL
with	NULL
close	NULL
homol-ogies	NULL
to	NULL
binding	NULL
sites	NULL
for	NULL
other	NULL
known	NULL
transcription	NULL
factors	NULL
:	NULL
AP-3	NULL
(	NULL
54	NULL
)	NULL
,	NULL
the	NULL
CD28-responsive	NULL
element	NULL
(	NULL
16	NULL
)	NULL
,	NULL
NF-IL6	NULL
(	NULL
71	NULL
)	NULL
,	NULL
NF-kB	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
14	NULL
)	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
(	NULL
8	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

We	NULL
performed	NULL
supershift	NULL
assays	NULL
with	NULL
specific	NULL
antibodies	NULL
for	NULL
each	NULL
of	NULL
the	NULL
members	NULL
of	NULL
the	NULL
NF-kB	NULL
family	NULL
(	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
RelB	NULL
[	NULL
a	NULL
gift	NULL
from	NULL
U.	NULL
Siebenlist	NULL
]	NULL
)	NULL
and	NULL
competition	NULL
EMSAs	NULL
with	NULL
consensus	NULL
binding	NULL
sites	NULL
corresponding	NULL
to	NULL
the	NULL
CD28-responsive	NULL
element	NULL
,	NULL
NF-IL6	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

These	NULL
experiments	NULL
indicate	NULL
that	NULL
the	NULL
AP3-L	NULL
motif	NULL
does	NULL
not	NULL
contain	NULL
a	NULL
recognition	NULL
site	NULL
for	NULL
any	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
we	NULL
used	NULL
TPA-ionomycin-treated	NULL
nuclear	NULL
extracts	NULL
from	NULL
A3.01	NULL
cells	NULL
in	NULL
gel	NULL
shift	NULL
experiments	NULL
,	NULL
we	NULL
observed	NULL
the	NULL
binding	NULL
of	NULL
an	NULL
inducible	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
to	NULL
the	NULL
AP3-L	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
retarded	NULL
band	NULL
was	NULL
observed	NULL
with	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
ionomycin	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
binding	NULL
was	NULL
specific	NULL
as	NULL
demonstrated	NULL
by	NULL
competition	NULL
experiments	NULL
with	NULL
the	NULL
same	NULL
unlabeled	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
competition	NULL
when	NULL
a	NULL
mutant	NULL
oligonucleotide	NULL
containing	NULL
four	NULL
point	NULL
mutations	NULL
centered	NULL
on	NULL
the	NULL
AP3-L	NULL
binding	NULL
site	NULL
was	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
this	NULL
ionomycin-inducible	NULL
factor	NULL
to	NULL
the	NULL
AP3-L	NULL
probe	NULL
was	NULL
efficiently	NULL
competed	NULL
by	NULL
an	NULL
NF-AT	NULL
binding	NULL
site	NULL
derived	NULL
from	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
and	NULL
not	NULL
competed	NULL
by	NULL
the	NULL
same	NULL
site	NULL
containing	NULL
a	NULL
point	NULL
mutation	NULL
known	NULL
to	NULL
abrogate	NULL
NF-AT	NULL
binding	NULL
(	NULL
8	NULL
,	NULL
34	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
directly	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
HIV	NULL
AP3-L	NULL
site	NULL
,	NULL
we	NULL
used	NULL
two	NULL
dif-	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
-	NULL
6117	NULL
A	NULL
Jurkat	NULL
£	NULL
£	NULL
o	NULL
&	NULL
©	NULL
c	NULL
«	NULL
a	NULL
8	NULL
$	NULL
o	NULL
3	NULL
£	NULL
£	NULL
PD	NULL
9	NULL
_	NULL
as	NULL
0	NULL
0	NULL
5	NULL
'	NULL
%	NULL
a	NULL
2	NULL
28	NULL
ee	NULL
ss	NULL
-	NULL
aLse45t	NULL
t-	NULL
Ee	NULL
3	NULL
o-	NULL
oo	NULL
o	NULL
o	NULL
3	NULL
u	NULL
3	NULL
o	NULL
a	NULL
0	NULL
o	NULL
o	NULL
o	NULL
nuclear	NULL
extract	NULL
-	NULL
O	NULL
+	NULL
0	NULL
O0	NULL
O	NULL
O	NULL
m	NULL
045	NULL
T	NULL
>	NULL
%	NULL
X	NULL
C	NULL
2	NULL
T	NULL
AP3-Lqjy	NULL
Th	NULL
.	NULL

i	NULL
3	NULL
€	NULL
AP-3g5y4q	NULL
ve	NULL
#	NULL
bg	NULL
-	NULL
U	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
910	NULL
1112	NULL
131415	NULL
AP3-L	NULL
(	NULL
nt	NULL
617-626	NULL
)	NULL
TCAGTGTGGAAAATCTCTAGCA	NULL
whe	NULL
se	NULL
oe	NULL
ote	NULL
se	NULL
oe	NULL
t	NULL
ie	NULL
AP-3	NULL
TGTGGAAA	NULL
we	NULL
nle	NULL
oe	NULL
e	NULL
oe	NULL
weve	NULL
e	NULL
CD28RE	NULL
TGGAATTTCT	NULL
we	NULL
ne	NULL
se	NULL
e	NULL
ote	NULL
ste	NULL
oe	NULL
NF-kB	NULL
GGGAATNTCC	NULL
whe	NULL
ie	NULL
oe	NULL
se	NULL
ie	NULL
oe	NULL
e	NULL
oe	NULL
NF-IL6	NULL
TGNNGNAAT	NULL
LAK	NULL
*	NULL
#	NULL
NF-AT	NULL
GGAGGAAAAACTGTTTCAT	NULL
AP3-L	NULL
(	NULL
nt	NULL
617-626	NULL
)	NULL
TCAGTGTGGAAAATCTCTAGCA	NULL
AP3-L	NULL
mut	NULL
GTTT	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
the	NULL
AP3-L	NULL
motif	NULL
.	NULL

(	NULL
A	NULL
)	NULL
AP3-Ligy	NULL
or	NULL
AP3-Ley	NULL
,	NULL
,	NULL
oligonucleotide	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
cell	NULL
lines	NULL
of	NULL
different	NULL
origins	NULL
(	NULL
indicated	NULL
above	NULL
the	NULL
lanes	NULL
)	NULL
,	NULL
and	NULL
the	NULL
binding	NULL
reaction	NULL
products	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
.	NULL

When	NULL
indicated	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
TPA	NULL
(	NULL
10	NULL
ng/ml	NULL
for	NULL
6	NULL
h	NULL
)	NULL
,	NULL
with	NULL
anti-CD3	NULL
antibodies	NULL
(	NULL
1	NULL
pg/ml	NULL
for	NULL
2	NULL
or	NULL
6	NULL
h	NULL
)	NULL
,	NULL
or	NULL
with	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
antibodies	NULL
(	NULL
1	NULL
pg/ml	NULL
of	NULL
each	NULL
for	NULL
2	NULL
or	NULL
6	NULL
h	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Alignment	NULL
of	NULL
the	NULL
AP3-L	NULL
site	NULL
nucleotide	NULL
sequence	NULL
with	NULL
the	NULL
consensus	NULL
binding	NULL
sites	NULL
for	NULL
AP-3	NULL
(	NULL
54	NULL
)	NULL
,	NULL
CD28RE	NULL
(	NULL
16	NULL
)	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
14	NULL
)	NULL
,	NULL
NF-IL6	NULL
(	NULL
71	NULL
)	NULL
,	NULL
and	NULL
NF-AT	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Conserved	NULL
residues	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
asterisk	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Mutagenesis	NULL
of	NULL
the	NULL
AP3-L	NULL
motif	NULL
was	NULL
realized	NULL
by	NULL
replacing	NULL
a	NULL
TGGA	NULL
motif	NULL
centrally	NULL
located	NULL
in	NULL
the	NULL
footprinted	NULL
area	NULL
with	NULL
the	NULL
sequence	NULL
GTTT	NULL
.	NULL

ferent	NULL
antibodies	NULL
directed	NULL
against	NULL
NF-AT1	NULL
(	NULL
anti-67.1	NULL
and	NULL
an-tiR59	NULL
[	NULL
30	NULL
,	NULL
53	NULL
]	NULL
;	NULL
a	NULL
gift	NULL
from	NULL
A.	NULL
Rao	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
anti-NF-AT1	NULL
antibodies	NULL
to	NULL
binding	NULL
reaction	NULL
mixtures	NULL
containing	NULL
either	NULL
uninduced	NULL
or	NULL
TPA-ionomycin-inducible	NULL
extracts	NULL
and	NULL
the	NULL
AP3-L	NULL
probe	NULL
resulted	NULL
in	NULL
the	NULL
retardation	NULL
of	NULL
the	NULL
TPA-ionomycin-inducible	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

No	NULL
supershifted	NULL
complex	NULL
was	NULL
observed	NULL
with	NULL
control	NULL
antibodies	NULL
or	NULL
when	NULL
the	NULL
antibodies	NULL
were	NULL
added	NULL
to	NULL
the	NULL
probe	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Last	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
purified	NULL
NF-AT1	NULL
DNA-binding	NULL
domain	NULL
(	NULL
DBD	NULL
)	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
HIV	NULL
AP3-L	NULL
probe	NULL
.	NULL

Comparison	NULL
of	NULL
binding	NULL
of	NULL
increasing	NULL
amounts	NULL
of	NULL
the	NULL
NF-AT1	NULL
DBD	NULL
(	NULL
49	NULL
)	NULL
to	NULL
probes	NULL
corresponding	NULL
to	NULL
6118	NULL
VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

AP3-L	NULL
wt	NULL
__	NULL
AP3-L	NULL
mut	NULL
-_-	NULL
NF-ATjpowt	NULL
-	NULL
omut	NULL
petitor	NULL
.	NULL

_	NULL
_	NULL
M	NULL
t	NULL
M	NULL
TPA/iono	NULL
-o	NULL
4	NULL
bob	NULL
t	NULL
t	NULL
to	NULL
bo	NULL
bo	NULL
bob	NULL
bob	NULL
b	NULL
b	NULL
bobo	NULL
t	NULL
bob	NULL
tot	NULL
b	NULL
+o	NULL
#	NULL
i	NULL
Wu	NULL
-	NULL
HHRRHW	NULL
assay	NULL
supershift	NULL
blocking	NULL
@	NULL
@	NULL
i	NULL
+-	NULL
5	NULL
:	NULL
TPA/iono	NULL
a	NULL
CJ	NULL
hy	NULL
reiibes	NULL
@	NULL
a	NULL
®	NULL
6NN	NULL
bie	NULL
02	NULL
2	NULL
ogfogﬁf	NULL
02102355	NULL
“	NULL
?	NULL

55255	NULL
fT	NULL
antibodies	NULL
.	NULL

z	NULL
0	NULL
<	NULL
Z	NULL
O	NULL
<	NULL
<	NULL
20	NULL
<	NULL
20o	NULL
<	NULL
<	NULL
U	NULL
_	NULL
<	NULL
-	NULL
supershift	NULL
a	NULL
``	NULL
g	NULL
<	NULL
-	NULL
NF-AT	NULL
.	NULL
'	NULL

<	NULL
-	NULL
NF-AT	NULL
WW	NULL
w-	NULL
«	NULL
-	NULL
@	NULL
--	NULL
probe	NULL
AP3-Lqiy	NULL
NF-ATjp	NULL
p	NULL
NFAT-DBD	NULL
_-_	NULL
]	NULL
=	NULL
_	NULL
--	NULL
--	NULL
-	NULL
)	NULL
--	NULL
@	NULL
@	NULL
@	NULL
«	NULL
-	NULL
us	NULL
@	NULL
g	NULL
10	NULL
5	NULL
-O-	NULL
_	NULL
AP3-L	NULL
wt	NULL
E	NULL
-A-	NULL
-	NULL
AP3-L	NULL
mut	NULL
m	NULL
-	NULL
50	NULL
@	NULL
$	NULL
el	NULL
@	NULL
€	NULL
o	NULL
1	NULL
10	NULL
100	NULL
_	NULL
1000	NULL
Competitor	NULL
(	NULL
fold	NULL
molar	NULL
excess	NULL
)	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

The	NULL
AP3-L	NULL
motif	NULL
is	NULL
a	NULL
NF-AT	NULL
binding	NULL
site	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Competition	NULL
experiments	NULL
.	NULL

AP3-L	NULL
wt	NULL
and	NULL
mutated	NULL
oligonucleotides	NULL
were	NULL
tested	NULL
in	NULL
competition	NULL
EMSAs	NULL
.	NULL

The	NULL
AP3-L	NULL
wt	NULL
oligonucleotide	NULL
was	NULL
5'-end	NULL
labeled	NULL
and	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

This	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
TPA-ionomycin	NULL
(	NULL
jiono	NULL
)	NULL
-treated	NULL
A3.01	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
(	NULL
3-	NULL
,	NULL
9-	NULL
,	NULL
27-	NULL
,	NULL
81-	NULL
,	NULL
and	NULL
243-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
the	NULL
homologous	NULL
oligonucleotide	NULL
,	NULL
of	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
four	NULL
substitutions	NULL
in	NULL
the	NULL
AP3-L	NULL
motif	NULL
(	NULL
AP3-L	NULL
mut	NULL
[	NULL
Fig	NULL
.	NULL

3C	NULL
]	NULL
)	NULL
,	NULL
of	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-AT	NULL
;	NULL
,	NULL
,	NULL
site	NULL
,	NULL
or	NULL
of	NULL
a	NULL
mutated	NULL
version	NULL
known	NULL
to	NULL
abolish	NULL
NF-AT	NULL
binding	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Supershift	NULL
assays	NULL
.	NULL

Untreated	NULL
or	NULL
TPA-ionomycin-treated	NULL
A3.01	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
radiolabeled	NULL
AP3-L	NULL
wt	NULL
oligonucleotide	NULL
.	NULL

Two	NULL
NF-ATp-specific	NULL
antisera	NULL
,	NULL
anti-67.1	NULL
and	NULL
anti-R59	NULL
(	NULL
30	NULL
,	NULL
53	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
A.	NULL
Rao	NULL
)	NULL
,	NULL
were	NULL
added	NULL
either	NULL
at	NULL
the	NULL
beginning	NULL
(	NULL
anti-R59	NULL
)	NULL
or	NULL
at	NULL
the	NULL
end	NULL
(	NULL
anti-67.1	NULL
)	NULL
of	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

Preimmune	NULL
rabbit	NULL
serum	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

The	NULL
possibility	NULL
that	NULL
the	NULL
antibody	NULL
itself	NULL
binds	NULL
to	NULL
DNA	NULL
was	NULL
ruled	NULL
out	NULL
by	NULL
performing	NULL
the	NULL
binding	NULL
reaction	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
extract	NULL
(	NULL
anti-67.1	NULL
alone	NULL
,	NULL
anti-R59	NULL
alone	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Recombinant	NULL
NF-AT	NULL
binds	NULL
to	NULL
the	NULL
AP3-L	NULL
motif	NULL
.	NULL

Purified	NULL
recombinant	NULL
NF-AT	NULL
DBD	NULL
was	NULL
added	NULL
in	NULL
increasing	NULL
concentrations	NULL
(	NULL
0.125	NULL
,	NULL
0.25	NULL
,	NULL
0.5	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
4	NULL
ng	NULL
)	NULL
to	NULL
radiolabeled	NULL
probes	NULL
corresponding	NULL
to	NULL
the	NULL
AP3-L	NULL
binding	NULL
site	NULL
and	NULL
to	NULL
the	NULL
NF-AT	NULL
;	NULL
site	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Competition	NULL
graph	NULL
.	NULL

The	NULL
gel	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
was	NULL
quantified	NULL
with	NULL
using	NULL
a	NULL
phosphorimager	NULL
(	NULL
Instant	NULL
Imager	NULL
;	NULL
Packard	NULL
)	NULL
.	NULL

Complex	NULL
formation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
unlabeled	NULL
competitor	NULL
DNA	NULL
was	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

A	NULL
ISRESG15	NULL
AGGcAAAcceaaacto	NULL
Tits	NULL
irkr	NULL
«	NULL
s	NULL
DBF	NULL
(	NULL
nt	NULL
653-677	NULL
)	NULL
AGGGACTTGAAAGCGAAAGTAAAGCCAGAG	NULL
fP	NULL
ff	NULL
DBF	NULL
mut	NULL
cee	NULL
-	NULL
ccc	NULL
DBF	NULL
wt	NULL
DBF	NULL
mut	NULL
ISREggiswt	NULL
-	NULL
ISREgq1smut	NULL
petitor	NULL
_	NULL
cu	NULL
]	NULL
_	NULL
--	NULL
]	NULL
C	NULL
@	NULL
100	NULL
<	NULL
-O-	NULL
DBF	NULL
wt	NULL
~	NULL
§	NULL
-A-	NULL
DBF	NULL
mut	NULL
m	NULL
-	NULL
50	NULL
@	NULL
2	NULL
8	NULL
0	NULL
di	NULL
.	NULL

0	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
Competitor	NULL
(	NULL
fold	NULL
molar	NULL
excess	NULL
)	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
HS4	NULL
DBF	NULL
binding	NULL
site	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
DBF	NULL
wt	NULL
oligonucleotide	NULL
is	NULL
aligned	NULL
with	NULL
the	NULL
ISRE	NULL
from	NULL
the	NULL
ISG15	NULL
gene	NULL
.	NULL

Conserved	NULL
residues	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
asterisk	NULL
.	NULL

Bases	NULL
that	NULL
are	NULL
changed	NULL
in	NULL
the	NULL
mutated	NULL
version	NULL
of	NULL
this	NULL
oligonucleotide	NULL
(	NULL
DBF	NULL
mut	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
DBF	NULL
wt	NULL
and	NULL
mutated	NULL
(	NULL
mut	NULL
)	NULL
oligonucleotides	NULL
were	NULL
tested	NULL
in	NULL
competition	NULL
EMSAs	NULL
.	NULL

The	NULL
DBF	NULL
wt	NULL
oligonucleotide	NULL
was	NULL
5'-end	NULL
labeled	NULL
and	NULL
used	NULL
as	NULL
probe	NULL
.	NULL

This	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
A3.01	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
(	NULL
3-	NULL
,	NULL
9-	NULL
,	NULL
27-	NULL
,	NULL
81-	NULL
,	NULL
and	NULL
243-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
the	NULL
homologous	NULL
DBF	NULL
wt	NULL
oligonucleotide	NULL
,	NULL
of	NULL
the	NULL
DBF	NULL
mut	NULL
oligonucleotide	NULL
,	NULL
of	NULL
the	NULL
ISREsq	NULL
;	NULL
s	NULL
oligonucleotide	NULL
(	NULL
ISREgq	NULL
;	NULL
swt	NULL
)	NULL
,	NULL
or	NULL
of	NULL
a	NULL
mutant	NULL
version	NULL
derived	NULL
from	NULL
it	NULL
(	NULL
C	NULL
)	NULL
Levels	NULL
of	NULL
complex	NULL
formation	NULL
of	NULL
EMSAs	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
were	NULL
quantified	NULL
by	NULL
radioimaging	NULL
analysis	NULL
(	NULL
InstantImager	NULL
)	NULL
.	NULL

Complex	NULL
formation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
unlabeled	NULL
competitor	NULL
DNA	NULL
was	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
.	NULL

the	NULL
AP3-L	NULL
site	NULL
or	NULL
the	NULL
NF-AT	NULL
,	NULL
,	NULL
;	NULL
site	NULL
showed	NULL
relatively	NULL
higher	NULL
binding	NULL
to	NULL
the	NULL
HIV	NULL
AP3-L	NULL
probe	NULL
than	NULL
to	NULL
the	NULL
NF-AT	NULL
,	NULL
,	NULL
,	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrate	NULL
that	NULL
the	NULL
HIV	NULL
AP3-L	NULL
site	NULL
corresponds	NULL
to	NULL
a	NULL
bona	NULL
fide	NULL
high-affinity	NULL
NF-AT	NULL
binding	NULL
site	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
DBF	NULL
site	NULL
.	NULL

To	NULL
abolish	NULL
binding	NULL
of	NULL
factors	NULL
to	NULL
the	NULL
DBF	NULL
site	NULL
(	NULL
nt	NULL
648	NULL
to	NULL
677	NULL
)	NULL
,	NULL
we	NULL
substituted	NULL
two	NULL
conserved	NULL
central	NULL
groups	NULL
of	NULL
A	NULL
residues	NULL
for	NULL
C	NULL
residues	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

These	NULL
mutations	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
oligonucleotide	NULL
to	NULL
compete	NULL
the	NULL
binding	NULL
of	NULL
factors	NULL
to	NULL
the	NULL
DBF	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
probe	NULL
,	NULL
whereas	NULL
unlabeled	NULL
DBF	NULL
wt	NULL
oligonucleotide	NULL
was	NULL
an	NULL
efficient	NULL
competitor	NULL
,	NULL
therefore	NULL
confirming	NULL
the	NULL
loss	NULL
of	NULL
DBF	NULL
binding	NULL
to	NULL
the	NULL
mutated	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

We	NULL
)	NULL
previously	NULL
noted	NULL
a	NULL
strong	NULL
homology	NULL
of	NULL
the	NULL
DBF	NULL
site	NULL
to	NULL
the	NULL
IFN-stimulated	NULL
regulatory	NULL
element	NULL
(	NULL
ISRE	NULL
)	NULL
(	NULL
13	NULL
,	NULL
76	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
serves	NULL
as	NULL
a	NULL
recognition	NULL
site	NULL
for	NULL
members	NULL
of	NULL
the	NULL
IFN	NULL
regulatory	NULL
factor	NULL
(	NULL
IRF	NULL
)	NULL
family	NULL
,	NULL
which	NULL
includes	NULL
IRF1	NULL
,	NULL
IRF2	NULL
,	NULL
and	NULL
ICSBP	NULL
,	NULL
and	NULL
members	NULL
of	NULL
the	NULL
STAT	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
33	NULL
and	NULL
67	NULL
)	NULL
.	NULL

Under	NULL
basal	NULL
conditions	NULL
,	NULL
the	NULL
ISRE	NULL
is	NULL
occupied	NULL
by	NULL
the	NULL
constitutively	NULL
expressed	NULL
IRF	NULL
factors	NULL
.	NULL

In	NULL
response	NULL
to	NULL
IFN-	NULL
«	NULL
stimulation	NULL
,	NULL
the	NULL
ISRE	NULL
becomes	NULL
occupied	NULL
by	NULL
an	NULL
additional	NULL
complex	NULL
,	NULL
called	NULL
Vou	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
6119	NULL
probe	NULL
DBF	NULL
ISRE	NULL
HIV	NULL
1sG15	NULL
probe	NULL
DBFHiy	NULL
ISREsG15	NULL
Jurkat	NULL
-	NULL
IFN-o	NULL
_	NULL
+	NULL
IFN-0	NULL
IFN-	NULL
.	NULL

+	NULL
IFN-	NULL
«	NULL
I	NULL
SAN	NULL
IFN-o	NULL
.	NULL

+	NULL
IFN-o	NULL
.	NULL

=	NULL
IFN-c	NULL
+	NULL
IFN-hall	NULL
Nalin	NULL
)	NULL
To	NULL
fo	NULL
I	NULL
-	NULL
l	NULL
U	NULL
-	NULL
W	NULL
Ue	NULL
-	NULL
le	NULL
Wo	NULL
ll	NULL
W	NULL
W	NULL
5	NULL
5	NULL
3	NULL
8	NULL
3	NULL
8	NULL
$	NULL
855,855	NULL
-	NULL
oo	NULL
sff	NULL
Here	NULL
ee	NULL
C	NULL
®	NULL
=	NULL
%	NULL
Ess	NULL
$	NULL
5	NULL
a	NULL
2	NULL
5	NULL
5	NULL
E	NULL
9	NULL
¢	NULL
£99	NULL
antibodies	NULL
-	NULL
S558	NULL
SEgs	NULL
o	NULL
$	NULL
fis	NULL
:	NULL
-	NULL
$	NULL
§s	NULL
:	NULL
.	NULL

-	NULL
antibodies	NULL
zo	NULL
<	NULL
<	NULL
z	NULL
o	NULL
<	NULL
<	NULL
2	NULL
Oo	NULL
<	NULL
<	NULL
2	NULL
Oo	NULL
<	NULL
<	NULL
ye	NULL
``	NULL
”	NULL
a	NULL
«	NULL
-	NULL
supershift	NULL
Wil	NULL
<	NULL
-	NULL
supershift	NULL
*	NULL
|\	NULL
<	NULL
-	NULL
IsGFs	NULL
we	NULL
se	NULL
wt	NULL
<	NULL
-	NULL
IRF	NULL
<	NULL
-	NULL
IRF	NULL
®	NULL
»	NULL
=	NULL
-	NULL
a	NULL
#	NULL
=	NULL
a	NULL
®	NULL
u	NULL
a	NULL
ws	NULL
«	NULL
n	NULL
w*	NULL
tree	NULL
probe	NULL
-	NULL
>	NULL
r	NULL
``	NULL
``	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
111213	NULL
14	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
1314	NULL
15	NULL
16	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

The	NULL
HIV-1	NULL
DBF	NULL
site	NULL
binds	NULL
IRFs	NULL
.	NULL

(	NULL
A	NULL
)	NULL
DBFwigry	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
8	NULL
)	NULL
or	NULL
ISRErgq	NULL
;	NULL
5wt	NULL
(	NULL
lanes	NULL
9	NULL
to	NULL
14	NULL
)	NULL
oligonucleotide	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
(	NULL
-IFN-a	NULL
)	NULL
or	NULL
IFN-induced	NULL
(	NULL
+IFN-	NULL
«	NULL
)	NULL
Jurkat	NULL
cells	NULL
.	NULL

Supershift	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antibody	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-IRF-1	NULL
antibody	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
7	NULL
,	NULL
10	NULL
,	NULL
and	NULL
13	NULL
)	NULL
,	NULL
of	NULL
anti-IRF-2	NULL
antibody	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
and	NULL
14	NULL
)	NULL
,	NULL
or	NULL
of	NULL
purified	NULL
rabbit	NULL
IgG	NULL
as	NULL
a	NULL
control	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
DBFWtny	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
8	NULL
)	NULL
or	NULL
ISREgq	NULL
;	NULL
swt	NULL
(	NULL
lanes	NULL
9	NULL
to	NULL
16	NULL
)	NULL
oligonucleotide	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
(	NULL
-IFN-	NULL
«	NULL
)	NULL
or	NULL
IFN-induced	NULL
(	NULL
+IFN-a	NULL
)	NULL
(	NULL
50	NULL
U/ml	NULL
for	NULL
30	NULL
min	NULL
)	NULL
SAN	NULL
cells	NULL
.	NULL

Supershift	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antibody	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
13	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-Stat1	NULL
antibody	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
7	NULL
,	NULL
11	NULL
,	NULL
and	NULL
15	NULL
)	NULL
,	NULL
of	NULL
anti-Stat2	NULL
antibody	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
8	NULL
,	NULL
12	NULL
,	NULL
and	NULL
16	NULL
)	NULL
or	NULL
of	NULL
preimmune	NULL
serum	NULL
as	NULL
a	NULL
control	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
6	NULL
,	NULL
10	NULL
,	NULL
and	NULL
14	NULL
)	NULL
.	NULL

ISGF3	NULL
,	NULL
composed	NULL
of	NULL
STAT1	NULL
,	NULL
STAT2	NULL
,	NULL
and	NULL
the	NULL
p48	NULL
protein	NULL
(	NULL
24	NULL
,	NULL
56	NULL
)	NULL
.	NULL

To	NULL
compare	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
HIV-1	NULL
DBF	NULL
site	NULL
with	NULL
that	NULL
of	NULL
a	NULL
classical	NULL
ISRE	NULL
,	NULL
the	NULL
ISRE	NULL
from	NULL
the	NULL
ISG15	NULL
gene	NULL
was	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
in	NULL
gel	NULL
retardation	NULL
experiments	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
the	NULL
DBF	NULL
retarded	NULL
band	NULL
was	NULL
competed	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
ISREs	NULL
,	NULL
;	NULL
;	NULL
wt	NULL
oligonucleotide	NULL
as	NULL
efficiently	NULL
as	NULL
by	NULL
the	NULL
homologous	NULL
DBF	NULL
wt	NULL
oligonucleotide	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
smut	NULL
oligonucleotide	NULL
containing	NULL
mutations	NULL
abolishing	NULL
IRF	NULL
binding	NULL
did	NULL
not	NULL
have	NULL
any	NULL
inhibitory	NULL
effect	NULL
on	NULL
complex	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
reverse	NULL
experiments	NULL
in	NULL
which	NULL
a	NULL
labeled	NULL
probe	NULL
corresponding	NULL
to	NULL
the	NULL
ISRE	NULL
:	NULL
s	NULL
,	NULL
-	NULL
;	NULL
5	NULL
oligonucleotide	NULL
was	NULL
used	NULL
and	NULL
competed	NULL
by	NULL
the	NULL
DBF	NULL
wt	NULL
oligonucleotide	NULL
confirmed	NULL
these	NULL
observations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
from	NULL
these	NULL
experiments	NULL
that	NULL
the	NULL
DBF	NULL
wt	NULL
and	NULL
oligonucleotides	NULL
are	NULL
recognized	NULL
by	NULL
related	NULL
and/or	NULL
identical	NULL
proteins	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
present	NULL
in	NULL
the	NULL
DBF-re-tarded	NULL
complex	NULL
,	NULL
we	NULL
performed	NULL
supershift	NULL
assays	NULL
with	NULL
antibodies	NULL
specific	NULL
for	NULL
individual	NULL
IRF	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
DBFyy	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
probe	NULL
in	NULL
EMSAs	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
untreated	NULL
and	NULL
IFN-	NULL
«	NULL
-treated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
8	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
both	NULL
anti-IRF1	NULL
and	NULL
anti-IRF2	NULL
antibodies	NULL
generated	NULL
a	NULL
supershifted	NULL
complex	NULL
in	NULL
uninduced	NULL
extracts	NULL
(	NULL
lane	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
same	NULL
pattern	NULL
was	NULL
observed	NULL
with	NULL
IFN-	NULL
«	NULL
-induced	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
binding	NULL
and	NULL
supershifted	NULL
complexes	NULL
was	NULL
observed	NULL
when	NULL
the	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
lanes	NULL
9	NULL
to	NULL
14	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
observations	NULL
that	NULL
the	NULL
IRF	NULL
factors	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
DBF	NULL
site	NULL
to	NULL
bind	NULL
the	NULL
IFN-	NULL
«	NULL
-induced	NULL
ISGF3	NULL
complex	NULL
,	NULL
anti-Statl	NULL
and	NULL
anti-Stat2	NULL
antibodies	NULL
were	NULL
used	NULL
in	NULL
supershift	NULL
assays	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
SAN	NULL
cells	NULL
,	NULL
a	NULL
cell	NULL
line	NULL
in	NULL
which	NULL
the	NULL
ISGF3	NULL
induction	NULL
is	NULL
readily	NULL
visualized	NULL
(	NULL
35	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Using	NULL
the	NULL
DBF	NULL
probe	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
pattern	NULL
of	NULL
binding	NULL
observed	NULL
with	NULL
uninduced	NULL
SAN	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
IFN-	NULL
«	NULL
-induced	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
retarded	NULL
complex	NULL
did	NULL
not	NULL
contain	NULL
ISGF3	NULL
since	NULL
it	NULL
was	NULL
not	NULL
af-	NULL
fected	NULL
by	NULL
anti-Statl	NULL
and	NULL
anti-Stat2	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
7	NULL
and	NULL
4	NULL
to	NULL
8	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
similar	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
ISREsp	NULL
,	NULL
«	NULL
probe	NULL
,	NULL
a	NULL
slowly	NULL
migrating	NULL
ISGF3	NULL
band	NULL
was	NULL
induced	NULL
upon	NULL
IFN-	NULL
«	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
compare	NULL
lanes	NULL
9	NULL
and	NULL
13	NULL
)	NULL
.	NULL

Anti-Stat1	NULL
and	NULL
anti-Stat2	NULL
antibodies	NULL
abolished	NULL
this	NULL
ISGF3	NULL
band	NULL
,	NULL
and	NULL
a	NULL
supershifted	NULL
complex	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
15	NULL
and	NULL
16	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
while	NULL
preimmune	NULL
serum	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
complex	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
14	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
DBF	NULL
site	NULL
present	NULL
in	NULL
the	NULL
HIV-1	NULL
leader	NULL
region	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
ISRE	NULL
and	NULL
specifically	NULL
binds	NULL
the	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
proteins	NULL
.	NULL

(	NULL
v	NULL
)	NULL
Spl	NULL
sites	NULL
.	NULL

Footprinting	NULL
analysis	NULL
of	NULL
the	NULL
HIV-1	NULL
leader	NULL
region	NULL
with	NULL
purified	NULL
Sp1	NULL
identified	NULL
strong	NULL
binding	NULL
sites	NULL
in	NULL
a	NULL
GC-rich	NULL
sequence	NULL
extending	NULL
from	NULL
nt	NULL
725	NULL
to	NULL
746	NULL
(	NULL
13	NULL
)	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
three	NULL
motifs	NULL
with	NULL
close	NULL
homology	NULL
to	NULL
the	NULL
Sp1	NULL
consensus	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

A	NULL
2-bp	NULL
mutation	NULL
(	NULL
GG	NULL
to	NULL
TT	NULL
)	NULL
that	NULL
interferes	NULL
with	NULL
Sp1	NULL
binding	NULL
(	NULL
37	NULL
)	NULL
was	NULL
introduced	NULL
into	NULL
each	NULL
of	NULL
these	NULL
potential	NULL
Sp1	NULL
sites	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
this	NULL
mutation	NULL
,	NULL
designated	NULL
Sp1imut1	NULL
,	NULL
on	NULL
Sp1	NULL
binding	NULL
affinity	NULL
was	NULL
analyzed	NULL
by	NULL
competition	NULL
EMSAs	NULL
with	NULL
the	NULL
Splwt	NULL
oligonucleotide	NULL
as	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
this	NULL
probe	NULL
with	NULL
affinity-purified	NULL
human	NULL
Spl	NULL
resulted	NULL
in	NULL
a	NULL
retarded	NULL
complex	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
the	NULL
Splwt	NULL
oligonucleotide	NULL
but	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
degree	NULL
by	NULL
the	NULL
same	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
6-bp	NULL
substitution	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
Sp1lmut1	NULL
mutation	NULL
decreased	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
Sp1	NULL
to	NULL
the	NULL
affected	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

The	NULL
RNA	NULL
leader	NULL
sequence	NULL
of	NULL
HIV-1	NULL
is	NULL
organized	NULL
in	NULL
a	NULL
complex	NULL
stem-loop	NULL
secondary	NULL
structure	NULL
encompassing	NULL
nt	NULL
457	NULL
to	NULL
1180	NULL
that	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
packaging	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
in	NULL
particles	NULL
(	NULL
6	NULL
,	NULL
27	NULL
)	NULL
.	NULL

According	NULL
to	NULL
this	NULL
model	NULL
,	NULL
four	NULL
of	NULL
the	NULL
six	NULL
G	NULL
residues	NULL
which	NULL
were	NULL
mutated	NULL
in	NULL
Splmut1	NULL
appear	NULL
unimportant	NULL
for	NULL
base	NULL
pairing	NULL
,	NULL
and	NULL
their	NULL
mutation	NULL
might	NULL
therefore	NULL
not	NULL
affect	NULL
RNA	NULL
packaging	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
two	NULL
G	NULL
residues	NULL
(	NULL
G	NULL
;	NULL
,	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
base	NULL
pairing	NULL
,	NULL
and	NULL
their	NULL
disruption	NULL
might	NULL
affect	NULL
the	NULL
packaging	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
a	NULL
second	NULL
mutation	NULL
of	NULL
the	NULL
Sp1	NULL
sites	NULL
,	NULL
designated	NULL
Sp1mut2	NULL
,	NULL
was	NULL
generated	NULL
6120	NULL
VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
kent	NULL
Sp1	NULL
(	NULL
nt	NULL
724-743	NULL
)	NULL
CGGCAAGAGGCGAGGGGCGGCGACTGGTGAG	NULL
1a	NULL
1a	NULL
Spimut1	NULL
TP	NULL
TF	NULL
TF	NULL
ia	NULL
AE	NULL
1a	NULL
1	NULL
1	NULL
Sp1imut2	NULL
TT	NULL
ll	NULL
[	NULL
elelefelefelelelelel	NULL
Sp1	NULL
consensus	NULL
TA*	NULL
``	NULL
A	NULL
PAAT	NULL
Spiwt	NULL
Spimut1	NULL
*	NULL
--	NULL
mmm	NULL
Sp1imut2	NULL
competitor	NULL
T	NULL
100	NULL
-	NULL
@	NULL
-	NULL
_	NULL
Spiwt	NULL
2	NULL
-B-	NULL
_	NULL
Spimuti1	NULL
C	NULL
5	NULL
50	NULL
-A-	NULL
Spimut2	NULL
®	NULL
&	NULL
d	NULL
E	NULL
,	NULL
0	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
Competitor	NULL
(	NULL
fold	NULL
molar	NULL
excess	NULL
)	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
HS4	NULL
Sp1	NULL
binding	NULL
sites	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
Spiwt	NULL
oligonucleotide	NULL
,	NULL
with	NULL
underlined	NULL
bases	NULL
indicating	NULL
the	NULL
three	NULL
potential	NULL
Sp1	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
recognition	NULL
core	NULL
sequence	NULL
5'-GG-3	NULL
'	NULL
of	NULL
each	NULL
site	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
thicker	NULL
bar	NULL
.	NULL

For	NULL
Spimut1	NULL
and	NULL
Sp1imut2	NULL
oligonucleotides	NULL
,	NULL
only	NULL
the	NULL
bases	NULL
that	NULL
are	NULL
changed	NULL
compared	NULL
with	NULL
the	NULL
wt	NULL
sequence	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
Sp1	NULL
consensus	NULL
DNA	NULL
binding	NULL
site	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
effects	NULL
of	NULL
Spimut1	NULL
and	NULL
Spimut2	NULL
mutations	NULL
were	NULL
tested	NULL
in	NULL
competition	NULL
EMSAs	NULL
.	NULL

Spiwt	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
0.05	NULL
fpu	NULL
of	NULL
affinity-purified	NULL
Spl	NULL
(	NULL
Promega	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
(	NULL
3-	NULL
,	NULL
9-	NULL
,	NULL
27-	NULL
,	NULL
81-	NULL
,	NULL
and	NULL
243-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
the	NULL
homologous	NULL
Spiwt	NULL
oligonucleotide	NULL
,	NULL
of	NULL
the	NULL
Spimut1	NULL
oligonucleotide	NULL
or	NULL
of	NULL
the	NULL
Spimut2	NULL
oligonucleotide	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Levels	NULL
of	NULL
complex	NULL
formation	NULL
of	NULL
EMSAs	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
were	NULL
quantified	NULL
by	NULL
radioimaging	NULL
analysis	NULL
(	NULL
InstantImager	NULL
)	NULL
.	NULL

Complex	NULL
formation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
unlabeled	NULL
competitor	NULL
DNA	NULL
was	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
.	NULL

so	NULL
that	NULL
G	NULL
,	NULL
,	NULL
,	NULL
and	NULL
G	NULL
,	NULL
,	NULL
,	NULL
were	NULL
not	NULL
modified	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

As	NULL
observed	NULL
with	NULL
the	NULL
Spimut1	NULL
oligonucleotide	NULL
,	NULL
competition	NULL
EMSAs	NULL
showed	NULL
that	NULL
the	NULL
Sp1imut2	NULL
oligonucleotide	NULL
was	NULL
significantly	NULL
less	NULL
efficient	NULL
as	NULL
a	NULL
competitor	NULL
than	NULL
was	NULL
the	NULL
Spiwt	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
and	NULL
C	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
this	NULL
mutation	NULL
also	NULL
greatly	NULL
decreased	NULL
binding	NULL
to	NULL
the	NULL
Sp1	NULL
sites	NULL
.	NULL

Generation	NULL
of	NULL
HIV-1	NULL
proviruses	NULL
containing	NULL
individual	NULL
or	NULL
combinations	NULL
of	NULL
mutated	NULL
binding	NULL
sites	NULL
.	NULL

To	NULL
address	NULL
the	NULL
biological	NULL
significance	NULL
of	NULL
each	NULL
of	NULL
the	NULL
above	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
life	NULL
cycle	NULL
,	NULL
the	NULL
mutations	NULL
described	NULL
above	NULL
were	NULL
introduced	NULL
individually	NULL
or	NULL
in	NULL
combination	NULL
into	NULL
an	NULL
infectious	NULL
clone	NULL
of	NULL
HIV-1	NULL
.	NULL

In	NULL
vitro	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
sites	NULL
J.	NULL
ViRoL	NULL
.	NULL

was	NULL
performed	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
5	NULL
'	NULL
portion	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
(	NULL
nt	NULL
1	NULL
to	NULL
1447	NULL
)	NULL
and	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
mutated	NULL
sites	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
mutation	NULL
in	NULL
pHIVAPS/SP1	NULL
corresponds	NULL
to	NULL
Splmut1	NULL
and	NULL
to	NULL
two	NULL
additional	NULL
substitutions	NULL
(	NULL
C	NULL
;	NULL
gqyp	NULL
-	NULL
>	NULL
A	NULL
,	NULL
Cész	NULL
-	NULL
>	NULL
A	NULL
)	NULL
designed	NULL
to	NULL
restore	NULL
base	NULL
pairing	NULL
in	NULL
the	NULL
packaging-signal	NULL
secondary	NULL
stem-loop	NULL
structure	NULL
.	NULL

The	NULL
mutation	NULL
in	NULL
pHIVASP1	NULL
corresponds	NULL
to	NULL
Splmut2	NULL
and	NULL
should	NULL
not	NULL
impair	NULL
the	NULL
packaging	NULL
signal	NULL
(	NULL
see	NULL
above	NULL
)	NULL
.	NULL

After	NULL
site-directed	NULL
mutagenesis	NULL
and	NULL
confirmation	NULL
of	NULL
the	NULL
mutations	NULL
by	NULL
sequencing	NULL
,	NULL
fragments	NULL
containing	NULL
these	NULL
mutations	NULL
(	NULL
Mrol-BssH2	NULL
for	NULL
all	NULL
mutations	NULL
except	NULL
Sp1	NULL
;	NULL
Mrol-SphI	NULL
for	NULL
the	NULL
Sp1	NULL
mutations	NULL
)	NULL
were	NULL
subcloned	NULL
back	NULL
into	NULL
the	NULL
corresponding	NULL
sites	NULL
of	NULL
a	NULL
derivative	NULL
of	NULL
pILIC	NULL
referred	NULL
to	NULL
as	NULL
pHIV	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Replication	NULL
properties	NULL
of	NULL
mutant	NULL
viruses	NULL
.	NULL

(	NULL
i	NULL
)	NULL
Generation	NULL
of	NULL
wt	NULL
and	NULL
mutant	NULL
HIV-1	NULL
stocks	NULL
by	NULL
transfection-cocultivation	NULL
.	NULL

wt	NULL
and	NULL
mutant	NULL
HIV-1	NULL
infectious	NULL
proviruses	NULL
were	NULL
generated	NULL
from	NULL
the	NULL
single-LTR-containing	NULL
constructs	NULL
by	NULL
BamHI	NULL
digestion	NULL
and	NULL
self-ligation	NULL
.	NULL

To	NULL
obtain	NULL
stocks	NULL
of	NULL
infectious	NULL
viruses	NULL
and	NULL
to	NULL
obtain	NULL
an	NULL
initial	NULL
measurement	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
mutant	NULL
viruses	NULL
to	NULL
replicate	NULL
,	NULL
these	NULL
proviruses	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
cocultivated	NULL
with	NULL
SupT1	NULL
cells	NULL
1	NULL
day	NULL
following	NULL
transfection	NULL
.	NULL

Progeny	NULL
virus	NULL
production	NULL
in	NULL
coculture	NULL
supernatants	NULL
was	NULL
then	NULL
monitored	NULL
by	NULL
measuring	NULL
the	NULL
level	NULL
of	NULL
p24	NULL
gag	NULL
antigen	NULL
over	NULL
a	NULL
50-day	NULL
period	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Cell-free	NULL
supernatants	NULL
were	NULL
harvested	NULL
at	NULL
the	NULL
peak	NULL
of	NULL
viral	NULL
production	NULL
to	NULL
generate	NULL
virus	NULL
stocks	NULL
for	NULL
subsequent	NULL
infectivity	NULL
studies	NULL
.	NULL

Transfection-cocultivation	NULL
with	NULL
wt	NULL
and	NULL
mutant	NULL
HIV	NULL
proviral	NULL
DNAsresulted	NULL
in	NULL
virus	NULL
production	NULL
detected	NULL
at	NULL
different	NULL
times	NULL
following	NULL
transfection	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
growth	NULL
char-acteristics	NULL
,	NULL
the	NULL
nine	NULL
HS4	NULL
mutant	NULL
proviruses	NULL
were	NULL
classified	NULL
into	NULL
four	NULL
replicative	NULL
phenotypes	NULL
:	NULL
(	NULL
i	NULL
)	NULL
mutant	NULL
proviruses	NULL
pHIVADBF	NULL
,	NULL
pHIVAAP3-L	NULL
,	NULL
and	NULL
pHIVAAP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L	NULL
demonstrated	NULL
a	NULL
replication	NULL
phenotype	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wt	NULL
provirus	NULL
pHIV	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
virus	NULL
production	NULL
occurred	NULL
with	NULL
slightly	NULL
delayed	NULL
kinetics	NULL
with	NULL
mutants	NULL
pHIVAAP3-L/DBF	NULL
and	NULL
pHIVAAP-1	NULL
(	NULL
II	NULL
)	NULL
/AP3-L/DBF	NULL
in	NULL
comparison	NULL
to	NULL
wild-type	NULL
pHIV	NULL
(	NULL
detection	NULL
24	NULL
days	NULL
following	NULL
transfection	NULL
)	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
proviruses	NULL
pHIVAAP-1	NULL
(	NULL
L	NULL
,	NULL
IL	NULL
,	NULL
IMI	NULL
)	NULL
/AP3-L	NULL
and	NULL
pHIVAAP-1	NULL
(	NULL
LILIII	NULL
)	NULL
/AP3-L/DBF	NULL
exhibited	NULL
a	NULL
severely	NULL
reduced	NULL
replication	NULL
phenotype	NULL
since	NULL
virus	NULL
could	NULL
be	NULL
recovered	NULL
only	NULL
44	NULL
to	NULL
48	NULL
days	NULL
posttransfection	NULL
,	NULL
and	NULL
in	NULL
addition	NULL
,	NULL
lower	NULL
concentrations	NULL
of	NULL
viral	NULL
antigen	NULL
were	NULL
produced	NULL
by	NULL
these	NULL
proviruses	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
no	NULL
virus	NULL
production	NULL
was	NULL
detected	NULL
during	NULL
a	NULL
60-day	NULL
observation	NULL
period	NULL
following	NULL
transfection	NULL
with	NULL
the	NULL
proviruses	NULL
pHIVAPS/SP1	NULL
and	NULL
pHIVASP1	NULL
,	NULL
indicating	NULL
that	NULL
proviruses	NULL
carrying	NULL
mutations	NULL
in	NULL
the	NULL
HS4	NULL
Spl	NULL
sites	NULL
were	NULL
totally	NULL
defective	NULL
in	NULL
terms	NULL
of	NULL
replication	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
possibility	NULL
of	NULL
reversion	NULL
to	NULL
a	NULL
wt	NULL
phenotype	NULL
as	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
growth	NULL
of	NULL
the	NULL
mutant	NULL
viruses	NULL
,	NULL
HIV-1	NULL
genomic	NULL
RNA	NULL
from	NULL
each	NULL
virus	NULL
stock	NULL
was	NULL
purified	NULL
and	NULL
analyzed	NULL
by	NULL
RT-PCR	NULL
with	NULL
a	NULL
primer	NULL
pair	NULL
that	NULL
amplified	NULL
325	NULL
bp	NULL
of	NULL
the	NULL
5	NULL
'	NULL
portion	NULL
of	NULL
the	NULL
genome	NULL
(	NULL
nt	NULL
489	NULL
to	NULL
814	NULL
)	NULL
containing	NULL
the	NULL
mutated	NULL
binding	NULL
sites	NULL
.	NULL

PCR	NULL
fragments	NULL
were	NULL
subcloned	NULL
,	NULL
and	NULL
five	NULL
individual	NULL
clones	NULL
for	NULL
each	NULL
mutant	NULL
LTR	NULL
were	NULL
resequenced	NULL
.	NULL

This	NULL
analysis	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
original	NULL
mutations	NULL
in	NULL
the	NULL
HS4	NULL
region	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
Infections	NULL
of	NULL
human	NULL
PBMCs	NULL
and	NULL
T-cell	NULL
lines	NULL
with	NULL
wt	NULL
or	NULL
mutant	NULL
HIV-1	NULL
stocks	NULL
.	NULL

To	NULL
study	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
HS4	NULL
mutations	NULL
on	NULL
viral	NULL
growth	NULL
kinetics	NULL
,	NULL
we	NULL
infected	NULL
phytohemagglutinin-stimulated	NULL
PBMCs	NULL
with	NULL
wt	NULL
and	NULL
mutant	NULL
HIV-1	NULL
stocks	NULL
.	NULL

Infection	NULL
with	NULL
wt	NULL
virus	NULL
resulted	NULL
in	NULL
rapid	NULL
and	NULL
vigorous	NULL
virus	NULL
production	NULL
,	NULL
with	NULL
RT	NULL
activity	NULL
reaching	NULL
a	NULL
peak	NULL
on	NULL
days	NULL
4	NULL
to	NULL
6	NULL
postinfection	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
rapid	NULL
drop	NULL
reflecting	NULL
a	NULL
rapid	NULL
reduction	NULL
in	NULL
viable	NULL
cell	NULL
numbers	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
,	NULL
left	NULL
graph	NULL
)	NULL
.	NULL

Mutant	NULL
viruses	NULL
HIVADBF	NULL
,	NULL
HIVAAP3-L	NULL
,	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L	NULL
replicated	NULL
efficiently	NULL
with	NULL
replication	NULL
kinetics	NULL
and	NULL
levels	NULL
of	NULL
virus	NULL
production	NULL
that	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
400	NULL
350	NULL
|	NULL
300	NULL
250	NULL
]	NULL
200	NULL
150	NULL
|	NULL
100	NULL
p24	NULL
value	NULL
(	NULL
ng/ml	NULL
)	NULL
50	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
-	NULL
6121	NULL
time	NULL
(	NULL
days	NULL
postinfection	NULL
)	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Effect	NULL
of	NULL
HS4	NULL
mutations	NULL
on	NULL
HIV-1	NULL
replication	NULL
in	NULL
T-lymphoid	NULL
cells	NULL
.	NULL

Infectious	NULL
molecular	NULL
clones	NULL
of	NULL
HIV-1	NULL
containing	NULL
the	NULL
HS4	NULL
mutations	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
after	NULL
different	NULL
times	NULL
(	NULL
0	NULL
to	NULL
50	NULL
days	NULL
)	NULL
and	NULL
tested	NULL
for	NULL
virus	NULL
production	NULL
by	NULL
measuring	NULL
secreted	NULL
p24	NULL
antigen	NULL
.	NULL

Results	NULL
for	NULL
pHIV	NULL
(	NULL
#	NULL
)	NULL
,	NULL
pHIVADBF	NULL
(	NULL
0	NULL
)	NULL
,	NULL
pHIVAAP3-L	NULL
(	NULL
&	NULL
)	NULL
,	NULL
pHIVAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L	NULL
(	NULL
x	NULL
)	NULL
,	NULL
pHIVVAAP-1	NULL
(	NULL
LILIII	NULL
)	NULL
/AP3-L	NULL
(	NULL
MD	NULL
,	NULL
pHIVAAP3-L/DBF	NULL
(	NULL
@	NULL
)	NULL
,	NULL
pHIVAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L/DBF	NULL
(	NULL
A	NULL
)	NULL
,	NULL
pHIVAAP-1	NULL
(	NULL
LILIID/AP3-L/DBF	NULL
(	NULL
O	NULL
)	NULL
,	NULL
pHIVAPS/SP1	NULL
(	NULL
/	NULL
)	NULL
,	NULL
and	NULL
pHIVASP1	NULL
(	NULL
<	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
of	NULL
three	NULL
is	NULL
shown	NULL
.	NULL

were	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
the	NULL
wt	NULL
control	NULL
virus	NULL
,	NULL
indicating	NULL
that	NULL
individual	NULL
mutation	NULL
of	NULL
the	NULL
DBF	NULL
or	NULL
AP3-L	NULL
site	NULL
and	NULL
the	NULL
double	NULL
mutation	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L	NULL
did	NULL
not	NULL
affect	NULL
HIV-1	NULL
replication	NULL
in	NULL
PBMCs	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
,	NULL
left	NULL
)	NULL
.	NULL

Virus	NULL
production	NULL
was	NULL
observed	NULL
with	NULL
mutant	NULL
viruses	NULL
HIVAAP3-L/DBF	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L/	NULL
DBF	NULL
to	NULL
the	NULL
same	NULL
level	NULL
as	NULL
with	NULL
wt	NULL
HIV	NULL
,	NULL
with	NULL
slightly	NULL
delayed	NULL
replication	NULL
kinetics	NULL
(	NULL
the	NULL
peak	NULL
of	NULL
infection	NULL
was	NULL
on	NULL
day	NULL
8	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

9B	NULL
,	NULL
left	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
infection	NULL
of	NULL
PBMCs	NULL
with	NULL
mutant	NULL
viruses	NULL
HIVAAP-1	NULL
(	NULL
LILIII	NULL
)	NULL
/AP3-L	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
L	NULL
,	NULL
IL	NULL
,	NULL
II	NULL
)	NULL
/AP3-L/	NULL
DBF	NULL
produced	NULL
very	NULL
low	NULL
RT	NULL
release	NULL
(	NULL
about	NULL
8	NULL
times	NULL
less	NULL
than	NULL
the	NULL
amount	NULL
released	NULL
from	NULL
cultures	NULL
infected	NULL
with	NULL
the	NULL
wt	NULL
HIV	NULL
at	NULL
the	NULL
peak	NULL
of	NULL
virus	NULL
production	NULL
)	NULL
,	NULL
demonstrating	NULL
severely	NULL
reduced	NULL
growth	NULL
kinetics	NULL
(	NULL
Fig	NULL
.	NULL

9C	NULL
,	NULL
left	NULL
)	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
those	NULL
obtained	NULL
after	NULL
transfection-cocultivation	NULL
assays	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
growth	NULL
properties	NULL
of	NULL
mutant	NULL
viruses	NULL
on	NULL
the	NULL
T-lymphocyte	NULL
cell	NULL
lines	NULL
Jurkat	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
and	NULL
SupT1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
assayed	NULL
.	NULL

However	NULL
,	NULL
although	NULL
HIVAAP-1	NULL
(	NULL
L	NULL
,	NULL
IL	NULL
,	NULL
HI	NULL
)	NULL
/AP3-L/DBF	NULL
demonstrated	NULL
delayed	NULL
kinetics	NULL
and	NULL
produced	NULL
lower	NULL
concentrations	NULL
of	NULL
viral	NULL
antigen	NULL
than	NULL
did	NULL
the	NULL
wt	NULL
in	NULL
Jurkat	NULL
and	NULL
SupT1	NULL
,	NULL
this	NULL
mutant	NULL
was	NULL
less	NULL
defective	NULL
for	NULL
replication	NULL
in	NULL
T-cell	NULL
lines	NULL
than	NULL
it	NULL
was	NULL
in	NULL
stimulated	NULL
PBMCs	NULL
.	NULL

These	NULL
differences	NULL
may	NULL
be	NULL
due	NULL
to	NULL
different	NULL
levels	NULL
of	NULL
specific	NULL
transcription	NULL
factors	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
examined	NULL
.	NULL

Such	NULL
cell-type-specific	NULL
differences	NULL
in	NULL
the	NULL
replication	NULL
properties	NULL
of	NULL
HIV-1	NULL
have	NULL
been	NULL
reported	NULL
by	NULL
others	NULL
studying	NULL
Tat	NULL
activation	NULL
response	NULL
element	NULL
(	NULL
TAR	NULL
)	NULL
and	NULL
LTR	NULL
mutant	NULL
viruses	NULL
25	NULL
,	NULL
42	NULL
)	NULL
.	NULL

(	NULL
Thus	NULL
)	NULL
,	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
sites	NULL
downstream	NULL
of	NULL
the	NULL
HIV-1	NULL
transcription	NULL
start	NULL
site	NULL
is	NULL
critical	NULL
for	NULL
HIV-1	NULL
replication	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
indicating	NULL
a	NULL
positive	NULL
regulatory	NULL
function	NULL
for	NULL
this	NULL
region	NULL
.	NULL

Our	NULL
findings	NULL
strongly	NULL
suggest	NULL
a	NULL
crucial	NULL
role	NULL
of	NULL
the	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
and	NULL
AP-1	NULL
(	NULL
II	NULL
)	NULL
sites	NULL
on	NULL
HIV-1	NULL
replication	NULL
[	NULL
compare	NULL
viruses	NULL
HIVAAP-1	NULL
(	NULL
IID	NULL
)	NULL
/AP3-L	NULL
with	NULL
HIVAAP-1	NULL
(	NULL
L	NULL
,	NULL
ILIM	NULL
)	NULL
/AP3-L	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L/DBF	NULL
with	NULL
HIVAAP-1	NULL
(	NULL
LILIIN	NULL
)	NULL
/	NULL
AP3-L/DBF	NULL
]	NULL
.	NULL

Mutations	NULL
do	NULL
not	NULL
affect	NULL
virus	NULL
RNA	NULL
packaging	NULL
.	NULL

As	NULL
discussed	NULL
above	NULL
,	NULL
the	NULL
RNA	NULL
leader	NULL
sequence	NULL
of	NULL
HIV-1	NULL
is	NULL
assumed	NULL
to	NULL
adopt	NULL
a	NULL
stable	NULL
secondary	NULL
structure	NULL
that	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
packaging	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
in	NULL
particles	NULL
(	NULL
6	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
each	NULL
of	NULL
the	NULL
HS4	NULL
mutations	NULL
could	NULL
,	NULL
in	NULL
principle	NULL
,	NULL
be	NULL
deleterious	NULL
to	NULL
virus	NULL
rep	NULL
lication	NULL
by	NULL
impairing	NULL
RNA	NULL
packaging	NULL
.	NULL

To	NULL
test	NULL
such	NULL
a	NULL
possibility	NULL
,	NULL
we	NULL
used	NULL
RNase	NULL
protection	NULL
assays	NULL
to	NULL
quantify	NULL
HIV	NULL
RNA	NULL
from	NULL
equivalent	NULL
amounts	NULL
of	NULL
viral	NULL
particles	NULL
from	NULL
each	NULL
mutant	NULL
virus	NULL
stock	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
showed	NULL
that	NULL
the	NULL
wt	NULL
and	NULL
mutant	NULL
viruses	NULL
contained	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
packaged	NULL
RNA	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
)	NULL
.	NULL

As	NULL
an	NULL
internal	NULL
control	NULL
,	NULL
we	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
HIV-1-specific	NULL
proteins	NULL
in	NULL
each	NULL
of	NULL
the	NULL
mutant	NULL
viruses	NULL
.	NULL

Lysates	NULL
from	NULL
equivalent	NULL
amounts	NULL
of	NULL
RT	NULL
activity	NULL
from	NULL
the	NULL
wild-type	NULL
and	NULL
mutant	NULL
virus	NULL
stocks	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analyses	NULL
were	NULL
performed	NULL
with	NULL
purified	NULL
human	NULL
anti-HIV-1	NULL
IgG	NULL
.	NULL

Similar	NULL
levels	NULL
of	NULL
p24	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
and	NULL
of	NULL
the	NULL
other	NULL
viral	NULL
structural	NULL
proteins	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
detected	NULL
in	NULL
all	NULL
lysates	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
reduced	NULL
replication	NULL
phenotypes	NULL
we	NULL
observed	NULL
with	NULL
mutant	NULL
viruses	NULL
were	NULL
not	NULL
due	NULL
to	NULL
defects	NULL
in	NULL
RNA	NULL
packaging	NULL
.	NULL

Since	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
generate	NULL
virus	NULL
stocks	NULL
with	NULL
the	NULL
SP1	NULL
mutants	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
mutations	NULL
on	NULL
packaging	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
into	NULL
particles	NULL
could	NULL
not	NULL
be	NULL
as-sessed	NULL
.	NULL

Downstream	NULL
binding	NULL
sites	NULL
play	NULL
a	NULL
positive	NULL
regulatory	NULL
role	NULL
on	NULL
HIV-1	NULL
transcription	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
transcriptional	NULL
regulatory	NULL
function	NULL
of	NULL
the	NULL
HS4	NULL
binding	NULL
sites	NULL
,	NULL
the	NULL
single-LTR-containing	NULL
proviral	NULL
constructs	NULL
carrying	NULL
the	NULL
HS4	NULL
mutations	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
purified	NULL
24	NULL
and	NULL
48	NULL
h	NULL
posttransfection	NULL
.	NULL

Steady-state	NULL
levels	NULL
of	NULL
HIV-1	NULL
mRNA	NULL
were	NULL
measured	NULL
by	NULL
the	NULL
RNase	NULL
protection	NULL
assay	NULL
with	NULL
an	NULL
HIV-1	NULL
promoter-specific	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

11A	NULL
)	NULL
.	NULL

RNase	NULL
protection	NULL
analysis	NULL
of	NULL
the	NULL
same	NULL
cellular	NULL
extracts	NULL
with	NULL
an	NULL
antisense	NULL
probe	NULL
for	NULL
the	NULL
GAPDH	NULL
gene	NULL
was	NULL
performed	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
to	NULL
correct	NULL
sample-to-sample	NULL
variations	NULL
in	NULL
mRNA	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

11A	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

11B	NULL
,	NULL
individual	NULL
mutation	NULL
of	NULL
the	NULL
DBF	NULL
or	NULL
AP3-L	NULL
site	NULL
as	NULL
well	NULL
as	NULL
the	NULL
double	NULL
mutation	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L	NULL
reduced	NULL
the	NULL
viral	NULL
RNA	NULL
level	NULL
(	NULL
to	NULL
64	NULL
,	NULL
47	NULL
,	NULL
and	NULL
51	NULL
%	NULL
of	NULL
the	NULL
wt	NULL
level	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
although	NULL
these	NULL
mutations	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
HIV-1	NULL
replication	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
AP3-L/DBF	NULL
and	NULL
of	NULL
the	NULL
AP-1	NULL
(	NULL
IIl	NULL
)	NULL
/	NULL
AP3-L/DBF	NULL
sites	NULL
resulted	NULL
in	NULL
a	NULL
dramatic	NULL
decrease	NULL
of	NULL
LTR-mediated	NULL
transcription	NULL
,	NULL
resulting	NULL
in	NULL
as	NULL
little	NULL
as	NULL
24	NULL
and	NULL
18	NULL
%	NULL
of	NULL
the	NULL
wt	NULL
expression	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

11B	NULL
)	NULL
.	NULL

These	NULL
transfection	NULL
results	NULL
contrast	NULL
with	NULL
our	NULL
infection	NULL
experiments	NULL
,	NULL
in	NULL
which	NULL
the	NULL
same	NULL
mutations	NULL
only	NULL
slightly	NULL
delayed	NULL
HIV-1	NULL
replication	NULL
(	NULL
see	NULL
above	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
HIV	NULL
genome	NULL
compensate	NULL
for	NULL
the	NULL
deleterious	NULL
effects	NULL
of	NULL
these	NULL
muta-	NULL
6122	NULL
VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
PBMC	NULL
1600	NULL
3	NULL
E	NULL
1200	NULL
5	NULL
S	NULL
§	NULL
800	NULL
'	NULL
a	NULL
>	NULL
ba	NULL
>	NULL
o	NULL
400	NULL
0	NULL
4	NULL
t	NULL
1	NULL
0	NULL
5	NULL
10	NULL
15	NULL
days	NULL
postinfection	NULL
_	NULL
,	NULL
_	NULL
1200	NULL
3	NULL
E	NULL
5	NULL
soo	NULL
3	NULL
3	NULL
E	NULL
pa	NULL
400	NULL
[	NULL
a	NULL
0	NULL
days	NULL
postinfection	NULL
1200	NULL
€	NULL
E	NULL
800	NULL
I	NULL
8	NULL
3	NULL
s	NULL
400	NULL
lsp	NULL
!	NULL

P4	NULL
days	NULL
postinfection	NULL
J.	NULL
ViRoL	NULL
.	NULL

Jurkat	NULL
16000	NULL
12000	NULL
8000	NULL
RT	NULL
value	NULL
(	NULL
cpm/ul	NULL
)	NULL
4000	NULL
&	NULL
tn	NULL
10	NULL
15	NULL
20	NULL
25	NULL
days	NULL
postinfection	NULL
16000	NULL
12000	NULL
8000	NULL
4000	NULL
RT	NULL
value	NULL
(	NULL
cpm/ul	NULL
)	NULL
&	NULL
J	NULL
10	NULL
15	NULL
20	NULL
25	NULL
days	NULL
postinfection	NULL
12000	NULL
8000	NULL
4000	NULL
RT	NULL
value	NULL
(	NULL
cpm/ul	NULL
)	NULL
&	NULL
tn	NULL
10	NULL
15	NULL
20	NULL
25	NULL
days	NULL
postinfection	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
HS4	NULL
binding	NULL
sites	NULL
affect	NULL
HIV-1	NULL
growth	NULL
kinetics	NULL
.	NULL

PHA-activated	NULL
human	NULL
PBMCs	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
equivalent	NULL
amounts	NULL
of	NULL
RT	NULL
activity	NULL
of	NULL
wt	NULL
or	NULL
mutant	NULL
HIV	NULL
infectious	NULL
stocks	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
at	NULL
different	NULL
times	NULL
following	NULL
infection	NULL
and	NULL
analyzed	NULL
for	NULL
RT	NULL
activity	NULL
.	NULL

Results	NULL
for	NULL
HIV	NULL
(	NULL
#	NULL
)	NULL
,	NULL
HIVADBF	NULL
(	NULL
0	NULL
)	NULL
,	NULL
HIVAAP3-L	NULL
(	NULL
A	NULL
)	NULL
,	NULL
HIVAAP-1	NULL
(	NULL
IIMY/AP3-L	NULL
(	NULL
x	NULL
)	NULL
,	NULL
HIVVAAP-1	NULL
(	NULL
LILID	NULL
)	NULL
/AP3-L	NULL
(	NULL
@	NULL
)	NULL
,	NULL
HIVAAP3-L/DBF	NULL
(	NULL
@	NULL
)	NULL
,	NULL
HIVAAP-1	NULL
(	NULL
IIM	NULL
)	NULL
/AP3-L/DBF	NULL
(	NULL
A	NULL
)	NULL
,	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
LILIID/AP3-L/DBF	NULL
(	NULL
0	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
means	NULL
of	NULL
duplicate	NULL
samples	NULL
are	NULL
presented	NULL
.	NULL

Infections	NULL
were	NULL
performed	NULL
three	NULL
times	NULL
with	NULL
identical	NULL
results	NULL
.	NULL

A	NULL
representative	NULL
experiment	NULL
is	NULL
shown	NULL
.	NULL

tions	NULL
on	NULL
viral	NULL
transcription	NULL
.	NULL

Mutation	NULL
of	NULL
AP-1	NULL
(	NULL
L	NULL
,	NULL
ILIM	NULL
)	NULL
/AP3-L	NULL
and	NULL
of	NULL
AP-1	NULL
(	NULL
LILIII	NULL
)	NULL
/AP3-L/DBF	NULL
sites	NULL
also	NULL
resulted	NULL
in	NULL
decreased	NULL
HIV-1	NULL
mRNA	NULL
levels	NULL
(	NULL
28	NULL
and	NULL
26	NULL
%	NULL
respectively	NULL
[	NULL
Fig	NULL
.	NULL

11B	NULL
]	NULL
)	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
our	NULL
infection	NULL
studies	NULL
in	NULL
which	NULL
these	NULL
mutant	NULL
viruses	NULL
demonstrated	NULL
a	NULL
severely	NULL
reduced	NULL
replication	NULL
phenotype	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
mutations	NULL
of	NULL
the	NULL
Sp1	NULL
sites	NULL
were	NULL
lethal	NULL
for	NULL
the	NULL
virus	NULL
and	NULL
were	NULL
therefore	NULL
expected	NULL
to	NULL
demonstrate	NULL
the	NULL
most	NULL
significant	NULL
effects	NULL
on	NULL
HIV-1	NULL
transcription	NULL
.	NULL

However	NULL
,	NULL
transfection	NULL
of	NULL
pHIVAPS/SP1	NULL
and	NULL
pHIVASP1	NULL
had	NULL
almost	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
viral	NULL
mRNA	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
Sp1	NULL
sites	NULL
had	NULL
no	NULL
positive	NULL
function	NULL
on	NULL
the	NULL
HIV-1	NULL
promoter	NULL
under	NULL
these	NULL
experimental	NULL
conditions	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
a	NULL
construction	NULL
containing	NULL
the	NULL
HIV	NULL
LTR	NULL
carrying	NULL
the	NULL
same	NULL
mutations	NULL
was	NULL
cotransfected	NULL
with	NULL
a	NULL
Tat	NULL
ex	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
Ue	NULL
A	NULL
m	NULL
3e	NULL
Fl	NULL
)	NULL
O	NULL
m	NULL
u	NULL
&	NULL
3	NULL
a	NULL
o	NULL
<	NULL
o	NULL
<	NULL
IFE	NULL
=	NULL
=	NULL
a	NULL
2	NULL
&	NULL
2	NULL
)	NULL
)	NULL
|	NULL
Le	NULL
&	NULL
E	NULL
2a	NULL
E	NULL
S	NULL
0	NULL
o	NULL
cr	NULL
orc	NULL
lp	NULL
3	NULL
©	NULL
o.	NULL
o	NULL
.	NULL

0	NULL
.	NULL

A	NULL
.	NULL

A	NULL
.	NULL

A.	NULL
g	NULL
4	NULL
o	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
x	NULL
se	NULL
2	NULL
2	NULL
22	NULL
2	NULL
(	NULL
ny	NULL
3	NULL
$	NULL
2222	NULL
2	NULL
2	NULL
2	NULL
2	NULL
>	NULL
£	NULL
Z	NULL
E	NULL
E	NULL
=	NULL
#	NULL
#	NULL
=	NULL
242	NULL
-	NULL
WW	NULL
e	NULL
190	NULL
-	NULL
#	NULL
ad	NULL
<	NULL
-	NULL
s	NULL
:	NULL
:	NULL
157	NULL
-	NULL
in	NULL
147	NULL
-	NULL
®	NULL
110	NULL
-	NULL
®	NULL
880080808000	NULL
<	NULL
-	NULL
sit	NULL
:	NULL
-	NULL
‘	NULL
.	NULL

--	NULL
-—-67	NULL
-	NULL
®	NULL
B	NULL
MW	NULL
(	NULL
kDa	NULL
)	NULL
43	NULL
dll	NULL
“	NULL
$	NULL
0	NULL
.	NULL

24	NULL
Ts	NULL
L	NULL
<	NULL
-	NULL
p	NULL
t	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

HS4	NULL
mutations	NULL
do	NULL
not	NULL
affect	NULL
HIV	NULL
genomic	NULL
packaging	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Equivalent	NULL
amounts	NULL
of	NULL
viral	NULL
particles	NULL
(	NULL
assessed	NULL
by	NULL
the	NULL
RT	NULL
assay	NULL
)	NULL
from	NULL
each	NULL
mutant	NULL
HIV	NULL
stock	NULL
were	NULL
pelleted	NULL
by	NULL
ultracentrifugation	NULL
.	NULL

After	NULL
lysis	NULL
of	NULL
viral	NULL
particles	NULL
in	NULL
guanidine	NULL
thiocyanate	NULL
,	NULL
HIV-1	NULL
RNA	NULL
was	NULL
detected	NULL
by	NULL
RNase	NULL
protection	NULL
analysis	NULL
with	NULL
an	NULL
antisense	NULL
HIV-1	NULL
riboprobe	NULL
which	NULL
protects	NULL
two	NULL
bands	NULL
(	NULL
200	NULL
and	NULL
83	NULL
nt	NULL
)	NULL
corresponding	NULL
to	NULL
the	NULL
3	NULL
'	NULL
and	NULL
5°	NULL
LTR	NULL
,	NULL
respectively	NULL
.	NULL

Lane	NULL
Marker	NULL
contains	NULL
pSK-/Apell	NULL
markers	NULL
,	NULL
whose	NULL
sizes	NULL
(	NULL
in	NULL
nucleotides	NULL
)	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

Intensities	NULL
of	NULL
RNA	NULL
bands	NULL
were	NULL
quantified	NULL
by	NULL
radioimaging	NULL
analysis	NULL
(	NULL
InstantImager	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
ultracentrifuged	NULL
viral	NULL
stocks	NULL
described	NULL
in	NULL
panel	NULL
A	NULL
were	NULL
lysed	NULL
in	NULL
Laemmli	NULL
buffer	NULL
,	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-HIV-1	NULL
immunoglobulin	NULL
(	NULL
donated	NULL
by	NULL
Alfred	NULL
Prince	NULL
,	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
)	NULL
,	NULL
and	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
with	NULL
a	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-human	NULL
IgG	NULL
.	NULL

MW	NULL
,	NULL
molecular	NULL
mass	NULL
(	NULL
indicated	NULL
in	NULL
kilodaltons	NULL
)	NULL
.	NULL

pression	NULL
vector	NULL
(	NULL
59	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

11C	NULL
)	NULL
,	NULL
except	NULL
for	NULL
pLTRAAP-1	NULL
(	NULL
L	NULL
,	NULL
II	NULL
,	NULL
IID	NULL
)	NULL
/AP3L	NULL
,	NULL
which	NULL
showed	NULL
normal	NULL
transcriptional	NULL
activity	NULL
,	NULL
whereas	NULL
it	NULL
showed	NULL
defective	NULL
activity	NULL
in	NULL
the	NULL
complete	NULL
virus	NULL
transfection	NULL
assay	NULL
.	NULL

This	NULL
discrepancy	NULL
could	NULL
be	NULL
due	NULL
to	NULL
the	NULL
role	NULL
of	NULL
other	NULL
HIV-encoded	NULL
proteins	NULL
that	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
transcriptional	NULL
regulation	NULL
or	NULL
to	NULL
pleiotropic	NULL
effects	NULL
at	NULL
the	NULL
level	NULL
of	NULL
RNA	NULL
stability	NULL
or	NULL
dimerization	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
other	NULL
cell	NULL
lines	NULL
(	NULL
Raji	NULL
,	NULL
SupT1	NULL
)	NULL
and	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
demonstrate	NULL
that	NULL
the	NULL
positive	NULL
regulatory	NULL
function	NULL
of	NULL
the	NULL
downstream	NULL
binding	NULL
sites	NULL
takes	NULL
place	NULL
in	NULL
part	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
.	NULL

DISCUSSION	NULL
A	NULL
cluster	NULL
of	NULL
binding	NULL
sites	NULL
for	NULL
several	NULL
transcription	NULL
factors	NULL
(	NULL
AP-1	NULL
,	NULL
AP3-L/NF-AT	NULL
,	NULL
DBF/IRF	NULL
,	NULL
and	NULL
SP1	NULL
)	NULL
has	NULL
been	NULL
identified	NULL
downstream	NULL
of	NULL
the	NULL
HIV-1	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
characterized	NULL
each	NULL
of	NULL
these	NULL
binding	NULL
sites	NULL
and	NULL
have	NULL
identified	NULL
minimal	NULL
point	NULL
mutations	NULL
that	NULL
elimi-	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
-	NULL
6123	NULL
nated	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
factors	NULL
to	NULL
their	NULL
respective	NULL
sites	NULL
.	NULL

The	NULL
AP3-L	NULL
site	NULL
is	NULL
shown	NULL
to	NULL
bind	NULL
an	NULL
ionomycin-inducible	NULL
factor	NULL
corresponding	NULL
to	NULL
NF-AT	NULL
,	NULL
and	NULL
the	NULL
DBF	NULL
site	NULL
binds	NULL
IRF1	NULL
and	NULL
IRF2	NULL
factors	NULL
.	NULL

HIV-1	NULL
proviruses	NULL
containing	NULL
individual	NULL
or	NULL
combinations	NULL
of	NULL
the	NULL
mutated	NULL
sites	NULL
were	NULL
generated	NULL
,	NULL
and	NULL
their	NULL
growth	NULL
kinetics	NULL
on	NULL
human	NULL
PBMCs	NULL
and	NULL
T-lymphocyte	NULL
cell	NULL
lines	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
wt	NULL
HIV-1	NULL
.	NULL

Individual	NULL
mutation	NULL
of	NULL
the	NULL
DBF	NULL
or	NULL
AP3-L	NULL
site	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
double	NULL
mutation	NULL
AP-1	NULL
(	NULL
HI	NULL
)	NULL
/AP3-L	NULL
,	NULL
did	NULL
not	NULL
affect	NULL
HIV-1	NULL
replication	NULL
.	NULL

Proviruses	NULL
carrying	NULL
mutations	NULL
in	NULL
the	NULL
Sp1	NULL
sites	NULL
were	NULL
found	NULL
to	NULL
be	NULL
defective	NULL
for	NULL
virus	NULL
replication	NULL
.	NULL

Virus	NULL
production	NULL
occurred	NULL
with	NULL
slightly	NULL
delayed	NULL
kinetics	NULL
with	NULL
viruses	NULL
containing	NULL
mutations	NULL
in	NULL
AP-1	NULL
(	NULL
IIl	NULL
)	NULL
/	NULL
AP3-L/DBF	NULL
sites	NULL
and	NULL
in	NULL
AP3-L/DBF	NULL
sites	NULL
.	NULL

Viruses	NULL
mutated	NULL
in	NULL
AP-1	NULL
(	NULL
LILII	NULL
)	NULL
/AP3-L	NULL
sites	NULL
and	NULL
in	NULL
AP-1	NULL
(	NULL
LILIII	NULL
)	NULL
/AP3-L/DBF	NULL
sites	NULL
exhibited	NULL
severely	NULL
reduced	NULL
replication	NULL
.	NULL

RNase	NULL
protection	NULL
assays	NULL
from	NULL
equivalent	NULL
amounts	NULL
of	NULL
viral	NULL
particles	NULL
from	NULL
each	NULL
mutant	NULL
HIV	NULL
stock	NULL
showed	NULL
no	NULL
RNA-packaging	NULL
defect	NULL
.	NULL

Further-more	NULL
,	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
HS4	NULL
region	NULL
nearly	NULL
completely	NULL
inhibited	NULL
HIV-1	NULL
LTR-directed	NULL
transcription	NULL
,	NULL
suggesting	NULL
that	NULL
cis-acting	NULL
elements	NULL
within	NULL
this	NULL
region	NULL
are	NULL
required	NULL
for	NULL
optimal	NULL
promoter	NULL
activity	NULL
.	NULL

Role	NULL
of	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
in	NULL
HIV-1	NULL
replication	NULL
.	NULL

(	NULL
i	NULL
)	NULL
AP-1	NULL
sites	NULL
.	NULL

Functionally	NULL
important	NULL
AP-1	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
regulatory	NULL
regions	NULL
of	NULL
cellular	NULL
genes	NULL
and	NULL
of	NULL
retroviruses	NULL
,	NULL
including	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
human	NULL
foamy	NULL
virus	NULL
,	NULL
and	NULL
feline	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
36	NULL
,	NULL
52	NULL
,	NULL
74	NULL
)	NULL
.	NULL

Further-more	NULL
,	NULL
AP-1	NULL
binding	NULL
sites	NULL
have	NULL
also	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
genome	NULL
of	NULL
the	NULL
lentivirus	NULL
visna	NULL
virus	NULL
,	NULL
where	NULL
they	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
basal	NULL
activity	NULL
and	NULL
transactivation	NULL
of	NULL
the	NULL
viral	NULL
LTR	NULL
by	NULL
the	NULL
virus-encoded	NULL
TAT	NULL
protein	NULL
(	NULL
19	NULL
,	NULL
29	NULL
)	NULL
.	NULL

HIVAAP3-L	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L	NULL
both	NULL
exhibit	NULL
a	NULL
replication	NULL
phenotype	NULL
similar	NULL
to	NULL
wt	NULL
HIV	NULL
,	NULL
and	NULL
HIVAAP3-L/DBF	NULL
and	NULL
HIVAAP-1	NULL
(	NULL
III	NULL
)	NULL
/AP3-L/DBF	NULL
both	NULL
display	NULL
slightly	NULL
delayed	NULL
replication	NULL
,	NULL
suggesting	NULL
that	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
the	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
site	NULL
may	NULL
not	NULL
be	NULL
critical	NULL
for	NULL
HIV-1	NULL
replication	NULL
,	NULL
although	NULL
this	NULL
site	NULL
binds	NULL
AP-1	NULL
with	NULL
a	NULL
stronger	NULL
affinity	NULL
than	NULL
does	NULL
either	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
or	NULL
AP-1	NULL
(	NULL
II	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
have	NULL
observed	NULL
a	NULL
severe	NULL
delay	NULL
in	NULL
replication	NULL
with	NULL
HIVAAP-1	NULL
(	NULL
LILIII	NULL
)	NULL
/AP3-L	NULL
and	NULL
with	NULL
HIVAAP-1	NULL
(	NULL
LIL	NULL
,	NULL
IM	NULL
}	NULL
)	NULL
/AP3-L/DBF	NULL
in	NULL
both	NULL
transfection	NULL
and	NULL
infection	NULL
assays	NULL
.	NULL

These	NULL
mutations	NULL
affect	NULL
viral	NULL
replication	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
our	NULL
transfection	NULL
studies	NULL
.	NULL

These	NULL
results	NULL
therefore	NULL
indicate	NULL
a	NULL
crucial	NULL
role	NULL
of	NULL
AP-1	NULL
(	NULL
I	NULL
)	NULL
and	NULL
AP-1	NULL
(	NULL
II	NULL
)	NULL
sites	NULL
in	NULL
HIV-1	NULL
transcription	NULL
and	NULL
replication	NULL
.	NULL

While	NULL
these	NULL
AP-1	NULL
sites	NULL
were	NULL
initially	NULL
characterized	NULL
by	NULL
in	NULL
vitro	NULL
footprinting	NULL
assays	NULL
with	NULL
purified	NULL
c-jun	NULL
protein	NULL
(	NULL
13	NULL
)	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
stress	NULL
that	NULL
we	NULL
have	NULL
not	NULL
yet	NULL
identified	NULL
the	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
these	NULL
sites	NULL
under	NULL
physiological	NULL
conditions	NULL
.	NULL

The	NULL
AP-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
is	NULL
composed	NULL
of	NULL
representatives	NULL
from	NULL
the	NULL
jun	NULL
and	NULL
fos	NULL
family	NULL
that	NULL
can	NULL
homo-	NULL
or	NULL
heterodimerize	NULL
(	NULL
4	NULL
,	NULL
15	NULL
,	NULL
41	NULL
,	NULL
65	NULL
,	NULL
73	NULL
,	NULL
84	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
jun	NULL
proteins	NULL
can	NULL
heterodimerize	NULL
with	NULL
ATF/CREB	NULL
proteins	NULL
,	NULL
thereby	NULL
further	NULL
increasing	NULL
the	NULL
potential	NULL
diversity	NULL
of	NULL
factors	NULL
bound	NULL
to	NULL
AP-1	NULL
sites	NULL
(	NULL
7	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Different	NULL
specificities	NULL
in	NULL
terms	NULL
of	NULL
DNA	NULL
binding	NULL
can	NULL
therefore	NULL
be	NULL
generated	NULL
depending	NULL
on	NULL
the	NULL
partners	NULL
in	NULL
the	NULL
complex	NULL
.	NULL

Preliminary	NULL
characterization	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
sites	NULL
I	NULL
and	NULL
III	NULL
suggested	NULL
that	NULL
these	NULL
sites	NULL
interact	NULL
with	NULL
factors	NULL
distinct	NULL
from	NULL
jun	NULL
and	NULL
fos	NULL
(	NULL
63	NULL
)	NULL
.	NULL

Further	NULL
characterization	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
these	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
leader	NULL
sequence	NULL
will	NULL
shed	NULL
new	NULL
light	NULL
on	NULL
their	NULL
role	NULL
in	NULL
HIV-1	NULL
transcriptional	NULL
regulation	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
AP3-L/NF-AT	NULL
motif	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
sequence	NULL
homology	NULL
and	NULL
gel	NULL
retardation	NULL
experiments	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
the	NULL
AP3-L	NULL
site	NULL
as	NULL
an	NULL
NF-AT	NULL
binding	NULL
site	NULL
.	NULL

Interestingly	NULL
,	NULL
uninduced	NULL
nuclear	NULL
extracts	NULL
from	NULL
several	NULL
lymphoid	NULL
cell	NULL
lines	NULL
contained	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
AP3-L	NULL
probe	NULL
,	NULL
even	NULL
though	NULL
the	NULL
NF-AT	NULL
binding	NULL
activity	NULL
is	NULL
typically	NULL
dependent	NULL
on	NULL
T-cell	NULL
activation	NULL
signals	NULL
(	NULL
Fig	NULL
.	NULL

6124	NULL
VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

pHIVADBF	NULL
pHIVAAP3L	NULL
pHIVAAP1	NULL
(	NULL
I/AP3L	NULL
pHIVAAP1	NULL
(	NULL
LILINYAP3L	NULL
pHIVAAP3LDBF	NULL
pHIVAAP1	NULL
(	NULL
IIVAP3LDBF	NULL
pHIVAAP1	NULL
(	NULL
LILIIYAPEL/DBF	NULL
pHIVAPS/ISP1	NULL
pHIVASP1	NULL
4	NULL
>	NULL
AIE	NULL
:	NULL
a	NULL
a	NULL
€	NULL
e	NULL
hae	NULL
rae	NULL
eee	NULL
aree	NULL
ae	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
24	NULL
48	NULL
time	NULL
(	NULL
hr	NULL
)	NULL
190	NULL
-	NULL
I	NULL
<	NULL
-	NULL
free	NULL
probe	NULL
ta	NULL
®	NULL
ae	NULL
to	NULL
#	NULL
#	NULL
)	NULL
<	NULL
-	NULL
sLTR	NULL
157	NULL
sbsBsBe0s0	NULL
=s	NULL
-	NULL
c~~	NULL
T	NULL
.	NULL

,	NULL
s	NULL
§	NULL
Transcription	NULL
(	NULL
relative	NULL
amount	NULL
)	NULL
Pd	NULL
S	NULL
o	NULL
ZiE1	NULL
=	NULL
l	NULL
lk	NULL
r	NULL
s	NULL
a	NULL
&	NULL
)	NULL
&	NULL
&	NULL
,	NULL
,	NULL
&	NULL
aA	NULL
EEE	NULL
¢	NULL
ge	NULL
z	NULL
.	NULL

@	NULL
&	NULL
&	NULL
&	NULL
2	NULL
c	NULL
citi	NULL
ts..	NULL
&	NULL
.	NULL

&	NULL
..	NULL
2	NULL
,	NULL
&	NULL
'	NULL
c	NULL
'	NULL
ck	NULL
as	NULL
&	NULL
&	NULL
..	NULL
§	NULL
.	NULL

7.	NULL
cises	NULL
£	NULL
£	NULL
,	NULL
&	NULL
>	NULL
ime	NULL
ammetcAnt	NULL
Io	NULL
g	NULL
iM	NULL
lE	NULL
£5	NULL
a.	NULL
lE	NULL
mllh	NULL
a	NULL
3	NULL
140	NULL
5	NULL
§	NULL
120	NULL
a	NULL
&	NULL
100	NULL
5	NULL
3	NULL
280	NULL
&	NULL
&	NULL
60	NULL
5	NULL
8	NULL
-	NULL
40	NULL
a	NULL
9	NULL
2°	NULL
#	NULL
5	NULL
§	NULL
o	NULL
l	NULL
wa	NULL
|	NULL
T	NULL
m	NULL
T	NULL
e	NULL
I	NULL
mee	NULL
=+	NULL
Tz	NULL
»	NULL
H	NULL
EEﬁﬁmmmma-a	NULL
.	NULL

allele	NULL
|	NULL
2g	NULL
&	NULL
)	NULL
.	NULL

§	NULL
.	NULL

&	NULL
,	NULL
3	NULL
a§	NULL
<	NULL
$	NULL
5454£§	NULL
§2Cmmn	NULL
:	NULL
2	NULL
—=a.n.o.§	NULL
:	NULL
s	NULL
Ee	NULL
s	NULL
as	NULL
\..	NULL
£	NULL
,	NULL
,	NULL
§	NULL
,	NULL
%	NULL
“	NULL
am	NULL
:	NULL
’	NULL
§554	NULL
%	NULL
IE	NULL
I	NULL
§	NULL
A	NULL
fills	NULL
§	NULL
<	NULL
3	NULL
A	NULL
a.	NULL
ﬁg	NULL
id	NULL
=	NULL
FIG	NULL
.	NULL

11	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
HS4	NULL
mutations	NULL
on	NULL
HIV-1	NULL
transcription	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
HIV-1	NULL
DNA	NULL
proviral	NULL
constructs	NULL
was	NULL
determined	NULL
following	NULL
transient	NULL
transfection	NULL
into	NULL
Jurkat	NULL
cells	NULL
and	NULL
analysis	NULL
by	NULL
an	NULL
RNase	NULL
protection	NULL
assay	NULL
24	NULL
and	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Names	NULL
of	NULL
the	NULL
proviral	NULL
constructs	NULL
transfected	NULL
are	NULL
indicated	NULL
at	NULL
the	NULL
top	NULL
of	NULL
each	NULL
lane	NULL
.	NULL

Cellular	NULL
lysates	NULL
were	NULL
incubated	NULL
with	NULL
two	NULL
specific	NULL
probes	NULL
corresponding	NULL
to	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
to	NULL
the	NULL
GAPDH	NULL
promoter	NULL
.	NULL

The	NULL
figure	NULL
shows	NULL
only	NULL
the	NULL
200-nt	NULL
protected	NULL
band	NULL
corresponding	NULL
to	NULL
the	NULL
HIV-1	NULL
3°	NULL
LTR	NULL
and	NULL
the	NULL
broad	NULL
band	NULL
(	NULL
5	NULL
nt	NULL
wide	NULL
)	NULL
corresponding	NULL
to	NULL
the	NULL
protected	NULL
GAPDH	NULL
probe	NULL
.	NULL

Undigested	NULL
HIV-1	NULL
probe	NULL
is	NULL
shown	NULL
for	NULL
reference	NULL
.	NULL

DNA	NULL
size	NULL
markers	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
left	NULL
for	NULL
reference	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RNA	NULL
bands	NULL
from	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
were	NULL
quantified	NULL
by	NULL
PhosphorImager	NULL
scanning	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

HIV-1	NULL
RNA	NULL
levels	NULL
measured	NULL
48	NULL
h	NULL
posttransfection	NULL
were	NULL
normalized	NULL
relative	NULL
to	NULL
J.	NULL
ViRoL	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

These	NULL
factors	NULL
present	NULL
in	NULL
uninduced	NULL
T	NULL
cells	NULL
could	NULL
correspond	NULL
to	NULL
newly	NULL
identified	NULL
members	NULL
of	NULL
the	NULL
NF-AT	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
NFAT3	NULL
or	NULL
NFATx/NFAT4/	NULL
NFATe3	NULL
(	NULL
31	NULL
,	NULL
32	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Individual	NULL
mutation	NULL
of	NULL
the	NULL
AP3-L/NF-AT	NULL
site	NULL
or	NULL
of	NULL
the	NULL
DBF	NULL
site	NULL
did	NULL
not	NULL
affect	NULL
HIV-1	NULL
replication	NULL
,	NULL
whereas	NULL
the	NULL
simultaneous	NULL
mutation	NULL
of	NULL
both	NULL
sites	NULL
(	NULL
AP3-L/DBF	NULL
)	NULL
slightly	NULL
delayed	NULL
replication	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
sites	NULL
may	NULL
functionally	NULL
substitute	NULL
for	NULL
each	NULL
other	NULL
in	NULL
positively	NULL
regulating	NULL
HIV-1	NULL
transcription	NULL
.	NULL

Another	NULL
NF-AT	NULL
binding	NULL
site	NULL
,	NULL
which	NULL
is	NULL
likely	NULL
to	NULL
functionally	NULL
complement	NULL
the	NULL
site	NULL
that	NULL
we	NULL
mutated	NULL
in	NULL
the	NULL
R	NULL
region	NULL
,	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
70	NULL
)	NULL
.	NULL

Functional	NULL
redundancy	NULL
is	NULL
a	NULL
common	NULL
feature	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
transcriptional	NULL
regulatory	NULL
regions	NULL
and	NULL
has	NULL
been	NULL
extensively	NULL
studied	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
SV40	NULL
enhancer	NULL
(	NULL
17	NULL
,	NULL
28	NULL
,	NULL
57	NULL
,	NULL
83	NULL
)	NULL
.	NULL

Virus	NULL
revertants	NULL
arising	NULL
after	NULL
the	NULL
mutation	NULL
of	NULL
enhancer	NULL
elements	NULL
contained	NULL
duplications	NULL
of	NULL
the	NULL
remaining	NULL
elements	NULL
,	NULL
implying	NULL
that	NULL
different	NULL
parts	NULL
of	NULL
an	NULL
enhancer	NULL
can	NULL
functionally	NULL
substitute	NULL
for	NULL
each	NULL
other	NULL
(	NULL
28	NULL
)	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
DBF/IRF	NULL
site	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
DBF	NULL
site	NULL
presents	NULL
a	NULL
sequence	NULL
homology	NULL
to	NULL
the	NULL
IFN	NULL
response	NULL
element	NULL
and	NULL
binds	NULL
a	NULL
complex	NULL
that	NULL
contains	NULL
both	NULL
the	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
proteins	NULL
.	NULL

The	NULL
IRF-1	NULL
protein	NULL
was	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
ISRE	NULL
of	NULL
IFN-a/B-stimulated	NULL
genes	NULL
(	NULL
24	NULL
,	NULL
45	NULL
)	NULL
.	NULL

It	NULL
is	NULL
present	NULL
in	NULL
low	NULL
concentrations	NULL
under	NULL
basal	NULL
conditions	NULL
and	NULL
is	NULL
induced	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
in	NULL
response	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
cytokines	NULL
including	NULL
IFN-y	NULL
,	NULL
IFN-	NULL
«	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
leukemia	NULL
inhibitory	NULL
factor	NULL
(	NULL
1	NULL
,	NULL
18	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
our	NULL
observations	NULL
,	NULL
Thornton	NULL
et	NULL
al	NULL
.	NULL

recently	NULL
demonstrated	NULL
that	NULL
the	NULL
DBF	NULL
site	NULL
binds	NULL
factors	NULL
specific	NULL
for	NULL
known	NULL
ISREs	NULL
(	NULL
76	NULL
)	NULL
.	NULL

These	NULL
authors	NULL
have	NULL
shown	NULL
that	NULL
cells	NULL
expressing	NULL
a	NULL
dominant	NULL
negative	NULL
factor	NULL
of	NULL
the	NULL
IRF	NULL
family	NULL
are	NULL
nonpermissive	NULL
for	NULL
HIV-1	NULL
infection	NULL
,	NULL
suggesting	NULL
that	NULL
infection	NULL
by	NULL
HIV-1	NULL
is	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
regulated	NULL
by	NULL
an	NULL
IRF-dependent	NULL
transcriptional	NULL
pathway	NULL
(	NULL
s	NULL
)	NULL
(	NULL
76	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
their	NULL
observations	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
binding	NULL
of	NULL
the	NULL
ISGF3	NULL
complex	NULL
to	NULL
the	NULL
HIV	NULL
element	NULL
.	NULL

Our	NULL
binding	NULL
experiments	NULL
therefore	NULL
define	NULL
the	NULL
DBF	NULL
site	NULL
as	NULL
a	NULL
site	NULL
uniquely	NULL
bound	NULL
by	NULL
members	NULL
of	NULL
the	NULL
IRF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
not	NULL
by	NULL
the	NULL
ISGF3	NULL
complex	NULL
.	NULL

We	NULL
have	NULL
not	NULL
examined	NULL
in	NULL
this	NULL
report	NULL
the	NULL
possibility	NULL
that	NULL
this	NULL
site	NULL
functions	NULL
as	NULL
an	NULL
IFN-	NULL
@	NULL
/B-stimulated	NULL
response	NULL
element	NULL
and	NULL
therefore	NULL
confers	NULL
IFN	NULL
responsiveness	NULL
to	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Additionally	NULL
,	NULL
since	NULL
IRF-1	NULL
is	NULL
also	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
IFN-y	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
1	NULL
,	NULL
18	NULL
)	NULL
,	NULL
the	NULL
DBF	NULL
site	NULL
might	NULL
serve	NULL
,	NULL
in	NULL
cooperation	NULL
with	NULL
NF-kB	NULL
,	NULL
TCF-1a	NULL
,	NULL
and	NULL
NF-AT	NULL
,	NULL
to	NULL
increase	NULL
the	NULL
responsiveness	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
to	NULL
extracellular	NULL
activation	NULL
signals	NULL
.	NULL

Experiments	NULL
are	NULL
under	NULL
way	NULL
to	NULL
test	NULL
this	NULL
hypothesis	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
Sp1	NULL
sites	NULL
.	NULL

Whereas	NULL
mutations	NULL
of	NULL
the	NULL
Sp1	NULL
sites	NULL
in	NULL
the	NULL
HS4	NULL
region	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
HIV-1	NULL
promoter	NULL
activity	NULL
in	NULL
transient-transfection	NULL
assays	NULL
(	NULL
reference	NULL
13	NULL
and	NULL
see	NULL
above	NULL
)	NULL
we	NULL
observed	NULL
that	NULL
proviruses	NULL
containing	NULL
the	NULL
same	NULL
mutations	NULL
are	NULL
defective	NULL
for	NULL
virus	NULL
replication	NULL
.	NULL

Three	NULL
possible	NULL
explanations	NULL
can	NULL
be	NULL
proposed	NULL
to	NULL
explain	NULL
these	NULL
results	NULL
.	NULL

(	NULL
i	NULL
)	NULL
Transient-transfection	NULL
experiments	NULL
may	NULL
not	NULL
reflect	NULL
the	NULL
regulation	NULL
found	NULL
in	NULL
vivo	NULL
with	NULL
the	NULL
intact	NULL
provirus	NULL
since	NULL
transiently	NULL
transfected	NULL
DNA	NULL
is	NULL
not	NULL
assembled	NULL
the	NULL
levels	NULL
of	NULL
GAPDH	NULL
RNA	NULL
.	NULL

The	NULL
results	NULL
are	NULL
presented	NULL
as	NULL
histograms	NULL
indicating	NULL
the	NULL
relative	NULL
transcription	NULL
with	NULL
respect	NULL
to	NULL
that	NULL
of	NULL
wild-type	NULL
plasmid	NULL
pHIV	NULL
,	NULL
which	NULL
was	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
100	NULL
%	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Plasmids	NULL
containing	NULL
either	NULL
wt	NULL
or	NULL
mutated	NULL
HIV	NULL
LTR	NULL
driving	NULL
the	NULL
firefly	NULL
luciferase	NULL
were	NULL
cotransfected	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
Tat	NULL
and	NULL
with	NULL
a	NULL
control	NULL
plasmid	NULL
in	NULL
which	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
is	NULL
driving	NULL
the	NULL
renilla	NULL
luciferase	NULL
gene	NULL
expression	NULL
.	NULL

Luciferase	NULL
activities	NULL
(	NULL
firefly	NULL
and	NULL
renilla	NULL
)	NULL
were	NULL
measured	NULL
in	NULL
cellular	NULL
extracts	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
The	NULL
average	NULL
of	NULL
eight	NULL
different	NULL
transfections	NULL
(	NULL
+	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
)	NULL
with	NULL
two	NULL
different	NULL
DNA	NULL
preparations	NULL
are	NULL
shown	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
into	NULL
physiological	NULL
chromatin	NULL
.	NULL

Similar	NULL
discrepancies	NULL
between	NULL
transient	NULL
transfection	NULL
studies	NULL
and	NULL
in	NULL
vivo	NULL
functional	NULL
studies	NULL
have	NULL
been	NULL
reported	NULL
previously	NULL
for	NULL
HIV	NULL
(	NULL
25	NULL
,	NULL
42	NULL
,	NULL
82	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
The	NULL
Sp1	NULL
mutations	NULL
might	NULL
disrupt	NULL
RNA	NULL
packaging	NULL
and	NULL
cause	NULL
a	NULL
replication	NULL
defect	NULL
independent	NULL
of	NULL
transcription	NULL
.	NULL

Indeed	NULL
,	NULL
our	NULL
lack	NULL
of	NULL
understanding	NULL
of	NULL
the	NULL
folding	NULL
of	NULL
the	NULL
RNA	NULL
structure	NULL
involved	NULL
in	NULL
RNA	NULL
packaging	NULL
in	NULL
terms	NULL
of	NULL
tertiary	NULL
or	NULL
quaternary	NULL
RNA	NULL
interactions	NULL
might	NULL
have	NULL
hampered	NULL
our	NULL
efforts	NULL
not	NULL
to	NULL
disrupt	NULL
a	NULL
biologically	NULL
important	NULL
structure	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
The	NULL
HIV	NULL
leader	NULL
sequence	NULL
is	NULL
involved	NULL
in	NULL
other	NULL
RNA	NULL
functions	NULL
which	NULL
include	NULL
dimerization	NULL
,	NULL
translation	NULL
initiation	NULL
,	NULL
and	NULL
efficiency	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
conceivable	NULL
that	NULL
the	NULL
Sp1	NULL
mutations	NULL
affect	NULL
one	NULL
of	NULL
these	NULL
functions	NULL
and	NULL
,	NULL
as	NULL
a	NULL
consequence	NULL
,	NULL
HIV-1	NULL
replication	NULL
.	NULL

Similar	NULL
concerns	NULL
exist	NULL
for	NULL
other	NULL
mutations	NULL
studied	NULL
in	NULL
this	NULL
report	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
HIV	NULL
leader	NULL
RNA	NULL
is	NULL
organized	NULL
in	NULL
a	NULL
large	NULL
structure	NULL
that	NULL
plays	NULL
many	NULL
critical	NULL
roles	NULL
in	NULL
the	NULL
HIV	NULL
life	NULL
cycle	NULL
(	NULL
27	NULL
)	NULL
.	NULL

These	NULL
include	NULL
packaging	NULL
and	NULL
dimerization	NULL
of	NULL
the	NULL
RNA	NULL
genome	NULL
and	NULL
initiation	NULL
of	NULL
reverse	NULL
transcription	NULL
(	NULL
see	NULL
references	NULL
26	NULL
,	NULL
27	NULL
,	NULL
40	NULL
,	NULL
and	NULL
66	NULL
for	NULL
examples	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
disruption	NULL
of	NULL
this	NULL
RNA	NULL
structure	NULL
might	NULL
result	NULL
in	NULL
decreased	NULL
stability	NULL
of	NULL
HIV	NULL
RNA	NULL
.	NULL

While	NULL
we	NULL
have	NULL
excluded	NULL
a	NULL
packaging	NULL
defect	NULL
for	NULL
the	NULL
mutants	NULL
described	NULL
here	NULL
,	NULL
except	NULL
for	NULL
Sp1	NULL
mutations	NULL
,	NULL
other	NULL
pleiotropic	NULL
effects	NULL
of	NULL
these	NULL
mutations	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

Such	NULL
pleiotropic	NULL
effects	NULL
are	NULL
in	NULL
fact	NULL
likely	NULL
in	NULL
the	NULL
case	NULL
of	NULL
mutant	NULL
HIVAAP1	NULL
since	NULL
this	NULL
mutant	NULL
showed	NULL
delayed	NULL
replication	NULL
kinetics	NULL
as	NULL
a	NULL
virus	NULL
and	NULL
little	NULL
to	NULL
no	NULL
effect	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
in	NULL
transient-transfection	NULL
assays	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
other	NULL
viruses	NULL
,	NULL
a	NULL
close	NULL
correlation	NULL
exists	NULL
between	NULL
the	NULL
replication	NULL
kinetics	NULL
of	NULL
the	NULL
virus	NULL
and	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
mutations	NULL
in	NULL
transient-transfection	NULL
reporter	NULL
assays	NULL
,	NULL
and	NULL
it	NULL
is	NULL
therefore	NULL
likely	NULL
that	NULL
the	NULL
replication	NULL
defects	NULL
observed	NULL
are	NULL
transcriptional	NULL
in	NULL
nature	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
a	NULL
single	NULL
nucleosome	NULL
positioned	NULL
at	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
nuc-1	NULL
)	NULL
is	NULL
disrupted	NULL
during	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
(	NULL
78	NULL
,	NULL
81	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
mechanism	NULL
for	NULL
the	NULL
positioning	NULL
and	NULL
disruption	NULL
of	NULL
nuc-1	NULL
is	NULL
at	NULL
present	NULL
unclear	NULL
.	NULL

Three	NULL
distinct	NULL
mechanisms	NULL
potentially	NULL
contribute	NULL
to	NULL
the	NULL
ordering	NULL
of	NULL
nucleosomes	NULL
relative	NULL
to	NULL
nuclease-hypersensitive	NULL
sites	NULL
in	NULL
other	NULL
systems	NULL
:	NULL
(	NULL
i	NULL
)	NULL
sequence-directed	NULL
nucleosome	NULL
positioning	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
statistical	NULL
positioning	NULL
which	NULL
relies	NULL
on	NULL
the	NULL
generation	NULL
of	NULL
boundaries	NULL
by	NULL
nonhistone	NULL
proteins	NULL
causing	NULL
nucleosomal	NULL
arrays	NULL
to	NULL
phase	NULL
themselves	NULL
relative	NULL
to	NULL
these	NULL
boundaries	NULL
,	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
active	NULL
positioning	NULL
of	NULL
a	NULL
nucleosome	NULL
by	NULL
its	NULL
direct	NULL
or	NULL
indirect	NULL
interaction	NULL
with	NULL
a	NULL
trans-acting	NULL
factor	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
72	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
,	NULL
AP3-L	NULL
,	NULL
and	NULL
DBF	NULL
sites	NULL
lie	NULL
at	NULL
the	NULL
3	NULL
'	NULL
boundary	NULL
of	NULL
nuc-1	NULL
,	NULL
these	NULL
sites	NULL
could	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
positioning	NULL
of	NULL
nuc-1	NULL
at	NULL
its	NULL
3	NULL
'	NULL
boundary	NULL
.	NULL

This	NULL
could	NULL
occur	NULL
either	NULL
indirectly	NULL
through	NULL
a	NULL
boundary	NULL
effect	NULL
or	NULL
directly	NULL
through	NULL
an	NULL
interaction	NULL
between	NULL
a	NULL
nucleosomal	NULL
component	NULL
and	NULL
one	NULL
of	NULL
these	NULL
factors	NULL
.	NULL

The	NULL
Sp1	NULL
sites	NULL
lie	NULL
at	NULL
the	NULL
5	NULL
'	NULL
boundary	NULL
of	NULL
nuc-2	NULL
and	NULL
are	NULL
thus	NULL
likely	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
its	NULL
positioning	NULL
.	NULL

Recent	NULL
experiments	NULL
in	NULL
which	NULL
an	NULL
LTR	NULL
containing	NULL
mutations	NULL
in	NULL
most	NULL
of	NULL
the	NULL
HS4	NULL
binding	NULL
sites	NULL
[	NULL
AP-1	NULL
(	NULL
III	NULL
)	NULL
,	NULL
AP3-L	NULL
,	NULL
DBF	NULL
,	NULL
and	NULL
Spl	NULL
]	NULL
was	NULL
stably	NULL
integrated	NULL
into	NULL
HeLa	NULL
cells	NULL
have	NULL
shown	NULL
reduced	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
accompanied	NULL
by	NULL
the	NULL
disappearance	NULL
of	NULL
nuclease-hypersensitive	NULL
site	NULL
IV	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrate	NULL
that	NULL
these	NULL
sites	NULL
collectively	NULL
contribute	NULL
to	NULL
the	NULL
establishment	NULL
of	NULL
a	NULL
nucleosome-free	NULL
region	NULL
corresponding	NULL
to	NULL
HS4	NULL
and	NULL
are	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
the	NULL
results	NULL
reported	NULL
here	NULL
.	NULL

A	NULL
study	NULL
of	NULL
the	NULL
chromatin	NULL
organization	NULL
of	NULL
the	NULL
leader	NULL
sequence	NULL
of	NULL
HIV-1	NULL
with	NULL
the	NULL
mutants	NULL
described	NULL
in	NULL
this	NULL
paper	NULL
will	NULL
further	NULL
define	NULL
which	NULL
factors	NULL
are	NULL
critical	NULL
for	NULL
the	NULL
establishment	NULL
of	NULL
the	NULL
native	NULL
chromatin	NULL
organization	NULL
of	NULL
integrated	NULL
HIV-1	NULL
.	NULL

The	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
are	NULL
both	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
T-cell	NULL
activation	NULL
sig-nals	NULL
,	NULL
as	NULL
is	NULL
the	NULL
disruption	NULL
of	NULL
nuc-1	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
conceivable	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
-	NULL
6125	NULL
that	NULL
these	NULL
factors	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
disruption	NULL
by	NULL
competing	NULL
with	NULL
nuc-1	NULL
histones	NULL
for	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

Our	NULL
observations	NULL
indicate	NULL
that	NULL
the	NULL
HS4	NULL
binding	NULL
sites	NULL
characterized	NULL
here	NULL
constitute	NULL
a	NULL
novel	NULL
enhancer	NULL
that	NULL
functions	NULL
independently	NULL
of	NULL
,	NULL
or	NULL
in	NULL
concert	NULL
with	NULL
,	NULL
other	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
LTR	NULL
to	NULL
activate	NULL
HIV-1	NULL
transcription	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
mutated	NULL
proviruses	NULL
with	NULL
no	NULL
functional	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
are	NULL
still	NULL
competent	NULL
in	NULL
terms	NULL
of	NULL
viral	NULL
replication	NULL
(	NULL
44	NULL
,	NULL
48	NULL
,	NULL
64	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
can	NULL
be	NULL
complemented	NULL
by	NULL
other	NULL
cis-acting	NULL
elements	NULL
located	NULL
in	NULL
the	NULL
viral	NULL
genome	NULL
.	NULL

The	NULL
binding	NULL
sites	NULL
studied	NULL
in	NULL
this	NULL
report	NULL
could	NULL
play	NULL
such	NULL
a	NULL
role	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
conjunction	NULL
with	NULL
cis	NULL
elements	NULL
of	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
.	NULL

Binding	NULL
of	NULL
these	NULL
factors	NULL
downstream	NULL
of	NULL
the	NULL
HIV-1	NULL
transcription	NULL
start	NULL
site	NULL
could	NULL
cause	NULL
additional	NULL
cellular	NULL
specificity	NULL
,	NULL
increase	NULL
the	NULL
strength	NULL
of	NULL
the	NULL
promoter-enhancer	NULL
unit	NULL
located	NULL
in	NULL
the	NULL
LTR	NULL
,	NULL
or	NULL
provide	NULL
a	NULL
mechanism	NULL
to	NULL
broaden	NULL
the	NULL
viral	NULL
response	NULL
to	NULL
extracellular	NULL
stimuli	NULL
and	NULL
activate	NULL
transcription	NULL
under	NULL
a	NULL
wider	NULL
variety	NULL
of	NULL
cellular	NULL
conditions	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
integrated	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
provirus	NULL
contains	NULL
a	NULL
DNase	NULL
I-hypersensitive	NULL
site	NULL
immediately	NULL
downstream	NULL
of	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
(	NULL
61	NULL
)	NULL
,	NULL
in	NULL
a	NULL
position	NULL
similar	NULL
to	NULL
the	NULL
DNase	NULL
I-hypersensitive	NULL
site	NULL
4	NULL
of	NULL
HIV-1	NULL
.	NULL

This	NULL
region	NULL
of	NULL
the	NULL
provirus	NULL
contains	NULL
a	NULL
cis-acting	NULL
element	NULL
responsible	NULL
for	NULL
the	NULL
selective	NULL
suppression	NULL
of	NULL
viral	NULL
transcription	NULL
in	NULL
embryonic	NULL
carcinoma	NULL
cells	NULL
(	NULL
46	NULL
,	NULL
47	NULL
,	NULL
77	NULL
)	NULL
.	NULL

Since	NULL
Spl	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
mediate	NULL
the	NULL
formation	NULL
of	NULL
DNA	NULL
loops	NULL
between	NULL
Sp1	NULL
proteins	NULL
bound	NULL
at	NULL
two	NULL
different	NULL
sites	NULL
on	NULL
a	NULL
DNA	NULL
molecule	NULL
(	NULL
50	NULL
,	NULL
75	NULL
)	NULL
,	NULL
we	NULL
previously	NULL
proposed	NULL
that	NULL
Sp1	NULL
proteins	NULL
bound	NULL
at	NULL
the	NULL
promoter	NULL
(	NULL
37	NULL
)	NULL
and	NULL
Sp1	NULL
proteins	NULL
bound	NULL
in	NULL
the	NULL
HS4	NULL
region	NULL
interact	NULL
with	NULL
each	NULL
other	NULL
and	NULL
bring	NULL
in	NULL
close	NULL
proximity	NULL
the	NULL
two	NULL
nucleosome-free	NULL
regions	NULL
and	NULL
the	NULL
factors	NULL
interacting	NULL
with	NULL
them	NULL
(	NULL
81	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
loop	NULL
may	NULL
thus	NULL
be	NULL
important	NULL
for	NULL
positioning	NULL
sites	NULL
in	NULL
HS4	NULL
close	NULL
to	NULL
the	NULL
promoter	NULL
and	NULL
therefore	NULL
provides	NULL
a	NULL
structural	NULL
framework	NULL
in	NULL
which	NULL
the	NULL
interactions	NULL
described	NULL
above	NULL
could	NULL
take	NULL
place	NULL
.	NULL

The	NULL
observations	NULL
reported	NULL
here	NULL
demonstrate	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
HIV-1	NULL
infectivity	NULL
and	NULL
transcriptional	NULL
regulation	NULL
for	NULL
the	NULL
nuclease-hypersensitive	NULL
region	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

Demonstration	NULL
of	NULL
a	NULL
positive	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
transcribed	NULL
region	NULL
of	NULL
the	NULL
HIV	NULL
genome	NULL
introduces	NULL
an	NULL
additional	NULL
factor	NULL
into	NULL
an	NULL
already	NULL
complex	NULL
network	NULL
of	NULL
regulators	NULL
affecting	NULL
the	NULL
degree	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Chris	NULL
Schindler	NULL
,	NULL
Malcolm	NULL
Martin	NULL
,	NULL
Michael	NULL
Laspia	NULL
,	NULL
Christine	NULL
Metz	NULL
,	NULL
Anjana	NULL
Rao	NULL
,	NULL
Arnold	NULL
Rabson	NULL
,	NULL
and	NULL
Marc	NULL
Whatelet	NULL
for	NULL
reagents	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

We	NULL
thank	NULL
Alfred	NULL
Prince	NULL
for	NULL
reagents	NULL
obtained	NULL
through	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
,	NULL
NIAID	NULL
,	NULL
NIH	NULL
.	NULL

Carine	NULL
Van	NULL
Lint	NULL
is	NULL
``	NULL
Chercheur	NULL
Qualifié	NULL
``	NULL
of	NULL
the	NULL
``	NULL
Fonds	NULL
National	NULL
de	NULL
la	NULL
Recherche	NULL
Scientifique	NULL
``	NULL
(	NULL
FNRS	NULL
,	NULL
Belgium	NULL
)	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
of	NULL
the	NULL
U.S.	NULL
Public	NULL
Health	NULL
Service	NULL
(	NULL
NIGMS/NIAID	NULL
GMS1671-02	NULL
)	NULL
and	NULL
by	NULL
institutional	NULL
funds	NULL
from	NULL
the	NULL
Picower	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Abdollahi	NULL
,	NULL
A.	NULL
,	NULL
K.	NULL
A.	NULL
Lord	NULL
,	NULL
B.	NULL
Hoffman-Liebermann	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Liebermann	NULL
.	NULL

1991	NULL
.	NULL

Interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
is	NULL
a	NULL
myeloid	NULL
differentiation	NULL
primary	NULL
response	NULL
gene	NULL
induced	NULL
by	NULL
interleukin-6	NULL
and	NULL
leukemia	NULL
inhibitory	NULL
factor	NULL
:	NULL
role	NULL
in	NULL
growth	NULL
inhibition	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

2401-407	NULL
.	NULL

2	NULL
.	NULL

Adachi	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
S.	NULL
Koenig	NULL
,	NULL
T.	NULL
Folks	NULL
,	NULL
R.	NULL
Willey	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1986	NULL
.	NULL

Production	NULL
of	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-associated	NULL
retrovirus	NULL
in	NULL
human	NULL
and	NULL
nonhuman	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
infectious	NULL
molecular	NULL
clone	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

59:284-291	NULL
.	NULL

3	NULL
.	NULL

Aldovini	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
B.	NULL
Walker	NULL
.	NULL

1990	NULL
.	NULL

Techniques	NULL
in	NULL
HIV	NULL
research	NULL
.	NULL

Stockton	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
4	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Imagawa	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
R.	NULL
J.	NULL
Imbra	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
C.	NULL
Jonat	NULL
,	NULL
P.	NULL
Herrlich	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1987	NULL
.	NULL

Phorbol	NULL
ester-inducible	NULL
genes	NULL
contain	NULL
a	NULL
common	NULL
cis	NULL
element	NULL
recognized	NULL
by	NULL
a	NULL
TPA-modulated	NULL
trans-acting	NULL
factor	NULL
.	NULL

Cell	NULL
49:729-739	NULL
.	NULL

6126	NULL
5	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

VAN	NULL
LINT	NULL
ET	NULL
AL	NULL
.	NULL

Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

.	NULL

1993	NULL
.	NULL

Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley	NULL
Interscience	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
.	NULL

Baudin	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
Marquet	NULL
,	NULL
C.	NULL
Isel	NULL
,	NULL
J.	NULL
L.	NULL
Darlix	NULL
,	NULL
B.	NULL
Ehresmann	NULL
,	NULL
and	NULL
C.	NULL
Ehres-	NULL
mann	NULL
.	NULL

1993	NULL
.	NULL

Functional	NULL
sites	NULL
in	NULL
the	NULL
5	NULL
'	NULL
region	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
RNA	NULL
form	NULL
defined	NULL
structural	NULL
domains	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

229:382-397.	NULL
.	NULL

Benbrook	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
N.	NULL
C.	NULL
Jones	NULL
.	NULL

1990	NULL
.	NULL

Heterodimer	NULL
formation	NULL
between	NULL
CREB	NULL
and	NULL
JUN	NULL
proteins	NULL
.	NULL

Oncogene	NULL
5:295-302.	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
X.	NULL
Mao	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
K.	NULL
Kovary	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NFAT-1	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fra-1	NULL
and	NULL
JunB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1911-1919.	NULL
.	NULL

Bovolenta	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Lou	NULL
,	NULL
Y.	NULL
Kanno	NULL
,	NULL
B.-K.	NULL
Park	NULL
,	NULL
A.	NULL
Thornton	NULL
,	NULL
J.	NULL
E.	NULL
Coligan	NULL
,	NULL
M.	NULL
Schubert	NULL
,	NULL
and	NULL
K.	NULL
Ozato	NULL
.	NULL

1995	NULL
.	NULL

Vesicular	NULL
stomatitis	NULL
virus	NULL
infection	NULL
induces	NULL
a	NULL
nuclear	NULL
DNA-binding	NULL
factor	NULL
specific	NULL
for	NULL
the	NULL
interferon-stimulated	NULL
response	NULL
clement	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4173-4181	NULL
.	NULL

Bradford	NULL
,	NULL
M.	NULL
M.	NULL
1976	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72:248-254	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1991	NULL
.	NULL

Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2361-2368	NULL
.	NULL

El	NULL
Kharroubi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1996.	NULL
cis-acting	NULL
sequences	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
affect	NULL
its	NULL
chromatin	NULL
structure	NULL
and	NULL
transcriptional	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:2958-2966	NULL
.	NULL

EI	NULL
Kharroubi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
E.	NULL
Verdin	NULL
.	NULL

1994	NULL
.	NULL

Protein-DNA	NULL
interactions	NULL
within	NULL
DNase	NULL
I-hypersensitive	NULL
sites	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:19916-19924	NULL
.	NULL

Faisst	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
S.	NULL
Meyer	NULL
.	NULL

1992	NULL
.	NULL

Compilation	NULL
of	NULL
vertebrate-encoded	NULL
transcription	NULL
factors	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:3-26	NULL
.	NULL

Franza	NULL
,	NULL
B.	NULL
R.	NULL
J.	NULL
,	NULL
F.	NULL
J.	NULL
Rauscher	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
fos	NULL
complex	NULL
and	NULL
fos-related	NULL
antigens	NULL
recognize	NULL
sequence	NULL
elements	NULL
that	NULL
contain	NULL
AP1	NULL
binding	NULL
sites	NULL
.	NULL

Science	NULL
239:1150-1153	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Irving	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin-2	NULL
gene	NULL
enhancer	NULL
activity	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Science	NULL
251:313-316	NULL
.	NULL

Fromental	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Kanno	NULL
,	NULL
H.	NULL
Nomiyama	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1988	NULL
.	NULL

Cooper-ativity	NULL
and	NULL
hierarchical	NULL
levels	NULL
of	NULL
functional	NULL
organization	NULL
in	NULL
the	NULL
SV40	NULL
en-hancer	NULL
.	NULL

Cell	NULL
54:943-953	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
L.	NULL
F.	NULL
Reis	NULL
,	NULL
N.	NULL
Watanabe	NULL
,	NULL
Y.	NULL
Kimura	NULL
,	NULL
T.	NULL
Taniguchi	NULL
,	NULL
and	NULL
J.	NULL
Vilcek	NULL
,	NULL
1989	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
and	NULL
interferon-B	NULL
mRNAs	NULL
by	NULL
cytokines	NULL
and	NULL
activators	NULL
of	NULL
second-messenger	NULL
pathways	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:9936-9940	NULL
.	NULL

Gabuzda	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
J.	NULL
L.	NULL
Hess	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Small	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Clements	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
visna	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
macrophages	NULL
involves	NULL
cellular	NULL
factors	NULL
that	NULL
bind	NULL
sequences	NULL
containing	NULL
AP-1	NULL
sites	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:2728-2733	NULL
.	NULL

Gaynor	NULL
,	NULL
R.	NULL
1992	NULL
.	NULL

Cellular	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

AIDS	NULL
6:347-363	NULL
.	NULL

Gaynor	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
transacti-vator	NULL
protein	NULL
Tat	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

193:51-77	NULL
.	NULL

Hai	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

1991	NULL
.	NULL

Cross-family	NULL
dimerization	NULL
of	NULL
transcription	NULL
factors	NULL
Fos/Jun	NULL
and	NULL
ATF/CREB	NULL
alters	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:3720-3724	NULL
.	NULL

Haines	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Gillespie	NULL
.	NULL

1992	NULL
.	NULL

RNA	NULL
abundance	NULL
measured	NULL
by	NULL
a	NULL
lysate	NULL
RNase	NULL
protection	NULL
assay	NULL
.	NULL

BioTechniques	NULL
12:736-741	NULL
.	NULL

Harada	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
M.	NULL
Miyamoto	NULL
,	NULL
Y.	NULL
Kimura	NULL
,	NULL
M.	NULL
Maruyama	NULL
,	NULL
A.	NULL
Furia	NULL
,	NULL
T.	NULL
Miyata	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1989	NULL
.	NULL

Structurally	NULL
similar	NULL
but	NULL
functionally	NULL
distinct	NULL
factors	NULL
,	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
,	NULL
bind	NULL
to	NULL
the	NULL
same	NULL
regulatory	NULL
elements	NULL
of	NULL
IFN	NULL
and	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

Cell	NULL
58:729-739.	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
Hsu	NULL
,	NULL
E.	NULL
Race	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
growth	NULL
kinetics	NULL
are	NULL
exhibited	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
TAR	NULL
mutants	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:5899-5910	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
Ulich	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
critical	NULL
role	NULL
for	NULL
the	NULL
TAR	NULL
element	NULL
in	NULL
promoting	NULL
efficient	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
reverse	NULL
transcription	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:4017-4027	NULL
.	NULL

Harrison	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Lever	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
packaging	NULL
signal	NULL
and	NULL
major	NULL
splice	NULL
donor	NULL
region	NULL
have	NULL
a	NULL
conserved	NULL
stable	NULL
secondary	NULL
structure	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:4144-4153	NULL
.	NULL

Herr	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
J.	NULL
Clarke	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
SV40	NULL
enhancer	NULL
is	NULL
composed	NULL
of	NULL
multiple	NULL
functional	NULL
elements	NULL
that	NULL
can	NULL
compensate	NULL
for	NULL
one	NULL
another	NULL
.	NULL

Cell	NULL
45:461-470	NULL
.	NULL

Hess	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Small	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Clements	NULL
.	NULL

1989	NULL
.	NULL

Sequences	NULL
in	NULL
the	NULL
visna	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
that	NULL
control	NULL
transcriptional	NULL
activity	NULL
and	NULL
respond	NULL
to	NULL
viral	NULL
frans-activation	NULL
:	NULL
involvement	NULL
of	NULL
AP-1	NULL
sites	NULL
in	NULL
basal	NULL
activity	NULL
and	NULL
frens-activation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3001-3015	NULL
.	NULL

Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1994	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFATp	NULL
in	NULL
a	NULL
neuronal	NULL
cell	NULL
line	NULL
and	NULL
in	NULL
the	NULL
murine	NULL
nervous	NULL
system	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:28181-28186	NULL
.	NULL

Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
X.	NULL
Li	NULL
,	NULL
U.	NULL
Francke	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1995	NULL
.	NULL

NFATc3	NULL
,	NULL
a	NULL
lymphoid-specific	NULL
NFATc	NULL
family	NULL
member	NULL
that	NULL
is	NULL
32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

S1	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

calcium-regulated	NULL
and	NULL
exhibits	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:19898-19907	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
Y.-L.	NULL
Sun	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
and	NULL
X.	NULL
Xu	NULL
.	NULL

1995	NULL
.	NULL

Isolation	NULL
of	NULL
two	NULL
new	NULL
members	NULL
of	NULL
the	NULL
NF-AT	NULL
gene	NULL
family	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
NF-AT	NULL
proteins	NULL
.	NULL

Immunity	NULL
2461-472	NULL
.	NULL

Thie	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Witthuhn	NULL
,	NULL
F.	NULL
W.	NULL
Quelle	NULL
,	NULL
K.	NULL
Yamamoto	NULL
,	NULL
and	NULL
O.	NULL
Silvennoinen	NULL
.	NULL

1995	NULL
.	NULL

Signaling	NULL
through	NULL
the	NULL
hematopoietic	NULL
cytokine	NULL
receptors	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:369-398	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
P.G	NULL
.	NULL

Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
similar	NULL
DNA-binding	NULL
motif	NULL
in	NULL
NFAT	NULL
family	NULL
proteins	NULL
and	NULL
the	NULL
rel	NULL
homology	NULL
region	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:4138-4145	NULL
.	NULL

James	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
J	NULL
.	NULL

He	NULL
,	NULL
P.	NULL
Collins	NULL
,	NULL
M.	NULL
J.	NULL
Allalunis-Turner	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Day	NULL
.	NULL

1993	NULL
.	NULL

Localization	NULL
of	NULL
chromosome	NULL
9p	NULL
homozygous	NULL
deletions	NULL
in	NULL
glioma	NULL
cell	NULL
lines	NULL
with	NULL
markers	NULL
constituting	NULL
a	NULL
continuous	NULL
linkage	NULL
group	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

53:3674-3676	NULL
.	NULL

Jeang	NULL
,	NULL
K.-T.	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
E.	NULL
Santos	NULL
,	NULL
and	NULL
S.-J	NULL
.	NULL

Kim	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
HTLV-1	NULL
LTR	NULL
by	NULL
Jun	NULL
occurs	NULL
through	NULL
the	NULL
Tax-responsive	NULL
21-bp	NULL
elements	NULL
.	NULL

Virology	NULL
181:218-227	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
Kadonaga	NULL
,	NULL
P.	NULL
Luciw	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1986	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
AIDS	NULL
retrovirus	NULL
promoter	NULL
by	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
,	NULL
Sp1	NULL
.	NULL

Science	NULL
232	NULL
:	NULL
755-759	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

1993	NULL
.	NULL

Tat	NULL
and	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5:461-468	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1994	NULL
.	NULL

Control	NULL
of	NULL
RNA	NULL
initiation	NULL
and	NULL
elongation	NULL
at	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:717-743	NULL
.	NULL

Kang	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J.	NULL
K.	NULL
Wakefield	NULL
,	NULL
and	NULL
C.	NULL
D.	NULL
Morrow	NULL
.	NULL

1996	NULL
.	NULL

Mutations	NULL
in	NULL
both	NULL
the	NULL
US	NULL
region	NULL
and	NULL
the	NULL
primer-binding	NULL
site	NULL
influence	NULL
the	NULL
selection	NULL
of	NULL
the	NULL
tRNA	NULL
used	NULL
for	NULL
the	NULL
initiation	NULL
of	NULL
HIV-1	NULL
reverse	NULL
transcription	NULL
.	NULL

Virology	NULL
222:401-414	NULL
.	NULL

Karin	NULL
,	NULL
M.	NULL
1991	NULL
.	NULL

The	NULL
AP1	NULL
complex	NULL
and	NULL
its	NULL
role	NULL
in	NULL
transcriptional	NULL
control	NULL
by	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
p.	NULL
235-253	NULL
.	NULL

In	NULL
P.	NULL
Cohen	NULL
and	NULL
J.	NULL
G.	NULL
Foulkes	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
The	NULL
hormonal	NULL
control	NULL
regulation	NULL
of	NULL
gene	NULL
transcription	NULL
.	NULL

Elsevier	NULL
Science	NULL
,	NULL
Amster-dam	NULL
,	NULL
The	NULL
Netherlands	NULL
.	NULL

Kim	NULL
,	NULL
J.	NULL
Y.	NULL
H.	NULL
,	NULL
F.	NULL
Gonzalez-Scarano	NULL
,	NULL
S.	NULL
L.	NULL
Zeichner	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Alwine	NULL
.	NULL

1993	NULL
.	NULL

Replication	NULL
of	NULL
type	NULL
1	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
containing	NULL
linker	NULL
substitution	NULL
mutations	NULL
in	NULL
the	NULL
-201	NULL
to	NULL
-130	NULL
region	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:1658-1662	NULL
.	NULL

Laspia	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
P.	NULL
Wendel	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathews	NULL
.	NULL

1993	NULL
.	NULL

HIV-1	NULL
Tat	NULL
overcomes	NULL
inefficient	NULL
transcriptional	NULL
elongation	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

232:732-746	NULL
.	NULL

Leonard	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Parrott	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
W.	NULL
Turner	NULL
,	NULL
E.	NULL
K.	NULL
Ross	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
are	NULL
not	NULL
required	NULL
for	NULL
virus	NULL
infectivity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4919-4924	NULL
.	NULL

Levy	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
D.	NULL
S.	NULL
Kessler	NULL
,	NULL
R.	NULL
Pine	NULL
,	NULL
N.	NULL
Reich	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
.	NULL

1988	NULL
.	NULL

Interferon-induced	NULL
nuclear	NULL
factors	NULL
that	NULL
bind	NULL
a	NULL
shared	NULL
promoter	NULL
element	NULL
correlate	NULL
with	NULL
positive	NULL
and	NULL
negative	NULL
transcriptional	NULL
control	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:383-393	NULL
.	NULL

Loh	NULL
,	NULL
T.	NULL
P.	NULL
,	NULL
L.	NULL
L.	NULL
Sievert	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Scott	NULL
.	NULL

1988	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
retrovirus	NULL
expression	NULL
in	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
mediated	NULL
by	NULL
an	NULL
intragenic	NULL
domain	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:4086-4095	NULL
.	NULL

Loh	NULL
,	NULL
T.	NULL
P.	NULL
,	NULL
L.	NULL
L.	NULL
Sievert	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Scott	NULL
.	NULL

1994	NULL
.	NULL

Proviral	NULL
sequences	NULL
that	NULL
restrict	NULL
retroviral	NULL
expression	NULL
in	NULL
mouse	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:3775-3784	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
J.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
Haseltine	NULL
.	NULL

1989	NULL
.	NULL

Effects	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
mutations	NULL
on	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4115-4119	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Mechanisms	NULL
of	NULL
transactivation	NULL
by	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:141-147	NULL
.	NULL

Mastrangelo	NULL
,	NULL
L.	NULL
,	NULL
A.	NULL
Courey	NULL
,	NULL
J	NULL
.	NULL

Wall	NULL
,	NULL
S.	NULL
Jackson	NULL
,	NULL
and	NULL
P.	NULL
Hough	NULL
.	NULL

1991.	NULL
cDNA	NULL
looping	NULL
and	NULL
Sp1	NULL
multimer	NULL
links	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
transcriptional	NULL
synergism	NULL
and	NULL
enhancement	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:5670-5674	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Y.	NULL
Naito	NULL
,	NULL
H.	NULL
Tokumitsu	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
F.	NULL
Saito	NULL
,	NULL
C.	NULL
Hannum	NULL
,	NULL
K.-I	NULL
.	NULL

Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1995	NULL
.	NULL

NFATx	NULL
,	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
family	NULL
that	NULL
is	NULL
expressed	NULL
predominantly	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2697-2706	NULL
.	NULL

Maurer	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
Serfling	NULL
,	NULL
V.	NULL
Ter	NULL
Meulen	NULL
,	NULL
and	NULL
A.	NULL
Rehwilm	NULL
.	NULL

1991	NULL
.	NULL

Transcription	NULL
factor	NULL
AP1	NULL
modulates	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
foamy	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:6553-6557	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1993	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
cyclosporin-sensitive	NULL
T	NULL
cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
.	NULL

Science	NULL
262:750-754	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Transcription	NULL
factors	NULL
AP-3	NULL
and	NULL
AP-2	NULL
interact	NULL
with	NULL
the	NULL
SV40	NULL
enhancer	NULL
in	NULL
a	NULL
mutually	NULL
exclusive	NULL
manner	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

1455-1460	NULL
.	NULL

Mitchell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
C.	NULL
Wang	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1987	NULL
.	NULL

Positive	NULL
and	NULL
negative	NULL
regulation	NULL
of	NULL
transcription	NULL
in	NULL
vitro	NULL
:	NULL
enhancer-binding	NULL
protein	NULL
AP-2	NULL
is	NULL
inhibited	NULL
by	NULL
SV40	NULL
T	NULL
antigen	NULL
.	NULL

Cell	NULL
50:847-861	NULL
.	NULL

Miyamoto	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
Y.	NULL
Kimura	NULL
,	NULL
M.	NULL
Maruyama	NULL
,	NULL
H.	NULL
Harada	NULL
,	NULL
Y.	NULL
Sudo	NULL
,	NULL
T.	NULL
Miyata	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1988	NULL
.	NULL

Regulated	NULL
expression	NULL
of	NULL
a	NULL
gene	NULL
encoding	NULL
a	NULL
nuclear	NULL
factor	NULL
,	NULL
IRF-1	NULL
,	NULL
that	NULL
specifically	NULL
binds	NULL
to	NULL
IFN-B	NULL
gene	NULL
regulatory	NULL
elements	NULL
.	NULL

Cell	NULL
54:903-913	NULL
.	NULL

Ondek	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
Gloss	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
SV40	NULL
enhancer	NULL
contains	NULL
two	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71.	NULL
distinct	NULL
levels	NULL
of	NULL
organization	NULL
.	NULL

Nature	NULL
333:40-45	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-alpha	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor-kappa	NULL
B.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Oft	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Emiliani	NULL
,	NULL
C.	NULL
Van	NULL
Lint	NULL
,	NULL
G.	NULL
Herbein	NULL
,	NULL
J.	NULL
Lovett	NULL
,	NULL
N.	NULL
Chirmule	NULL
,	NULL
T.	NULL
McCloskey	NULL
,	NULL
S.	NULL
Pahwa	NULL
,	NULL
and	NULL
E.	NULL
Verdin	NULL
.	NULL

1997	NULL
.	NULL

Immune	NULL
hyperactivation	NULL
of	NULL
HIV-1	NULL
infected	NULL
T	NULL
cells	NULL
mediated	NULL
by	NULL
Tat	NULL
and	NULL
the	NULL
CD28	NULL
pathway	NULL
.	NULL

Science	NULL
275:1481-1485	NULL
.	NULL

Pazin	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
P.	NULL
L.	NULL
Sheridan	NULL
,	NULL
K.	NULL
Cannon	NULL
,	NULL
Z.	NULL
Cao	NULL
,	NULL
J.	NULL
G.	NULL
Keck	NULL
,	NULL
J.	NULL
T.	NULL
Kadonaga	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1996	NULL
.	NULL

NF-kappa	NULL
B-mediated	NULL
chromatin	NULL
reconfiguration	NULL
and	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
in	NULL
vitro	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

10:37-49	NULL
.	NULL

Rasmussen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
E.	NULL
Gilboa	NULL
.	NULL

1987	NULL
.	NULL

Significance	NULL
of	NULL
DNase-1	NULL
hypersensitive	NULL
sites	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeats	NULL
of	NULL
a	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
vector	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:1368-1374	NULL
.	NULL

Risse	NULL
,	NULL
G.	NULL
,	NULL
K.	NULL
Joos	NULL
,	NULL
M.	NULL
Neuberg	NULL
,	NULL
H.-J	NULL
.	NULL

Bruller	NULL
,	NULL
and	NULL
R.	NULL
Muller	NULL
.	NULL

1989	NULL
.	NULL

Asymmetrical	NULL
recognition	NULL
of	NULL
the	NULL
palindromic	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
TRE	NULL
)	NULL
by	NULL
Fos	NULL
protein	NULL
complexes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:3825-3832	NULL
.	NULL

Roebuck	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
D.	NULL
A.	NULL
Brenner	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Kagnoff	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
c-fos-responsive	NULL
elements	NULL
downstream	NULL
of	NULL
TAR	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

92:1336-1348	NULL
.	NULL

Ross	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
G.	NULL
Englund	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1991	NULL
.	NULL

Contribution	NULL
of	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
motifs	NULL
to	NULL
the	NULL
replicative	NULL
capacity	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
distinct	NULL
patterns	NULL
of	NULL
viral	NULL
growth	NULL
are	NULL
determined	NULL
by	NULL
T-cell	NULL
types	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4350-4358	NULL
.	NULL

Ryseck	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1991.	NULL
c-jun	NULL
,	NULL
junB	NULL
and	NULL
junD	NULL
differ	NULL
in	NULL
their	NULL
binding	NULL
affinities	NULL
to	NULL
AP-1	NULL
and	NULL
CRE	NULL
consensus	NULL
sequences	NULL
:	NULL
effect	NULL
of	NULL
Fos	NULL
proteins	NULL
.	NULL

Oncogene	NULL
6:533-542	NULL
.	NULL

Sakuragi	NULL
,	NULL
J.-L.	NULL
,	NULL
and	NULL
A.	NULL
T.	NULL
Panganiban	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
RNA	NULL
outside	NULL
the	NULL
primary	NULL
encapsidation	NULL
and	NULL
dimer	NULL
linkage	NULL
region	NULL
affects	NULL
RNA	NULL
dimer	NULL
stability	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:3250-3254	NULL
.	NULL

Schindler	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
responses	NULL
to	NULL
polypep-tide	NULL
ligands	NULL
:	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

64:621-651	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Inducibility	NULL
of	NULL
«	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-kB	NULL
by	NULL
a	NULL
posttranscriptional	NULL
mechanism	NULL
.	NULL

Cell	NULL
47:921-928	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Sheridan	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
C.	NULL
T.	NULL
Sheline	NULL
,	NULL
K.	NULL
Cannon	NULL
,	NULL
M.	NULL
L	NULL
Voz	NULL
,	NULL
M.	NULL
J.	NULL
Pazin	NULL
,	NULL
J.	NULL
T.	NULL
Kadonaga	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
by	NULL
the	NULL
LEF-1	NULL
HMG	NULL
protein	NULL
on	NULL
nucleosome-assembled	NULL
DNA	NULL
in	NULL
vitro	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:2090-2104	NULL
.	NULL

Shirakawa	NULL
,	NULL
F.	NULL
,	NULL
K.	NULL
Saito	NULL
,	NULL
C.	NULL
A.	NULL
Bonagura	NULL
,	NULL
D.	NULL
L.	NULL
Galson	NULL
,	NULL
M.	NULL
J.	NULL
Fenton	NULL
,	NULL
A.	NULL
C.	NULL
Webb	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Auron	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
human	NULL
prointerleukin-16	NULL
gene	NULL
requires	NULL
72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

81	NULL
.	NULL

82	NULL
.	NULL

83	NULL
.	NULL

84	NULL
.	NULL

HIV-1	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
BINDING	NULL
SITES	NULL
6127	NULL
DNA	NULL
sequences	NULL
both	NULL
proximal	NULL
and	NULL
distal	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
for	NULL
tissue-specific	NULL
induction	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1322-1344	NULL
.	NULL

Simpson	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
S.	NULL
Y.	NULL
Roth	NULL
,	NULL
R.	NULL
H.	NULL
Morse	NULL
,	NULL
H.	NULL
G.	NULL
Patterton	NULL
,	NULL
J.	NULL
P.	NULL
Cooper	NULL
,	NULL
M.	NULL
Murphy	NULL
,	NULL
M.	NULL
P.	NULL
Kladde	NULL
,	NULL
and	NULL
M.	NULL
Shimizu	NULL
.	NULL

1993	NULL
.	NULL

Nucleosome	NULL
positioning	NULL
and	NULL
transcription	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Symp	NULL
.	NULL

Quant	NULL
.	NULL

Biol	NULL
.	NULL

58:237-245	NULL
.	NULL

Smeal	NULL
,	NULL
T.	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
J.	NULL
Meek	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Different	NULL
requirements	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
Jun	NULL
:	NULL
Jun	NULL
and	NULL
Jun	NULL
:	NULL
Fos	NULL
complexes	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:2091-2100	NULL
.	NULL

Sparger	NULL
,	NULL
E.	NULL
E.	NULL
,	NULL
B.	NULL
L.	NULL
Shacklett	NULL
,	NULL
L.	NULL
Renshaw-Gegg	NULL
,	NULL
P.	NULL
A.	NULL
Barry	NULL
,	NULL
N.	NULL
C.	NULL
Ped-ersen	NULL
,	NULL
J.	NULL
H.	NULL
Elder	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Luciw	NULL
.	NULL

1992	NULL
.	NULL

Regulation	NULL
of	NULL
gene	NULL
expression	NULL
directed	NULL
by	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
the	NULL
feline	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Virology	NULL
187:165-177	NULL
.	NULL

Su	NULL
,	NULL
W.	NULL
,	NULL
S.	NULL
Jackson	NULL
,	NULL
R.	NULL
Tjian	NULL
,	NULL
and	NULL
H.	NULL
Echols	NULL
.	NULL

1991	NULL
.	NULL

DNA	NULL
looping	NULL
between	NULL
sites	NULL
for	NULL
transcriptional	NULL
activation	NULL
:	NULL
self-association	NULL
of	NULL
DNA-bound	NULL
Sp1	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:820-826	NULL
.	NULL

Thornton	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
R.	NULL
M.	NULL
L.	NULL
Buller	NULL
,	NULL
A.	NULL
L.	NULL
DeVico	NULL
,	NULL
I.	NULL
Ming-Wang	NULL
,	NULL
and	NULL
K.	NULL
Ozato	NULL
.	NULL

1996	NULL
.	NULL

Inhibition	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
and	NULL
vaccinia	NULL
virus	NULL
infection	NULL
by	NULL
a	NULL
dominant	NULL
negative	NULL
factor	NULL
of	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor	NULL
family	NULL
expressed	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:383-387	NULL
.	NULL

Tsukiyama	NULL
,	NULL
T.	NULL
,	NULL
O.	NULL
Niwa	NULL
,	NULL
and	NULL
K.	NULL
Yokoro	NULL
.	NULL

1990	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
of	NULL
the	NULL
5	NULL
'	NULL
noncoding	NULL
region	NULL
of	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
in	NULL
mouse	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
.	NULL

Virology	NULL
177:772-776	NULL
.	NULL

Van	NULL
Lint	NULL
,	NULL
C.	NULL
,	NULL
S.	NULL
Emiliani	NULL
,	NULL
M.	NULL
Ott	NULL
,	NULL
and	NULL
E.	NULL
Verdin	NULL
.	NULL

1996	NULL
.	NULL

Transcriptional	NULL
activation	NULL
and	NULL
chromatin	NULL
remodeling	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
histone	NULL
acetylation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:1112-1120	NULL
.	NULL

Van	NULL
Lint	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Ghysdael	NULL
,	NULL
P.	NULL
Paras	NULL
,	NULL
Jr.	NULL
,	NULL
A.	NULL
Burny	NULL
,	NULL
and	NULL
E.	NULL
Verdin	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
transcriptional	NULL
regulatory	NULL
element	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
nuclease-hypersensitive	NULL
site	NULL
in	NULL
the	NULL
pol	NULL
gene	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2632-2648	NULL
.	NULL

Verdin	NULL
,	NULL
E.	NULL
1991	NULL
.	NULL

DNase	NULL
I-hypersensitive	NULL
sites	NULL
are	NULL
associated	NULL
with	NULL
both	NULL
long	NULL
terminal	NULL
repeats	NULL
and	NULL
with	NULL
the	NULL
intragenic	NULL
enhancer	NULL
of	NULL
integrated	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:6790-6799	NULL
.	NULL

Verdin	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Paras	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
C.	NULL
Van	NULL
Lint	NULL
.	NULL

1993	NULL
.	NULL

Chromatin	NULL
disruption	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
during	NULL
transcriptional	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3249-3259	NULL
.	NULL

Zeichner	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
J.	NULL
Y.	NULL
Kim	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Alwine	NULL
.	NULL

1991	NULL
.	NULL

Linker-scanning	NULL
muta-tional	NULL
analysis	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:2436-2444	NULL
.	NULL

Zenke	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Grundstrom	NULL
,	NULL
H.	NULL
Matthes	NULL
,	NULL
M.	NULL
Wintzerith	NULL
,	NULL
C.	NULL
Schatz	NULL
,	NULL
A.	NULL
Wilde-man	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1986	NULL
.	NULL

Multiple	NULL
sequence	NULL
motifs	NULL
are	NULL
involved	NULL
in	NULL
SV40	NULL
enhancer	NULL
function	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:387-397	NULL
.	NULL

Zerial	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Toschi	NULL
,	NULL
R.	NULL
P.	NULL
Ryseck	NULL
,	NULL
M.	NULL
Schuermann	NULL
,	NULL
R.	NULL
Muller	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
product	NULL
of	NULL
a	NULL
novel	NULL
growth	NULL
factor	NULL
activated	NULL
gene	NULL
,	NULL
fosB	NULL
,	NULL
interacts	NULL
with	NULL
JUN	NULL
proteins	NULL
enhancing	NULL
their	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:805-813	NULL
.	NULL

